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ABSTRACT 
Natural products have played prominent roles in science and medicine due to their diverse 
chemical scaffolds and biological activities. Ribosomally synthesized and post-translationally 
modified peptides (RiPPs) have recently been recognized as a major class of natural products 
as a result of the genome sequencing efforts. The post-translational modifications endow 
them with diverse and rigid structures such as polycylic or macrocyclic scaffolds, which are 
valuable resources for developing new molecules with potential pharmaceutical applications. 
The studies described herein focus on the biosynthesis and engineering of lanthipeptide 
natural products, a large group of polycyclic RiPPs classified by their intramolecular 
thioether crosslinks, for expanded functionalities.  
   Protein-protein interactions (PPI) have been involved in many important biological and 
pathological processes, and are challenging drug targets for small molecules due to the 
relatively large and complex interaction interfaces. Cyclic RiPPs provide promising scaffolds 
for developing PPI inhibitors due to their 3D-like structure that mimics the native ligand, 
and the stability against cellular degradation. In Chapter 2, it is demonstrated that the 
substrate-tolerant lanthipeptide biosynthetic pathway could be utilized for combinatorial 
production of cyclic peptide libraries in Escherichia coli. One library with a ring scaffold 
derived from a native lanthipeptide was successfully coupled to a genetic selection system to 
select for inhibitors against the UEV-p6 interaction during HIV virus budding from the host 
cell. The hit compound generated from the selection exhibited in vitro activity against the 
target PPI, demonstrating for the first time that an active lanthipeptide natural product could 
be successfully evolved from an originally inactive scaffold under defined selection pressure.  
   In an effort to search for new lanthipeptide biosynthetic clusters, a new class of 
synthetases was discovered that is involved in the D-amino acid formation in lanthipeptides. 
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Chapter 3 describes the first in vitro reconstitution and characterization of a dehydrogenase 
that carries out the asymmetric reduction of dehydroalanine to D-alanine. The enzyme 
displays great substrate tolerance allowing incorporation of D-alanines into a range of non-
native substrates. As ribosomally synthesized peptides are generally limited to L-amino acid 
building blocks, methods to incorporate D-stereocenters for structure stabilization are 
valuable. This chapter demonstrated using E. coli as biosynthetic host to produce D-alanine-
containing ribosomal peptides. 
   The observed substrate tolerance of lanthipeptide synthetases has lead to the hypothesis 
that not only the enzyme, but also the substrates in part determine the outcome of product 
formation. Regarding the cyclization process, one possible mechanism would be 
thermodynamic control of ring formation, which requires the cyclization reaction to be 
reversible in order to obtain the desired ring topology. Chapter 4 demonstrates for the class I 
lanthipeptide cyclase NisC and class II lanthipeptide synthetase HalM2 that, indeed, the 
conjugate addition reactions are reversible and that the enzymes can open up all thioether 
rings in their products.  
   The studies described in Chapter 5 focus on the mode of action of haloduracin (Halα and 
Halβ), a two-component lanthipeptide bacteriocin (termed lantibiotic) that act in synergy to 
exhibit antimicrobial activity. It was previously proposed for the two-component lantibiotics 
that the α and β peptides recognize lipid II at the cell surface, and the lipid II-α-β complex 
induces pore formation on the membranes. In this chapter, lipid II analogues were 
synthesized that demonstrated the Halα-lipid II interaction. Interestingly, leakage assay on 
model membranes suggested that lipid II is not required for the membrane disruption 
activity, and the mode of action model was revised to include that the association of the α 
and β peptides with membrane phospholipids induces membrane disruption. 
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CHAPTER 1 : RIBOSOMALLY SYNTHESIZED AND POST-TRANSLATIONALLY 
MODIFIED NATURAL PRODUCTS:  BIOSYNTHESIS, MODE OF ACTION AND 
ENGINEERING1 
 
1.1 INTRODUCTION 
Natural products – chemical compounds produced by living organisms – have played 
prominent roles in science and medicine over the past century. The complex and diverse 
chemical scaffolds of natural products have inspired organic chemists to devise new 
methodologies and new strategies for total synthesis,(1) their biological activities have been 
applied in the food,  agricultural and medicinal industry, and they have been important lead 
compounds for development of new pharmaceuticals.(2)  
   Ribosomally synthesized and post-translationally modified peptides (RiPPs) are natural 
products that have only recently been recognized as a major class of compounds as a result 
of the genome sequencing efforts of the past decade.(3, 4) Because of their extensive post-
translational modifications (PTMs), RiPPs have greater structural diversity and more rigid 
structures compared to linear peptides, and often have polycyclic or macrocyclic scaffolds.(5, 6) 
The PTMs also endow them with expanded chemical functionalities such as improved target 
recognition and increased metabolic and chemical stability.(4) Thorough understanding of the 
biosynthesis processes leading to RiPPs will advance the bioengineering of molecules with 
novel structures and activities. 
   RiPP biosynthesis is initiated with a ribosomally-generated precursor peptide encoded by a 
structural gene. This precursor peptide usually contains an N-terminal leader peptide that is 
                                                
1 Reproduced in part with permission from “Ribosomally Synthesized and Post-Translationally Modified 
Peptide Natural Products: New Insights into the Role of Leader and Core Peptides during Biosynthesis” 
Chemistry 2013, 19, 7662. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
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important for recognition by the PTM enzymes and for export from the cell (Figure 1.1). 
This leader sequence is fused to a core peptide that is transformed into the final natural 
product. In some cases a C-terminal recognition sequence (RS) that is important for excision 
and cyclization of the core peptide is also present (Figure 1). Upon binding of the precursor 
peptide to the modifying enzyme(s), various post-translational modifications are installed in 
the core peptide. The leader peptide is usually removed by proteolytic cleavage in a late step 
of the maturation process, which yields the final natural product.(3) This chapter will describe 
the structure, biosynthesis and engineering of several classes of commonly studied or newly 
discovered RiPPs. 
 
Figure 1.1 General biosynthetic pathway of RiPPs. RS=recognition sequence. (Figure 
reproduced with permission from Yang et al. 2013(3)) 
 
 3 
1.2 OVERVIEW OF RIPP STRUCTURES AND BIOSYNTHESIS 
1.2.1 Lanthipeptides 
Lanthipeptides are a large group of polycyclic RiPPs classified by their intramolecular 
thioether crosslinks named lanthionine (Lan), methyllanthionine (MeLan) and labionin 
(Figure 1.2a).(7-12) Lanthipeptides with antimicrobial activities are called lantibiotics.(13) The 
polycyclic structure of lantibiotics constrains the conformational flexibility of the peptides, 
thereby conferring improved affinity for their targets, which thus far have been small 
molecules rather than macromolecules. One well-studied example is nisin (produced by 
certain strains of Lactococcus lactis), which possesses high antimicrobial potency against a wide 
range of gram-positive bacteria (Figure 1.2b). This natural product contains five thioether 
rings formed by one Lan and four MeLan residues(14) that are critical for its antimicrobial 
activity.(15-17) 
      The installation of the (Me)Lan residues in lanthipeptides is achieved in a two-step 
process: dehydration of Ser/Thr residues to dehydroalanine (Dha) and dehydrobutyrine 
(Dhb), and stereoselective intramolecular addition of Cys thiols to the resulting dehydro 
amino acids. In some cases, additional attack onto a second Dha residue results in the 
carbocyclic labionin linkages (Figure 1.2). The lanthipeptides are categorized into four classes 
according to the types of thioether linkage synthetases.(12) Class I lanthipeptides, including 
nisin, utilize a dehydratase (LanB) and a cyclase (LanC) to generate (Me)Lan residues (Figure 
1.2b); Class II lanthipeptides such as lacticin 481, use a single bifunctional synthetase 
(LanM).(18, 19) Most of the well-studied lanthipeptides discussed in this thesis belong to these 
two classes. The other two more recently discovered classes (III and IV) both feature 
trifunctional synthetases that contain an N-terminal phospholyase domain, a central kinase 
domain, and a C-terminal cyclase domain.(20) A subset of the class III synthetases produce 
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the labionin residues.(21) In addition to the installation of (Me)Lan or labionin linkages that 
define the lanthipeptide family, other tailoring PTMs are also observed, including formation 
of lysinoalanine (cinnamycin), hydroxyproline (microbisporicin), chlorotryptophan 
(microbisporicin), aminovinylcysteine (microbisporicin, epidermin, mersacidin), D-alanine 
(lacticin 3147, lactosin S), and D-aminobutyrate (carnolysin).(12, 22) Chapter 3 describes the in 
vitro reconstitution and characterization of the LanJ enzymes that are responsible for 
installing D-alanine during lanthipeptide biosynthesis.  
   After the introduction of PTMs on the core peptide, the full-length peptide is typically 
exported from the producing cell through an ABC transporter (LanT), and the leader 
peptide is cleaved by a protease LanP (class I lanthipeptides) or the protease domain of 
LanT (class II lanthipeptides), which yields the mature lanthipeptide.(23, 24) 
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1.2.2 Lasso peptides 
Lasso peptides are characterized by a unique structure that assembles a threaded lasso 
(Figure 1.3).(25) These peptides usually consist of 16-21 residues in which the N-terminal 
amine and the side chain carboxylate of a Glu/Asp residue at position 8 or 9 form a 
macrolactam, through which the C-terminal peptide tail is threaded. In class I and class III 
lasso peptides, this constrained lasso structure is reinforced by one (class III) or two (class I) 
additional disulfide bonds that connect the lasso ring to the peptide tail, whereas in class II 
lasso peptides, bulky residues are often located close to the lasso that sterically lock the 
threaded conformation (Figure 1.3b).(26) Structural analysis has also revealed that the lasso 
rings of all tested peptides wrap their tail portion in a right-handed conformation (Figure 
3c).(25) This unique structure provides lasso peptides with remarkable stability against 
chemical and enzymatic degradation, and imparts diverse bioactivities.(25, 27) Disruption of the 
lasso structure in microcin J25 (MccJ25) showed that it is a prerequisite for its antimicrobial 
activity.(28)  
Thus far, the biosynthetic machinery of lasso peptides is best understood for MccJ25(29-32) 
and capistruin.(33) Using MccJ25 as a prototypical example, the mcjA gene encodes for a 
precursor peptide that contains a 37-amino acid leader peptide and a 21-amino acid core 
sequence. The McjB enzyme is an ATP-dependent cysteine protease(29) that cleaves off the 
leader sequence.(31, 32) The McjC enzyme is an Asn synthetase homolog(30) that adenylates the 
side chain carboxylic acid of Glu8 and catalyzes lactam formation.(29-31) The production of the 
correct lasso fold requires the presence of both McjB and McjC, indicating that they are 
functionally interdependent.(29, 32) In the last step, the McjD enzyme, an ABC transporter, is 
believed to export the final product from the cytoplasm.(29, 31) Interestingly, in the recently 
discovered lasso peptide gene clusters that encodes Astexins-1, -2 and -3, two isopeptidases 
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were found instead of the McjD-like ABC transporter. These proteases were able to 
selectively linearize the threaded lasso peptides by hydrolyzing the isopeptide bond that 
forms the macrolactam ring, which provides new information regarding the self-immunity 
and evolution of lasso peptides.(34) 
 
Figure 1.3 Biosynthesis of lasso peptides. a) Three classes of lasso peptides. Residues 
involved in the macrolactam formation are shown in blue, with the two connecting residues 
highlighted in red. b) Biosynthesis and structure of microcin J25 as a representative lasso 
peptide. c) Right-handed conformation of lasso peptides. (Figure reproduced with 
permission from Yang et al. 2013(3)) 
 
 
1.2.3 Linear azol(in)e containing peptides 
Linear azol(in)e containing peptides (LAPs) are non-macrocyclized RiPPs featuring multiple 
thiazole and (methyl)oxazole heterocycles, and sometimes their corresponding 2-electron 
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reduced azolines (e.g. Figure 1.4), which conformationally constrain the peptide.(4, 35, 36) LAP 
family members exhibit various bioactivities, such as the DNA gyrase inhibitor microcin 
B17,(37, 38) the β hemolytic factor streptolysin S,(39) and the antibiotic plantazolicin.(40) The 
thiazol(in)e and oxazol(in)e heterocycles are critical for the biological functions of the 
LAPs.(35, 36) 
LAPs are generated from a precursor peptide comprised of a leader sequence and a core 
peptide rich in residues with a β-nucleophile (Ser, Thr and Cys). Typically, a subset of these 
residues are modified to form azol(in)e rings. The first step is the ATP-dependent 
cyclodehydration of Ser, Thr, and Cys to produce azoline heterocycles by a cyclodehydratase 
protein complex (C and D proteins).(38, 41) The D protein, a member of the YcaO/DUF181 
protein family, is responsible for the cyclodehydration reaction and uses ATP to 
phosphorylate the amide carbonyl oxygen of the peptide backbone.(42) The C protein 
regulates substrate binding and improves the catalytic activity of the D protein.(43) In the 
second step, a subset or all of the azoline rings are oxidized to the aromatic azoles by a 
flavin-dependent dehydrogenase designated the B-protein.(38, 44) Subsequently, the leader 
peptide is proteolytically removed and the mature LAP is exported from the cell.  
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1.2.4 Thiopeptides 
Thiopeptides or thiazolyl peptides are macrocyclic peptides featured by the central six-
member nitrogenous ring (piperidine, dehydroperidine, or pyridine). Thiopeptides also 
contain post-translationally modified thiazoles, dehydroalanines and dehydrobutyrines on the 
peptide backbone.(45) The complex structure generated from heavy PTMs endows them with 
antibacterial activities, and sometimes antimalarial and anti-cancer properties.(4, 46) 
   At least six different enzymes are involved in the biosynthesis of thiopeptides. Using the 
thiocillin (Figure 1.5) biosynthetic cluster(47) as example, the class I lanthipeptide dehydratase 
homolog protein TclK and TclL is likely involved in the formation of Dha and Dhb from 
Ser and Thr residues, respectively. And the LAPs homolog proteins TclJ and TclN are likely 
responsible for the cyclodehydration and dehydrogenation of Cys residues into thiazoles. 
The proposed roles for other tailoring enzymes include hydroxylation of Val, O-methylation 
or oxidative decarboxylation of Thr. Remarkably, the TclM enzyme in the cluster was 
recently demonstrated to be the first-reported “hetero Diels-Alderase” in enzymology, which 
catalyzes the critical heterocyclization of two Dha residues that forms the macrocyclic 
structure (Figure 1.5).(48) 
 
Figure 1.5 Heterocycle formation of thiocillins.(48)  
 11 
1.2.5 Cyanobactins 
Cyanobacticins are a group of head-to-tail macrocyclized peptides produced by various 
cyanobacteria, many of which are further modified with azol(in)e heterocycles and 
prenylated Ser, Thr, or Tyr residues (Figure 1.6). These cyclic peptides have various 
biological activities that have recently been reviewed.(49, 50)  
The cyanobactin precursor peptides contain a leader sequence and multiple cassettes that 
can contain different core sequences.(51-53) In each cassette, the core sequence is sandwiched 
between two flanking recognition sequences: a N-terminal protease recognition sequence 
that typically consist of G(L/V)E(A/P)S, and a C-terminal recognition sequence that 
contains AYDG(E).(54 ) 
The first step is the generation of azol(in)e rings from Ser, Thr and Cys residues catalyzed 
by the cyclodehydratase D (and the oxidase domain of another protein designated G), which 
shares similarity with the LAP biosynthetic machinery.(38, 52, 55, 56) Subsequently, a serine 
protease (the A protein) removes the N-terminal recognition sequence, generating a free 
amine. Next, a second serine protease (the G protein) recognizes the C-terminal recognition 
sequence and removes it to form an acyl enzyme intermediate, that then is attacked by the 
N-terminus of the peptide to achieve macrocyclization.(54, 57-59) Prenylation occurs after the 
cyclization step, and it has been recently shown that the prenyltransferase only acts on the 
cyclized peptide in the absence of the recognition sequence.(60) 
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1.2.6 Bottromycins  
Bottromycins represent a class of heavily modified RiPPs that contain unusual structures 
including a macrocyclic amidine, a decarboxylated C-terminal thiazole, and multiple carbon-
methylated amino acids (Figure 1.7). Bottromycins and their derivatives exhibit potent 
antimicrobial activity against bacterial pathogens such as methicillin-resistant Staphylococcus 
aureus (MRSA) and vancomycin-resistant enterococci (VRE).(61, 62) 
In contrast to other RiPPs characterized thus far, bottromycin does not have an N-
terminal leader peptide. Instead, a 37-residue sequence is attached to the C-terminus of the 
core peptide as a follower sequence, which is believed to have a similar function to the leader 
peptides in other RiPPs.(63-66) Multiple radical S-adenosylmethionine (SAM) methyltransferases 
catalyze the methylation of Pro, Phe and Val residues, while an O-methyltransferase is 
responsible for the methylation of an Asp residue. Another two proteins with sequence 
similarity to the D protein in LAP biosynthesis are proposed to be involved in thiazoline 
formation, and perhaps the macrocyclodehydration reaction that generates the amidine 
structure. Other genes in the cluster encode several proteases and a cytochrome P450 
enzyme that are likely involved in removal of the N-terminal Met and the follower peptide, 
as well as oxidative decarboxylation of the C-terminal residue.(63-66) 
 14 
 
Figure 1.7 Structure of bottromycin A2. (Figure reproduced with permission from Yang et 
al. 2013(3)) 
 
 
1.2.7 Microviridins 
Microviridins are a class of N-acetylated polycyclic peptides mostly produced by 
cyanobacteria. Microviridins are characterized by ester and amide crosslinks (Figure 1.8). 
These lactone or lactam structures are formed between the carboxyl groups of Asp/Glu and 
the hydroxyl groups of Ser/Thr, or with the amino groups of Lys, respectively.(67) The 
precursor peptide of microviridins contains an N-terminal leader sequence and a C-terminal 
core sequence. To date, the biosynthetic process has been partially elucidated.(68-71) The ester 
and amide bonds are introduced by two classes of ATP grasp ligases in a strictly ordered 
process. The ester bonds are generated prior to amide formation, with the larger lactone 
forming first and the smaller one forming second.(70) After formation of the overall tricyclic 
topology introduced by these two enzymes, the leader peptide is removed, and acetylation of 
the N-terminus yields the mature microviridin.(72)  
 15 
 
Figure 1.8 Structure of microviridin B. (Figure reproduced with permission from Yang et al. 
2013(3)) 
 
 
1.2.8 Sactipeptides 
Sactipeptides are characterized by thioether crosslinks, but unlike lanthipeptides, which have 
thioether crosslinks between Cys and the	   β-carbon of formerly Ser and Thr residues, the 
thioether bridges in sactipeptides are generated between cysteine and the α-carbon of a 
variety of amino acids (Figure 1.9).(73) These thioether bridges fold the backbone of 
sactipeptides into a hairpin-like structure. Structure determination has revealed that several 
sactipeptides, such as subtilosin A,(73, 74) thuricin CD,(75) and thuricin H,(76) possess an 
amphipathic structure, which is likely responsible for their antimicrobial bioactivities.(76, 77) 
The precursor peptide of sactipeptides contains an N-terminal leader sequence. During the 
biosynthesis, thioether bond formation is catalyzed by a radical SAM enzyme in a leader 
peptide-dependent manner.(78)  
 16 
 
Figure 1.9 Proposed biosynthesis of subtilosin A. (Figure reproduced with permission from 
Yang et al. 2013(3)). 
 
1.2.9 Proteusins 
Proteusins are a very recently classified RiPP family with polytheonamides as their first 
characterized members.(4),[46a] Polytheonamides are extensively modified peptides containing 
many unusual residues such as a novel N-acyl moiety, tert-leucines and other carbon-
methylated residues, as well as multiple D-configured amino acids that alternate with L-amino 
acids throughout the peptide backbone (Figure 1.10).(79) Due to their unique structures and 
strong hydrophobicity, polytheonamides are able to form helical structures that insert into 
the cell membrane as single molecule channels.(80) 
The precursor peptides possess a nitrile hydratase-like leader peptide (NHLP) or a Nif11 
nitrogen fixing protein-like leader peptide (N11P).(81, 82) The D-configured amino acids are 
generated by the radical S-adenosylmethionine (rSAM) epimerase PoyD with high 
regioselectivity,(83) and the Asn N-methylation is catalyzed by the SAM-dependent 
methyltransferase PoyE.(81) PoyF, which resembles the dehydratase domain of the class II 
lanthipeptide synthetase, LanM, is responsible for the first step in generation of the acylated 
N-terminus by dehydrating a Thr residue.(81)  
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1.3 ROLES OF THE LEADER AND CORE PEPTIDE DURING RIPP 
BIOSYNTHESIS 
1.3.1 How does leader peptide binding activate enzyme activity? 
   Recently, a model(3, 84, 85) has been put forth in which the leader peptide acts as an allosteric 
regulator that traps an active conformation of the enzyme that is otherwise present in very 
small amounts in the absence of the leader peptide (Figure 1.11). This model is supported by 
several recent observations that the RiPP biosynthetic machinery is able to introduce 
modifications on the core peptide without the presence of a leader peptide, albeit at a much 
slower rate. This model was first proposed when it was observed that in vitro, the 
lanthipeptide synthetase LctM that generates lacticin 481 (Figure 1.12) was able to very 
slowly dehydrate the core peptide of its substrate LctA in the absence of a leader peptide. If 
a small concentration of an active conformation of LctM is always present, it could explain a 
low basal level of activity even in the absence of leader peptide. Support for such a model 
also operating inside the producing organism is the recent observation that co-expression of 
the core peptide of the nisin precursor peptide NisA without the leader peptide attached 
with the dehydratase NisB and the cyclase NisC in L. lactis also resulted in a low level of 
posttranslational modification of the core peptide.(86) In the cases of other RiPP systems, 
modification on the core peptide in the absence of leader sequence was also observed for the 
Balh biosynthetic pathway of LAPs,(87) as well as biosynthesis of the lasso peptide MccJ25.(32)  
   This hypothesis is an example of the “conformational selection” model,(88) where active 
and inactive protein conformations have been observed to both exist in an ensemble, and a 
ligand, whether substrate or an allosteric effector, selects the conformation that it has the 
highest affinity for. In doing so, binding of the ligand can shift the distribution of 
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conformations that the enzyme adopts.(88) In Figure 1.11, binding of the leader peptide 
(ligand) shifts the preferred conformation of the enzyme to its active form.  
 
Figure 1.11 Proposed role of the leader peptide in activating their biosynthetic enzymes. The 
leader peptide is shown in red. The core peptide is shown in blue. In this figure, the active 
form is arbitrarily shown as an open form but it could also be a closed form with separate 
leader and core binding pockets (Figure reproduced with permission from Yang et al. 2013(3)). 
 
1.3.2 Sequence of the core peptide in part determines the final structure of RiPPs 
The biosynthetic machinery of RiPPs has remarkable substrate tolerance, as they are able to 
carry out modifications on various core peptides attached to the leader sequence. For 
example, the biosynthesis of cytolysin, a class II lantibiotic that is composed of two peptides 
with low sequence homology (Figure 1.12), requires seven dehydrations and three 
cyclizations on one substrate, as well as four dehydrations and two cyclizations on a second 
substrate. Yet a single CylM enzyme is able to process all the PTMs on both substrates, 
resulting in the installation of a total of six (Me)Lan residues.(89) Another example is the class 
II lanthipeptide synthetase ProcM in the prochlorosin biosynthetic pathway, which is able to 
modify up to 30 substrates with highly diverse core peptide sequences into polycyclic 
peptides (Figure 1.12).(90, 91) Interestingly, incubation of ProcM with an engineered chimeric 
peptide consisting of the prochlorosin leader peptide and lacticin 481 core peptide resulted 
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in a significant amount of lacticin 481 after leader peptide removal.(92) Besides lanthipeptides, 
other RiPP biosynthetic enzymes also display remarkable plasticity with respect to 
processing variants of the core peptides.(25, 26, 55, 63, 93-115)   
  How can the active site of a single enzyme install modifications on core peptides with 
varying sequences and convert each of them into a single product? These observations 
prompted us to speculate that perhaps the core peptides themselves partially determine the 
outcome of the modification process. In the case of lanthipeptides, additional observations 
that point in this direction are the observed phylogenetic divergence of cyclase enzymes that 
generate very similar ring topologies,(92) and the recent discovery that rings formed from a 
DhxDhxXxxXxxCys motif (Dhx = Dha or Dhb; Xxx is any amino acid) in the substrate 
peptides for several lanthipeptide have different stereochemistry from the canonical (2S, 6R) 
and (2S, 3S, 6R) configurations that is typically observed (Figure 1.12).(89) Indeed, the stereo-
specific outcome of the Dhb-Dhb-Xxx-Xxx-Cys motif is highly consistent, even when using 
synthetases of which the substrate does not orginally contain the motif.(116) Remarkably, a 
single point mutation of the second Dhb to Ala in the motif completely inverted the 
stereochemical outcome of the enzymatic modification.(116) These observations strongly 
suggest that for certain scaffolds the ring topology of the final product is not determined by 
just the synthetase, but also by the sequence of the substrate. 
 21 
 
Figure 1.12 Lanthipeptide structures that have been used for studies investigating the role of 
the leader and core peptide. The same shorthand notation is used as in Figure 1.2. (Me)Lan 
residues with unusual stereochemistry are shown in pink. Cytolysin is made up of CylLL’’ and 
CylLS’’. 
 
   One possible mechanism for the substrate-dependent enzymatic modification during 
lanthipeptide biosynthesis involves thermodynamic control of product formation, which 
suggests that the cyclization process might be reversible in order to obtain the “correct“ ring 
topology with lowest energy as the final product. However, this “reverse cyclization“ 
hypothesis has never been tested before. Chapter 4 provides the first evidence showing that 
the Michael-type cyclization process in lanthipeptide biosynthesis is indeed reversible.  
 22 
1.4 MODE OF ACTION OF LANTIBIOTICS 
As mentioned previously, lanthipeptides with antimicrobial activity are named lantibiotics. 
Mode of action studies have shown that many lantibiotics mainly act on the outer face of the 
cytoplasmic membrane of gram-positive bacteria, specifically targeting lipid II (Figure 1.13), 
a critical precursor molecule during the biosynthesis of the peptidoglycan cell wall.(117) For 
example, the lantibiotic mersacidin (Figure 1.13) binds to lipid II and thus inhibits cell wall 
biosynthesis,(118) while the lantibiotic nisin binds to lipid II and subsequently induces stable 
pore formation in the membrane that leads to cell death.(119, 120) Chapter 5 describes the 
progress on studying the mode of action of the two-component lantibiotic haloduracin. 
   One potential benefit of the lantibiotic mode of action is that they recognize the sugar-
pyrophosphate motif in lipid II,(121) which is more difficult to alter or mutate compared to 
the D-Ala-D-Ala terminus of lipid II that is recognized by vancomycin,(122) or other protein 
targets that are recognized by different antibiotics. This mechanism is likely to contribute to 
the relatively low resistance development of lantibiotics,(123) making them promising 
treatments against bacterial infections. For example, microbisporicin (also named as NAI-
107, Figure 1.13) is currently in late preclinical development, and displays superior efficacy in 
animal models than the drug of last resort, vancomycin.(124, 125)  
 
Figure 1.13 Structure of lipid II and lipid II-targeting lantibiotics. 
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1.5 ENGINEERING OF RIPPS 
As discussed above, the formation of polycyclic or macrocyclic scaffolds, as well as other 
PTMs such as the presence of D-amino acids, endow RiPPs with unique bioactivity and 
improved stability. Therefore, they have great potential to serve as scaffolds for the design 
and engineering of RiPP derivatives with novel structures and expanded functionalities. In 
addition, modification of known RiPP sequences will also be required in order to further 
improve the solubility, stability, and bioavailability for potential future pharmaceutical 
applications.  
   As the chemical synthesis of many challenging RiPP structures such as lasso peptides have 
not been achieved, current engineering strategies have focused on utilizing the RiPP 
biosynthetic pathway in combination with mutagenesis and incorporation of noncanonical 
amino acids. A great advantage of such a bioengineering approach is the high-tolerance of 
the RiPP synthetases to alternative substrates, as discussed in section 1.2. In addition, a 
single enzyme involved in the post-translational modification process is often multi-
functional and is able to carry out a number of catalytic events.  
    The typical bioengineering strategy is to introduce amino acid mutations on the core 
peptide, or to attach a non-native sequence to the leader peptide. In this way, incorporation 
of noncanonical amino acids has been achieved in lanthipeptides, cyanobactins, and lasso 
peptides, using heterologous expression systems in E. coli.(126-130) The catalytic tolerance of the 
biosynthetic machinery has also been challenged by combinatorial approaches, which in 
theory could generate libraries of RiPPs derivatives that are promising resources for chemical 
diversity and pharmaceutical screening.(56, 90) Examples include the in vivo construction of 
cyanobactin combinatorial libraries in E. coli using the trunkamide biosynthetic pathway,(131) 
the in vitro construction of cyanobactin derivatives using combinations of D proteins purified 
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from different biosynthetic pathways,(132) the  construction of LAP derivatives using the 
plantazolicin biosynthetic machinery,(133) thiopeptide variants using 
thiostrepton/thiocillin/nosiheptide pathways,(134) lasso peptide mutagenesis libraries using 
the MccJ25 maturation/export (BCD proteins) mechanisms in E. coli,(135) and lanthipeptide 
derivatives(136) using the nisin,(137) lacticin 3147,(138) actagardine,(111) mersacidin(98) or nukacin 
biosynthetic pathways.(100) Chapter 2 describes the successful construction of several 
combinatorial lanthipeptide libraries using the biosynthetic pathway of prochlorosins, as well 
as utilization of the library for selection of protein-protein interaction inhibitors as proof of 
concept.  
 
1.6. SUMMARY AND OUTLOOK 
The remarkable potential of manipulating the RiPPs biosynthetic pathways has just begun, 
which will benefit the development of new molecules with potential pharmaceutical values. 
For example, the application of lantibiotics could go beyond antimicrobial activity. As a 
proof of concept in Chapter 2, a putative protein-protein interaction inhibitor was evolved 
from an originally inactive lanthipeptide scaffold. And in Chapter 3, a novel lanthipeptide 
biosynthetic machinery was assembled to produce D-alanine-containing peptides.  
   Meanwhile, it is also important to thoroughly understand the biosynthetic mechanism and 
mode of action of RiPP natural products. Chapter 4 described the discovery of the reversible 
cyclization process during lanthipeptide ring formation, suggesting either thermodynamic 
control over product formation, or a consequence of co-evolution of enzyme and substrate. 
Chapter 5 provides new insights in the mode of action of the two-component lantibiotics.  
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CHAPTER 2 : CONSTRUCTION OF CYCLIC LANTHIPEPTIDE LIBRARIES FOR 
SELECTION OF PROTEIN-PROTEIN INTERACTION INHIBITORS 
 
2.1 INTRODUCTION 
2.1.1 Cyclic peptides as promising inhibitors of protein-protein interactions 
  Many important biological and pathological processes are mediated by protein–protein or 
peptide–protein interactions (PPI).(1) Interference with these interactions could open the 
door to control over cellular events.(2) However, the relatively large and complex protein 
interaction interfaces set a great challenge on inhibitor design, which requires ligands that 
can recognize binding epitopes displayed on primary, secondary or even tertiary structure.(3) 
While some PPI interfaces featuring a small pocket clustered with critical binding residues 
(“hot spots”) can still be targeted by small molecules,(4, 5) the majority of PPI interfaces 
(estimated >50%) contain hot spots that distribute in multiple subpockets along the 
surface.(6, 7) Such complexity requires inhibitors that mimic similar secondary or tertiary 
structure as the native ligands,(3) which are more 3D-like than the average member of current 
small molecule-based high-throughput libraries.(5, 8) 
   Comparing to small molecules inhibitors, cyclic peptides and antibodies hold much 
promise for recognizing the extended and dynamic protein interaction surfaces because of 
their ability to act as structural mimics of the native ligands. In addition, the constrained 
structure of cyclic peptides could potentially contribute to the selectivity and binding affinity 
in part due to their reduced conformational flexibility (which results in a smaller loss of 
entropy upon binding),(9, 10) as well as increased stability against cellular catabolism compared 
to their linear analogues.(11) Moreover, cyclic peptide-based agents are more bioavailable and 
amenable for chemical modifications than antibodies.(12, 13)  
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2.1.2 RiPPs provide promising scaffolds for cyclic peptide derivatives 
   The emerging discoveries of RiPP natural products with diverse cyclic structures (Chapter 
1) provide promising resources for designing cyclic peptide-like inhibitors against PPIs,(3) as 
many of these (macro)cyclic scaffolds bind to protein targets.(14, 15) However, one major 
hurdle is the synthetic challenge towards these complex structures, not to mention the need 
for powerful combinatorial approaches to achieve sufficient compound diversity for library 
selection. However, promising signs emerged recently that the biosynthetic machinery of 
these RiPPs are relatively substrate tolerant. As discussed in Chapter 1, several 
bioengineering strategies have been employed in efforts to generate RiPP-like derivatives, 
such as amino acid mutagenesis, incorporation of noncanonical amino acids using 
heterologous expression systems in E. coli,(16-21) and even using combinatorial approaches 
towards library generation.(22-32)  
   Many RiPP biosynthetic systems are tolerant and allow several amino acid mutations at 
certain positions. In the case of lanthipeptide engineering,(21) it has been shown for the 
nisin,(28) lacticin 3147,(29) mersacidin,(30) actagardine,(33) and nukacin(31) biosynthetic pathways 
that certain substitutions at particular residues are still tolerated by the synthetases and 
transporters. A different example is the construction of lasso peptide libraries in E. coli using 
the MccJ25 maturation and secretion machinery (BCD proteins). Saturation mutagenesis on 
three positions at either the tail region (G12, I13, T15) or the ring region (A3, H5, V6) 
yielded roughly 50% derivatives being produced with intracellular antimicrobial activity 
maintained at different level (indicated by a lack of cell growth when the self-immunity 
transporter D protein was not co-expressed), implying that the lasso structure was very likely 
formed in these mutants.(27)   
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   However, unsuccessful biosynthesis was observed when attempting to generate RiPP 
libraries with randomized amino acids at multiple positions. One example is the construction 
of cyanobactin libraries in E. coli using the trunkamide biosynthetic pathway. The success 
rate of producing detectable compounds in host cells dramatically decreased when more 
mutations were incorporated (~58% in a double-mutant library, ~14% in a quadruple-
mutant library and only ~1% in a hextuple-mutant library).(34) Yet, all of these detected 
products contained N to C macrocycles and thiazolines as indicated by MS, suggesting that 
this platform still holds great promise for further engineering. In the case of LAPs, an effort 
to construct libraries using the plantazolicin biosynthetic machinery in E. coli has shown that 
this pathway is much less permissive. With one amino acid position being mutated each 
time, 40% (29 out of 72) mutants produced detectable modified peptides that were secreted 
extracellularly.(25) There are multiple reasons explaining the failure to detect modified 
compounds for the above approaches. It could be that the synthetases failed to recognize 
and modify the non-native substrates, or that the transporters failed to secrete the peptides 
extracellularly (in the case of lasso peptides and LAPs), or it could be that the peptides were 
lethal to the host cell and thus the production was not favored.  
  Therefore, three factors are critical towards successful combinatorial biosynthesis of RiPP 
derivatives: the ability of the synthetases to tolerate non-native substrates (enzyme 
promiscuity), the ability of the host cells to tolerate the products made by the biosynthetic 
machinery (self-immunity), and the proper design of substrate sequences (library design) 
since the substrates in part determine the final outcome of the products, as discussed in 
Chapter 1. 
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2.1.3 Lanthipeptide biosynthetic machinery for combinatorial library construction 
   Although the structural diversity of lanthipeptides is a promising resource for cyclic 
peptide scaffolds, several lantibiotic biosynthetic pathways have shown limited substrate 
tolerance regarding non-native sequences as discussed above. This observation is not 
surprising from an evolution point of view, as all of these pathways (nisin, mersacidin, 
lacticin 3147, actagardine, and nukacin) are aiming to convert one precursor peptide into one 
single product with one specific structure in order to achieve antimicrobial activity. These 
pathways have been well-evolved for optimized functionality, since most of the detectable 
lantibiotic mutants could not exhibit improved bioactivity,(28-31, 33) which likely explains the 
limited promiscuity of these synthetases on non-native substrates. 
   Recent genome mining in the marine cyanobacterium Prochlorococcus MIT9313 lead to the 
discovery of a single promiscuous LanM enzyme, designated as ProcM, that could transform 
up to 30 different linear precursor peptides (designated as ProcAs) into single polycyclic 
lanthipeptide products (prochlorosins) with highly diverse ring topologies (Figure 2.1, Figure 
2.2).(23, 35-37) Similar clusters containing ProcM-like synthetases were also discovered by 
bioinformatic studies.(35, 38) Phylogenetic studies revealed that these clusters may represent 
evolutionary intermediates towards unknown functionality, possibly explaining the substrate 
tolerance of these synthetases,(35) which hold great promise for library generation.  
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Figure 2.1 Sequences of 30 ProcAs. Fully conserved residues in the leader peptide are 
shown in blue and highly conserved residues are shown in green. Ser/Thr residues in the 
core peptide are highlighted in red and Cys residues highlighted in blue. The GG/GA 
protease cleavage site is marked by a black arrow. (Figure adopted from Zhang et al.(35)) 
 
 
 
 
 
Figure 2.2 Six mature ProcAs (mProcA) with (methyl)lanthionine ring topologies solved by 
NMR or tandem MS.(23, 37)  
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2.1.4 Production of lanthipeptide libraries in E. co l i  
   There are several advantages of producing lanthipeptide libraries in E. coli. First of all, the 
expression yield in the native producer strain could be very low (for example, less than 10 μg 
of prochlorosins were obtained from 20 L of Prochlorococcus cell culture),(23) while recombinant 
over-expression in E. coli under a strong promoter (T7) could potentially improve the yield 
for convenient isolation and characterization. Secondly, reconstituting the lanthipeptide 
pathway could enable incorporation of non-proteinogenic amino acids into the peptides for 
expanded functionalities. Thirdly, an in vivo library platform could be easily coupled with a 
two-hybrid genetic selection system commonly engineered in E. coli or yeast strains where 
intracellular disruption of targeted protein-protein interactions is coupled with cell survival 
as selection marker (introduced below). 
 
2.1.5 Genetic reverse two-hybrid selection (RTHS) for inhibitors of PPI 
In a genetic reverse two-hybrid selection (RTHS) system, the successful disruption of 
protein complex formation is coupled to the transcription and expression of reporter genes 
required for cell survival (Figure 2.3). The regulation of these genes can then be monitored 
through colony growth on media containing selection markers.(39) For the purpose of 
selecting inhibitors that disrupt protein-protein interactions, RTHS has the advantage of 
being able to select for true hits that actually bind to the interfaces, while hits generated from 
traditional pull-down assays (such as phage-display) using one protein partner as bait often 
result in undesired binding at positions other than the interaction interfaces. The RTHS 
system is a promising platform as it has been successfully coupled with split-intein mediated 
cyclic peptide libraries(40) for inhibitor selection against various protein interaction targets.(40-
44) 
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    Specifically, in the RTHS system, each partner of the target protein pair is fused to the 
homo or hetero-dimeric DNA-binding domain (DBD) of the phage λ repressors.(45, 46) The 
expression of the protein fusions is induced with IPTG, and the formation of the target 
protein complex drives the association of the DBD of λ repressors, which in turn, bind onto 
the operator-promoter sequence and repress the transcription of three downstream reporter 
genes: HIS3, Kan
R and lacZ. HIS3 encodes imidazole glycerol phosphate dehydratase that is 
essential for histidine biosynthesis in the selection strain (with hisB deleted in its 
chromosome(41)) in minimal medium. The second reporter KanR encodes aminoglycoside 3’-
phosphotransferase responsible for kanamycin resistance. The final reporter, β-galactosidase, 
quantitatively reports on the level of repression. Therefore, the formation of protein 
complexes induced by IPTG will inhibit cell growth on minimal media by blocking the 
expression of HIS3 and Kan
R  (Figure 2.3a). Such delayed cell growth within the selection 
time window (normally 2-3 days at 37 °C before ackground colonies start to grow back) is 
designated as IPTG-dependent growth inhibition.  
   For inhibitor selection, the expression of library peptides is controlled under an orthogonal 
promoter (such as the arabinose promoter Para). In the presence of arabinose, if there is an 
active peptide that is capable of inhibiting the target protein dimerization, the λ repressors 
will not bind to the operator-promoter sequence and thus release the transcription of the 
reporter genes. Therefore, the cells expressing the active “hit” will appear as survival 
colonies on the selection media (Figure 2.3b). This accelerated cell growh within the 
selection time window compared to background colonies is designated as arabinose-
dependent growth advantage. 
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Figure 2.3 Schematic representation of the RTHS system in E. coli. a) RTHS without an 
active PPI inhibitor leads to inhibited cell growth. b) RTHS with an active PPI inhibitor (red 
circle) leads to improved cell growth. 
 
   A collaboration with Prof. Benkovic from Pennsylvania State University and Prof. 
Tavassoli at the University of Southampton (UK) was established to allow access to different 
RTHS platforms. Initially, as a proof of concept, two essential components of cellular 
metabolism were targeted, the heterodimeric ribonucleotide reductase (RNR) and the 
homodimeric aminoimidazole carboxamide ribonucleotide transformylase/inosine 
monophosphate cyclohydrolase (ATIC), respectively.(41, 42) More recently, another critical 
protein-protein interaction during the HIV virus budding process, the heterodimeric 
association between human TSG101 protein and the HIV Gag protein,(47)  was also targeted. 
In this case, the essential domains responsible for complex formation (the UEV domain 
from TSG101, and the p6 peptide from Gag, Figure 2.4)(48) were fused to the λ repressor 
proteins.(44) 
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Figure 2.4 Structure of the TSG101 UEV domain and the HIV Gag p6 peptide.(49) a) 
Schematic representations of human TSG101 and HIV-1 Gag. The location of the UEV 
domain and P6 domain are highlighted in red and green. The sequence of the p6 peptide is 
shown separately. The nonapeptide PTAP sequence colored in green contributes the most 
critical interaction with UEV. b) Co-crystal structure of the UEV (ribbon structure) and 
HIV p6 peptide (stick structure) complex (PDB: 3OBU). 
 
 
2.1.6 Outline 
   In the first part of this chapter, I describe the successful development of a co-expression 
strategy where the linear substrate peptides (LanA) and the synthetase (LanM) were over-
expressed in E. coli, as previously lanthipeptides had only been produced in the native 
producer strain or by in vitro reconstitution. In this way, we were able to accumulate non-
toxic, modified lanthipeptides with a leader sequence attached with significantly improved 
yield. In addition, it was observed that much of the leader peptide of prochlorosins is not 
required for modifications by ProcM. 
    In the second part of this chapter, I describe the successful combinatorial production of 
several cyclic lanthipeptide libraries by ProcM in E. coli. ProcM exhibits remarkable substrate 
tolerance towards non-native substrates that contain certain fixed ring scaffolds, as all 
samples randomly selected from these libraries were fully dehydrated and cyclized. 
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   In the third part of this chapter, I present the selection of inhibitors against the UEV-P6 
interaction using a library mimicking the mProcA2.8 scaffold, and the in vitro characterization 
of the hit peptide.  
 
 
2.2 RESULTS AND DISCUSSION 
2.2.1 Production of lanthipeptides in E. co l i  
Previous to this work, manipulation of the lanthipeptide biosynthetic machinery had only 
been achieved in the native producer strain under specified growth condition, or by in vitro 
reconstitution, which is not a convenient platform for applications such as recombinant 
library production in high yield, incorporation of non-proteinogenic amino acids, or isotopic 
labeling in minimal media. Therefore, production of lantipeptides in E. coli was highly 
desirable, but previously only a single such example had been reported for a truncated analog 
of the class II lantibiotic nukacin ISK-1.7.(50) I present here the first successful production of 
mature full-length ProcA peptides (mProcA) in E. coli. 
   The pDUET vector series are bicistronic vectors that enable two genes of interest to be 
over-expressed in a host cell simultaneously under control of the T7 promoter. The various 
plasmid copy numbers of these vectors could also allow their use in combinations to achieve 
different expression levels of multiple proteins. Among them, the pRSFDuet vector has the 
highest copy number (>100 per cell). This vector was used for co-expression of hexa-
histidine tagged ProcA peptides and untagged ProcM enzyme in E. coli BL21(DE3).  
   The peptides expressed solubly and were purified by Ni2+-affinity chromatography. The 
yield was around 20-30 mg peptide per liter of culture. The purified peptides were then 
treated with endoproteinase GluC to remove most of the leader sequence, which generated a 
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2-fold dehydrated species for mProcA2.8 as judged by matrix-assisted laser 
desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) (Figure 2.5). 
Treating the core peptides with the thiol-alkylating reagents iodoacetamide (IAA) or N-
ethylmaleimide (NEM) yielded only small amounts of alkylation adduct, indicating that the 
cysteine residues had been mostly cyclized into lanthionine structures (Figure 2.5). Analysis 
by tandem MS (Figure 2.5) revealed the same fragmentation patterns as observed by in vitro 
reconstitution,(23) demonstrating that this mProcA2.8 was successfully modified in E. coli. 
Similarly, other mProcAs were also obtained by co-expression with ProcM, and had full 
modifications on the core peptide.(51) To date, this co-expression strategy was been 
successfully applied to the biosynthesis of various Class I and Class II lanthipeptides in E. 
coli.(35, 51-55)  
 
Figure 2.5 Production of mProcA2.8 in E. coli. a) Core peptide sequence of mature 
ProcA2.8. b) mProcA2.8 obtained by co-expression with ProcM in E. coli was digested with 
Glu-C. The resulting core peptide (cleaved before −5 position) revealed two dehydrations 
(calculated monoisotopic (mono.) mass 2391.97; observed 2392.20). The dehydrated peptide 
was not alkylated upon NEM treatment. * represents sodium adducts. ° represents 
incompletely digested core peptide fragments that were cleaved before residue −7 instead of 
 45 
residue −5 (calculated mono. mass 2634.10; observed 2634.28). c) Tandem MS on the core 
peptide (top panel) showed a similar fragmentation pattern as the one obtained by in vitro 
reconstitution(23), indicating the same ring topology was formed. 
 
 
2.2.2 Construction of lanthipeptide libraries with fully randomized sequences. 
    The promiscuity of ProcM was first challenged by fully randomized substrate sequences 
(abbreviated as Library 1). This library was generated by substituting the ProcA2.8 core 
peptide with a randomized peptide sequence of similar length (20 residues), while keeping 
the leader sequence as recognition motif for ProcM. To ensure that the peptide library had 
an average number of one to three thioether rings per molecule, the library was designed at 
the DNA level to contain one to three serine/threonine residues and one to three cysteine 
residues at random positions (Figure 2.6). For this library, an artificial Lys-C cleavage site 
was introduced between the leader and core peptides (denoted as G−1K) to allow complete 
removal of the leader sequence in vitro. 
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Figure 2.6 Library design and codon options. The charts shown are triplet DNA codons 
encoding the randomized amino acids (underlined region) in each library. For Library 1, the 
DDY codon is a good alternative when negatively charged residues are desired. For Library 
2 and 3, the alternative SNG codon was not used due to the presence of Pro residues. 
 
   Two libraries were designed using two different sets of DNA codons (HDY and DNY) 
that encode increased probability of cysteine and serine/threonine residues, although at the 
cost of reduced amino acid variation comparing to the commonly used NNK codon in 
saturation mutagenesis (Figure 2.6). PCR amplification was performed with a normal 
forward primer that overlaps with the 5’ end of the leader sequence, and a reverse primer 
that overlaps with the 3’ end of the leader sequence and also carrys the entire 60 bp of the 
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randomized sequence. After PCR amplification, the DNA products were digested with 
restriction enzymes and ligated into the multiple cloning site-1 (MCS1) of the pRSFDuet-1 
vector with procM inserted in MCS2. After transformation, about 20-25 plasmids from the 
colonies of each library were isolated and sequenced, and a total of seventeen samples were 
over-expressed and purified. All peptides expressed solubly, and the modifications on the 
core peptides were characterized as described above (Figure 2.7).  
   Among the randomly selected samples, nine peptides successfully showed formation of 
more than one thioether ring per molecule, and four samples had at least one ring 
incompletely formed. Phosphorylated intermediates (mass increase of 80 Da) and 
incomplete dehydrations were also observed. Mutation of the engineered LysC cleavage site 
in the leader sequence back to the wild type glycine (denoted as K−1G) slightly improved the 
dehydration effeciency, as tested on two library samples. Overall, the results shown in Table 
2.1 indicate that ring formation was very variable for this library. 
   It is noticed that sample 2C10 contains one 14-residue lanthionine ring, the size of which 
has not been observed in any native lanthipeptides. Stereochemistry characterization showed 
that this lanthionine residue mostly has the DL configuration rather than a mixture of 
stereoisomers (Figure 2.8), suggesting the formation of the ring is still by enzymatic 
catalysis.(37) Switching the position of Cys and Ser residue (2C10S) yielded complete 
dehydration and the same ring formation. Since the two residues are far apart from each 
other on the extended linear peptide, how ProcM can dehydrate and cyclize them in both 
cases remains an interesting question. One hypothesis is that certain pre-organization of the 
substrate conformation brought the two residues close together in the cyclization domain of 
the enzyme.  
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   In addition, when I tried to move the entire ring portion of peptide 2C10 closer to the 
leader peptide by removing the five residues between the leader and the ring sequence, it was 
observed that the mutants could not be dehydrated by ProcM anymore, regardless of the 
position of Cys and Ser residues (2C10T and 2C10TS, Figure 2.7). These observations imply 
that certain substrate structures (with pre-organized conformations) are favored by the 
enzyme over others. 
 
Table 2.1 Summary of all samples tested for library 1, 2 and 3. (All cysteine residues in the 
core peptides are highlighted in blue. All serine and threonine residues are highlighted in 
red.)  
ID Core peptide sequence Major dehydrations by MS IAA/NEM alkylation Conclusion 
Library 1 
0A6 ATTCFSTNIYCVTSADSCYF −3 H2O, −4 H2O Partial +1 IAA 2-3 rings 
2A2 CTFTSVAGTCGTITTTVSII −8 H2O, −7 H2O No IAA adduct 2 rings 
2A3 SFIYVTSANGCDFGYCSVND −2 H2O, −3 H2O No IAA adduct 2 rings 
2A3’ TANYYAGYTCTNSSISYFSV −6 H2O Partial +1 IAA 0-1 ring 
2A4 GYTNTNFGYCSDYCVFSICD −3 H2O +1 IAA,  +2 IAA 1-2 rings 
2A4 
K−1G GYTNTNFGYCSDYCVFSICD −3 H2O, −4 H2O +1 IAA, +2 IAA 1-2 rings 
2A12 SAVVISSCGSFAIYISINNC +3 PO3
2- with partial −1 
H2O 
Partial +1 IAA 0-1 rings 
2A15 FFADNSTNDFGCNNATYNVC −2 H2O No IAA adduct 2 rings 
2C1’ CNYSNYYCHINSLYCHNSFC −3 H2O +1 IAA, partial +2 IAA 2-3 rings 
2C5’ NSHCIFHINICFCNLHCCNH −1 H2O + 2 IAA, + 4 IAA 0-1 ring 
2C6 YNRSYHYCIFINSFFNHFNI −2 H2O, +1 PO3
2- with −1 
H2O 
Partial +1 IAA 0-1 ring 
2C10 YHHYNCYNFNLFNNYNNNSY −1 H2O No IAA adduct 1 ring 
2C10S YHHYNSYNFNLFNNYNNNCY −1 H2O No IAA adduct 1 ring 
2C10T 
K−1G CYNFNLFNNYNNNCY 0 H2O NA 0 ring 
2C10TS 
K−1G SYNFNLFNNYNNNCY 0 H2O NA 0 ring 
2C15 CNNYHLLHRIINCCHRSICS +1 PO3
2- with partial −1 
H2O 
+3 IAA, +4 IAA 1 ring 
2C15 
K−1G CNNYHLLHRIINCCHRSICS +1 PO3
2- with −1 H2O +3 IAA 1 ring 
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Table 2.1 continue 
Library 2A 
2.8-1 AACFNVHISMPPSHNNVHC −2 H2O No IAA adduct 2 rings 
2.8-2 AACDVNLHSMPPSLDFFVC −2 H2O No IAA adduct 2 rings 
2.8-3 AACVFHFDSMPPSYLDDDC −2 H2O No IAA adduct 2 rings 
2.8-4 AACNIDFLSMPPSIHHILC −2 H2O No NEM adduct 2 rings 
2.8-5 AACNIYYISMPPSHHFVYC −2 H2O No NEM adduct 2 rings 
2.8-6 AACHDNNNSMPPSFYHIFC −2 H2O No NEM adduct 2 rings 
2.8-7 AACHLNYNSMPPSFHILFC −2 H2O No NEM adduct 2 rings 
2.8-8 AACLNNLVSMPPSNIVVYC −2 H2O No NEM adduct 2 rings 
2.8-9 AACNIHIYSMPPSNNHFNC −2 H2O No NEM adduct 2 rings 
2.8-10 AACHDINLSMPPSFLNVIC −2 H2O No NEM adduct 2 rings 
2.8-11 AACILYLISMPPSNIFNDC −2 H2O No NEM adduct 2 rings 
2.8-12 AACFFDINSMPPSDDLYLC −2 H2O No NEM adduct 2 rings 
2.8-13 AACLIVDYSMPPSIDNHLC −2 H2O No NEM adduct 2 rings 
2.8-14 AACHINRISMPPSDIVDFC −2 H2O No NEM adduct 2 rings 
2.8-15 AACHHNNLSMPPSDYFVLC −2 H2O No NEM adduct 2 rings 
2.8-16 AACNDNNISMPPSIVFDFC −2 H2O No NEM adduct 2 rings 
2.8-17 AACIVNYHSMPPSLNILYC −2 H2O No NEM adduct 2 rings 
2.8-18 AACHLHILSMPPSVYIFLC −2 H2O No NEM adduct 2 rings 
2.8-19 AACNFLVDSMPPSLFVIIC −2 H2O No NEM adduct 2 rings 
Hit 3-3 AACLHFFLSMPPSHVLDIC −2 H2O No NEM adduct 2 rings 
Library 2B 
1.1-2 FFCDDITANRFTNILC −2 H2O +1, +2 NEM 0-1 ring 
1.1-2S FFCDDISANRFSNILC −2 H2O, −1 H2O,  
−0 H2O 
No NEM adduct on −2 H2O; 
+1 NEM on −1 H2O, +2 
NEM on −0 H2O 
0-2 rings 
1.1-2S 
E−1G 
FFCDDISANRFSNILC −2 H2O,  
minor −1 H2O 
No NEM adduct on −2 H2O; 
+1 NEM on −1 H2O 
1-2 rings 
1.1-3 FFCNFITANRFTNIDC −2 H2O +1, +2 NEM 0-1 ring 
1.1-3S FFCNFISANRFSNIDC −2 H2O No NEM adduct 2 rings 
1.1-4 FFCDHYTANRFTDVVC −2 H2O +1, +2 NEM 0-1 ring 
1.14 FFCNDDTANRFTDVFC −2 H2O Partial +1 NEM 1-2 rings 
1.15 FFCVVDTANRFTLVHC −2 H2O No NEM adduct 2 rings 
Library 3 
2C10-3 YHHYNSDVLLDLKKNDLECY GluC: −1 H2O No IAA 1 ring no cut in ring 
2C10-10 YHHYNSVINHLNDLQEKLCY GluC: −0 H2O No IAA adduct 1 ring 1 cut in ring 
2C10-11 YHHYNSQQVVIIQDNQVDCY GluC: −1 H2O No IAA adduct 1 ring 
2C10-14 YHHYNSMIKHKEHDHMIICY GluC: −1 H2O,  −0 H2O 
No IAA adduct 1 ring no cut in ring, 1 ring 1 cut in ring 
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Figure 2.7 Summary of MS analysis of 17 samples tested from Library 1. a) MALDI-TOF 
MS of purified peptides after digestion with Glu-C or Lys-C (bottom spectra), and alkylation 
by IAA (top spectra). The corresponding core peptide sequence of each sample is labeled 
beneath the figure. The remaining residues from the leader sequence are underlined. b) ESI 
tandem MS of selected library samples to investigate the possible ring topology. 
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Figure 2.8 GC−MS traces of derivatized Lan standards and derivatized Lan residues 
obtained from mProcA2.8 or 2C10.   Derivatized DD-Lan, DL-Lan, and LL-Lan standards 
(selected ion monitoring at 365 Da for Lan) are shown in black traces. Hydrolyzed and 
derivatized Lan residues from sample mProcA2.8 and 2C10 are shown in blue and red traces, 
respectively. The small shoulders on the derivatized DL-Lan peak in these two samples could 
be contributed by a combination of partial epimerization during HCl hydrolysis (37) and a 
small portion of LL-Lan residues formed by non-enzymatic ring cyclization,(56, 57) which has 
been reported previously.(56) 
 
2.2.3 Construction of lanthipeptide libraries with fixed ring scaffold 
    From the overall result of Library 1, ProcM exhibits good tolerance for non-native 
substrates, as most of the samples were partially dehydrated and cyclized. However, for the 
purpose of library selection and inhibitor characterization, homogeneous ring formation on 
each substrate is desired. Considering the probability that the substrate in part determines 
the final product structure as discussed in Chapter 1, an alternative library design strategy 
would be providing a precursor of a fixed scaffold with specific (Me)Lan ring structures to 
the enzyme, with randomization only on those residues within the rings (Figure 2.6). 
   The next step was to design the DNA triplet codons that encode each randomized amino 
acids within the rings. I used four criteria to ensure the quality of the libraries: (1) The 
randomized amino acids can not contain Ser/Thr/Cys as these might disturb the original 
ring scaffold by forming additional or alternative rings; (2) The randomized amino acids can 
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not contain potential stop codons to avoid truncated peptides; (3) There should not be 
significant bias that certain amino acids are more frequently encoded than the others. In 
other words, all amino acids should be as equally represented as possible; (4) Sufficient 
residue variety should be covered to ensure the library diversity, ideally between 105 library 
variants, which is the minimal size recommended for RTHS selection,(58) and 109 library 
variants, which is the upper limit resulted from plasmid transformation efficiency in E. coli.  
   Taking all considerations together, I chose the simple, non-overlapping ring scaffolds in 
mProcA2.8 (Library 2A), mProcA1.1 (Library 2B) and library member 2C10S (Library 3). 
Library 2A members contain two 7-amino acid lanthionine rings with randomized residues 
encoded by the triplet DNA codon NWY (GATC, AT, TC). Library 2B members contain 
two 5-amino acid methyllanthionine rings with randomized residues in the rings also 
encoded by NWY. And Library 3 members contain one 14-amino acid lanthionine rings with 
randomized residues encoded by VWK (GCA, AT, GT) for expanded amino acid variety 
such as positively charged residues. Both Library 2A and Library C use the wild-type 
ProcA2.8 leader sequence, while Library 2B uses the ProcA1.1(G−1E) mutant leader 
sequence (Figure 2.6). An alternative codon SNG also satisfied the criteria (Figure 2.6), but 
was not selected due to the presence of Pro residues, which might disrupt the secondary 
structure important for ring formation. 
   Following library construction, a total of 20 samples were tested for library 2A, and 
remarkably, ProcM was able to catalyze full dehydration and cyclization on all samples and 
turn them into the same ring topology as mProcA2.8 (Table 2.1, Figures 2.9 and 2.10).  
   Four samples from Library 3 were tested, and impressively, each of them also yielded 
complete lanthionine ring formation (Table 2.1, Figure 2.11). However, proteolytic cleavage 
inside this 14-residue ring was observed when two of the samples were digested with Glu-C 
 53 
(Table 2.1, Figure 2.11). The cleavage is likely due to the less restricted conformation of the 
loop region of the 14-residue ring, where the Glu residues are more accessible to the 
protease. Indeed, when glutamate is placed next to the lanthionine residue, no cleavage was 
observed (sample 2C10-3). This correlates well with the observation that few cleavages were 
found in smaller rings (e.g. no Glu-C cleavage was observed for the two Glu residues in the 
C-terminal ring of mProcA2.8). Collectively, although Library 3 has high potential for 
complete formation of cyclic structures, it is not as stable against proteolytic degradation as 
Library 2 with the mProcA2.8 scaffold, which limits its potential application.  
   Five samples were tested for Library 2B with the mProcA1.1 scaffold containing two 
methyllanthionine rings. However, incomplete cyclization was observed for four of the 
samples by NEM alkylation (Table 2.1, Figure 2.11). One explanation is the difficulty in 
forming MeLan rings due to the lower reactivity of the Dhb residues compared to Dha.(59, 60) 
This hypothesis was tested by mutating the two Thr residues to Ser in two samples (1.1-2S, 
1.1-3S). Indeed, complete ring formation was observed for both dehydrated species (Table 
2.1, Figure 2.11). However, incomplete dehydration intermediates were also observed for 
sample 1.1-2S, which might be caused by the Glu residue at the end of the leader peptide 
engineered for Glu-C cleavage. By mutating this Glu residue back to the wild-type Gly 
residue (sample 1.1-2S E−1G), the dehydration activity was significantly improved (Table 
2.1, Figure 2.11). Similar improvement on dehydration efficiency was also observed for 
Lib2A4 K−1G mutant (Table 2.1, Figure 2.7), indicating a negative effect of a charged 
residue adjacent to the core peptide. Therefore, the MeLan scaffold of mProcA1.1 is not 
ideal for library construction, but its Lan scaffold is still promising if using the wild-type 
leader sequence. At the time of this work, Library 2A with mProc2.8 scaffold was first 
selected for PPI inhibitor selection.  
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Figure 2.9. Continue on next page. 
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Figure 2.9 Summary of MALDI-TOF MS analysis of all samples tested from Library 2A. 
Purified peptides were digested with Glu-C, and treated with IAA or NEM. The two-fold 
dehydrated core peptides are highlighted in green, and the unmodified core peptide 
highlighted in yellow. Alkylated core peptides with two NEM adducts are highlighted in blue. 
a) All 20 samples were fully dehydrated and cyclized as no NEM adduct was observed. * 
indicates sodium adducts. ° represents incompletely digested core peptide fragments that 
were cleaved before residue −7 instead of residue −5 (refer to Figure 2.5). b) The control 
peptide (linear Hit3-3) was obtained by over-expression in the absence of ProcM. The two 
Cys residues in the core peptide were fully alkylated upon NEM treatment. The blue circle 
represents the incompletely digested core peptide (°) with two NEM adducts. 
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Figure 2.10 MALDI tandem MS of all samples tested from Library 2A. They all contain the 
same ring topology (two non-overlaping rings) as mProcA2.8. 
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Figure 2.11  Summary of MS analysis of samples tested from Library 2B and Library 3. a) 
MALDI-TOF MS of purified peptides after digestion with Glu-C (bottom line), and 
alkylation by IAA or NEM (top line). The corresponding core peptide sequence of each 
sample is labeled beneath the figure, the remaining residues from the leader sequence are 
underlined. (* indicates sodium adduct) b) ESI tandem MS of selected library samples to 
investigate the potential ring topology. For sample 2C10-10, the fragment pattern of the 
cyclized peptide with one Glu-C cleavage inside the ring is shown. 
 
 
 
 58 
2.2.4 More than half of the leader peptide is dispensable for ProcM modification 
    Next we moved on to investigate the role of the ProcA leader during the modification 
process, as prochlorosins tend to have unusually large leader sequences compared with other 
lantipeptides. It has been reported that for several RiPPs(61) (e.g. the lantibiotic lacticin 481,(62, 
63) the lasso peptide MccJ25,(64) and cyanobactin biosynthesis(65)) that the N-terminal regions 
of the leader sequence is not required for modifications on the core peptide. Herein I tested 
several ProcA mutants with different lengths of truncated leader sequence, with the aim to 
investigate if the unusually long leader peptide is important for ProcM’s tolerance of diverse 
core peptide sequences. Such leader peptide truncation, if successful, could also minimize 
the nonspecific binding effect contributed by the leader portion to the protein target during 
library selection.  
  A series of ProcA2.8 mutants lacking 30, 40, and 50 N-terminal amino acids (Figure 2.12) 
were co-expressed with ProcM in E. coli. MALDI-TOF MS analysis clearly showed that 
mutants lacking the 30 and 40 N-terminal residues were fully dehydrated by ProcM (Figure 
2.12). The peptides were subsequently digested by Asp-N and subjected to NEM alkylation. 
Compared with the linear control peptides that were expressed in the absence of ProcM and 
that were fully alkylated by NEM on their two free Cys residues, the ProcM-modified 
peptides did not react with NEM (Figure 2.12), indicating that these peptides were fully 
cyclized. Tandem MS analysis confirmed that the correct lanthionine rings of mProcA2.8 
were produced in both truncated substrates (Figure 2.13). Hence, ProcM is able to perform 
catalysis not only on substrates with dramatically varied core sequences but also on mutants 
that are significantly truncated in the leader peptide. Therefore, the possibility that the long 
ProcA leader peptides are correlated with ProcM’s substrate tolerance of highly varied core 
sequences is not supported by this study. Whether ProcM could modify the peptide lacking 
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the 50 N-terminal residues could not be determined because this mutant peptide could not 
be obtained, regardless of whether the peptide was co-expressed with ProcM or not, 
suggesting that a certain minimum length of ProcA2.8 might be necessary for peptide 
stability, at least in E. coli. 
 
Figure 2.12 ProcM modification of truncated ProcA2.8 derivatives. (a) Sequence of 
ProcA2.8 and schematic representation of the truncation variants. The purple arrow shows 
the physiological proteolytic cleavage site for leader peptide removal. The blue arrow shows 
the endoprotease Asp-N site that was used in this study to shorten the peptide and allow 
better analysis of the post-translational modifications on the core peptide. (b) MALDI-TOF 
MS analysis of full-length mProcA2.8-(31−82) that was obtained either by expressing the 
peptide alone (trace i) or by co-expression with ProcM (trace ii). (c) MALDI-TOF MS 
analysis of full-length mProcA-(41−82), presented in the same manner as for mProcA2.8-
(31−82) in panel B. (d) ProcA2.8-(31−82) peptides (unmodified and modified) were digested 
by Asp-N and subsequently treated with NEM. Trace i shows the unmodified peptide before 
NEM alkylation, and trace ii demonstrates complete NEM alkylation of this peptide. Traces 
iii and iv show the ProcM-modified peptide before and after NEM treatment, respectively. 
No derivatization of the modified peptides is observed, strongly suggesting formation of 
lanthionine rings in the ProcM-modified peptide. (e) MALDI-TOF MS analysis of Asp-N-
digested ProcA2.8-(41−82). The data are shown as in panel D. In all of the MS spectral data 
shown, the signals corresponding to the unmodified and the ProcM-modified peptides are 
highlighted in yellow and green, respectively, whereas the NEM-alkylated peptides are 
highlighted in light blue. Some nonhighlighted peaks were derived from proteolysis products 
of the leader peptide and Asp-N. (Figure adopted from Zhang et al.(35)) 
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Figure 2.13 ESI-tandem MS analysis of full-length and truncated mProcA2.8 peptides 
modified by ProcM. Peptides were then treated by Glu-C before MS analysis. The analysis 
indicates that truncated ProcA2.8 peptides have the same ring topology as that of full-length 
mProcA2.8 upon ProcM modification. L, full length mProcA2.8; L-30aa, mProcA2.8(31-82); 
L-40aa, mProcA2.8(41-82). 
 
2.2.5 Engineering compatible vectors for the selection system 
In order to couple the lanthipeptide co-expression system to the selection strains with RNR, 
ATIC or UEV-P6 RTHS integrated into the chromosome, we engineered new compatible 
library vectors. Three criteria are noted here. Firstly, the expression of the repressor fusion 
proteins is regulated under the lac promoter, thus the regulation of the library system requires 
an orthogonal promoter to independently control the expression of the library. The 
arabinose promoter was used due to its tight and tunable regulation of gene expression 
level.(66) Secondly, as the reporter strains are already resistant to ampicillin, kanamycin and 
spectinomycin,(41) I chose the chloramphenicol resistance gene (CmR) as the antibiotic 
marker. Thirdly, a low-copy number vector is desired for tunable library expression level 
starting from low concentration, and the P15A origin of replication (10-12 per cell) was 
chosen as the new vector backbone.(41) 
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   Two different vector systems were constructed. One involves a one-vector system with a 
bicistronic design under the control of the arabinose promoter vector (CmR) derived from 
the pACYCDuet backbone (Figure 2.14). And the second approach uses a two-vector 
system with library substrates and ProcM being expressed from two separate vectors (Figure 
2.14). Both systems were constructed and have been tested by over-expressing ProcA2.8 
with ProcM in E. coli BL21(DE3) and the RNR RTHS strain under high arabinose 
concentration (6.5 mM) in LB medium, which yielded fully cyclized peptides that were 
expressed solubly (Figure 2.15b). The one vector system (vector named as pARDuetXY) was 
also able to produce library sample 2C10S with the same modifications as when produced 
from the pRSFDuet vector (Figure 2.15d). However, the RTHS cells containing the two-
vector system failed to survive on the selection medium possibly due to the stress from the 
two additional antibiotics even when various antibiotic concentrations were tested (as low as 
8 µg/mL chloramphenicol with 4 µg/mL tetracycline). In contrast, cells transformed with 
the one-vector system grew fine in the presence of 35 µg/mL chloramphenicol and still kept 
the IPTG-dependent growth sensitivity. Therefore, the one-vector system (pARDuetXY) 
was selected for further experiments.  
 
Figure 2.14 Library vectors compatible with the RTHS selection strain. a) One vector 
system. For library construction, procM was cloned in MCS2, while library substrates were 
cloned in MCS1 without His6 tags. For modification test, the substrates were cloned 
downstream of the His6 tag for ease of purification. b) Two-vector system. Library 
substrates were cloned into the pAR4 plasmid, while procM was cloned into the pARTet 
plasmid. 
 62 
 
 
Figure 2.15 Modification test for library selection plasmids. Green dashed lines indicate fully 
dehydrated core peptide after Glu-C cleavage (two dehydrations for mProcA2.8, one 
dehydration for 2C10S). * indicates sodium adduct, ° represents incompletely digested core 
peptide fragments that were cleaved before residue −7 instead of residue −5 (refer to Figure 
2.5). a) MALDI-TOF MS shows that co-expression of ProcA2.8 and ProcM from the 
pRSFDuet vector in minimum medium yielded fully modified peptide at expression 
temperature up to 30 °C. Minor species with incomplete dehydrations were observed for the 
sample expressed at 30 °C (orange dashed line). b) MALDI-TOF MS shows that co-
expression from Para vectors at 18 °C under high arabinose concentration (6.5 mM) yielded 
fully modified ProcA2.8 peptide in both the E. coli RNR RTHS strain and BL21(DE3) strain. 
c) MALDI-TOF MS of ProcA2.8 leader truncation derivatives expressed from the 
pARDuetXY vector at high arabinose concentration (6.5 mM) at 18 °C in LB medium. The 
yield dramatically decreased with shorter leader peptide. d) MALDI-TOF MS shows the co-
expression of library sample 2C10S with ProcM with arabinose inducer at 18 °C also yielded 
fully dehydrated and cyclized product.  
 
2.2.6 Optimization for selection 
    In order to determine the optimal length of the leader peptide for selection, truncations of 
the ProcA2.8 leader sequence (removal of N-terminal 20, 30 or 40 amino acids) were 
performed using the pARDuetXY vector. However, little or no product (modified or 
unmodified) was observed with decreased leader peptide length even at high arabinose 
concentration, for reasons unknown (Figure 2.15). Therefore, I still used full-length 
ProcA2.8 leader peptide for library selection. 
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    The next step was temperature optimization: It was found that after transformation of the 
empty library vector, the selection strain could not grow well on selection media at 18 °C 
that was normally used for lanthipeptide production (data not shown). Therefore, I tested if 
the co-expression system could still generate modified lanthipeptide at higher temperature. 
Using ProcA2.8, I could still obtain mostly modified peptide expressed in minimal media at 
25 °C and 30 °C (Figure 2.15). No modifications were observed at 37 °C (data not shown,). 
Since higher temperature is desired for the selection strain to display a selection time window 
where the IPTG-dependent growth difference is sharp (ideally at 37 °C(41)), 30 °C was 
chosen as the selection temperature, which gives 3-4 days of growth inhibition before the 
background colonies start to appear.  
   In addition, the concentration of arabinose inducer is also important. The previously 
recommended concentration for a split-intein mediated library was 13 μM,(41, 44) which failed 
to generate hits for the lanthipeptide library. Therefore, inducer concentration higher than 13 
μM was chosen to increase the intracellular concentration of lanthipeptides in order to 
disrupt, for example, the UEV-P6 interaction (with a dissociation constant of 50 μM(49)).  I 
tested 65 μM, 130 μM and 330 μM arabinose in the UEV-P6 selection strain. However, 
significantly decreased cell growth on selection media was observed likely due to the 
expression burden of ProcM under increased inducer concentration (discussed in section 
2.3). Since the selection is based on the critical growth advantage in the presence of a hit 
molecule, it is not desired that expressing the hit itself dramatically slows down the cell 
growth. Therefore, as a balance between expression level and burden, 65 μM was used as 
arabinose inducer concentration. Indeed, I was not able to observe survival colonies within 
the selection time window at higher arabinose concentrations due to the significant delay of 
cell growth. 
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2.2.7 Library selection 
To construct the library plasmids for selection, a new forward primer was designed so that 
the N-terminal His6-tag was removed. The library PCR products were digested and ligated 
into MCS1 of the pARDuetXY vector with the gene encoding ProcM in MCS2. After 
electroporation of the ligation product into commercial E. coli (DH5α) competent cells, we 
obtained approximately 106 colonies calculated by dilution plating. The selection strain was 
transformed with the isolated plasmids from this library (105-106 transformants, the 
transformation efficiency was limited by the size of the plasmid) and plated onto histidine-
free minimal medium A at a density of 105 cells per plate (150 mm × 25 mm). The plates 
were incubated at 32 °C for two to four days until colonies were readily visible. 
Approximately 80 colonies that grew faster than the background colonies were picked and 
screened for IPTG-dependent growth inhibition and arabinose-dependent growth advantage 
in order to eliminate false positives (Figure 2.16). The expected phenotype was further 
confirmed by extracting and re-transforming the UEV-P6 selection strain with the selected 
plasmids (Figure 2.17). In order to eliminate non-specific inhibition, a different RTHS 
selection strain was also transformed with the plasmid and colonies exhibiting arabinose-
induced growth advantage only in the UEV-P6 strain were selected (Figure 2.17). After 
several rounds of screening, we identified two hits (2-5 and 3-3) that potentially inhibit the 
UEV-p6 interaction (Table 2.2). 
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Figure 2.16 Drop-spot assay of the colonies selected from the primary selection. Each 
colony was cultured in LB medium overnight and spotted as serial dilutions (with each drop 
containing from 106 to 103 colonies as shown in the figure) onto minimal medium in the 
presence or absence of IPTG or arabinose (ara). IPTG-dependent inhibition was evaluated 
by comparing the growth difference on each dilution level between plate a and b (or plate c 
and d), while arabinose-dependent growth advantage was evaluated by comparing the 
growth difference on each dilution level between plate b and d. Samples are labeled as 
column number followed by row number, and only those that displayed both IPTG-
dependent inhibition and arabinose-dependent growth advantage were selected as potential 
positive hits, such as Hit 2-5 and Hit 3-3 that are highlighted in red. 
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Figure 2.17 Drop-spot assay of the plasmids isolated from the second selection. The 
plasmids (from Figure 2.16) were used to re-transform the UEV-P6 strain (highlighted in 
orange frame) and another heterodimeric RTHS system (CMG2-PA, highlighted in blue 
frame). The drop spot assay showed that the UEV-P6 cells transformed with hit 2-5 and 3-3 
still exhibit arabinose-dependent activity by comparing the growth difference at each dilution 
level between plate b with plates d and f, while the corresponding CMG2-PA cells did not. 
This phenotype implied the specific inhibition of the UEV-P6 interaction. Plasmid 1-1, 1-2, 
1-3, 1-4, 3-1 and neg ProcM (only ProcM in pARDuetXY without a substrate insert) were 
used as negative controls. 
 
2.2.8 In vi tro  characterization of hit peptides generated from the genetic selection 
Plasmids isolated from hit 2-5 and hit 3-3 were sequenced and the results are listed in Table 
2.2. Interestingly, although hit 2-5 exhibited a stronger arabinose-dependent growth 
advantage than hit 3-3, the sequencing result indicated that this plasmid underwent 
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unexpected mutations where the entire MCS1 sequence was deleted and the actual open 
reading frame (ORF) is a N-terminally truncated ProcM. The hit 3-3 contains a normal 
library substrate in MCS1 with intact procM in MCS2.  
 
Table 2.2 Sequencing result of plasmid isolated from Hit2-5 and 3-3 
 Peptide sequence (ORF in MCS1) ProcM sequence (ORF in MCS2) 
Hit 3-3 
MGSEEQLKAFLTKVQADTSLQEQLKIEGADV
VAIAKAAGFSITTEDLNSHRQNLSDDELEGVA
GGAACLHFFLSMPPSHVLDIC 
Full-length ProcM (1-1069) 
Hit 2-5 NA (MCS1 was deleted) ProcM (residue 273-1069) 
 
   For large-scale overexpression of the 3-3 peptide, the substrate sequence was cloned into a 
pRSFDuet vector containing procM in MCS2, and the resulting His6-tagged peptide was co-
expressed in E. coli BL21(DE3) at 18 °C, which yielded completely dehydrated and cyclized 
peptide as characterized in Figure 2.10 and 2.11. 
   In vitro ELISA assay performed by the Tavassoli lab confirmed the ability of peptide 3-3 to 
disrupt the UEV-P6 interaction with an IC50 of 2.6 μM (Figure 2.19a), which is 4.5-fold less 
than the linear 3-3 peptide (expressed without ProcM, Figure 2.19b), indicating the 
importance of lanthionine ring formation. In contrast, linear or cyclized ProcA2.8 (Figure 
2.18c, d) did not exhibit significant inhibition at this concentration, which suggests that the 
library scaffold itself was not the major contribution to the activity. Interestingly, the core 
peptide of peptide 3-3, regardless of cyclization, did not exhibit any activity, indicating a 
combined effect from both the leader sequence and the core peptide. Overall, these data 
shows that an active cyclic lanthipeptide could be successfully evolved from an originally 
inactive scaffold under defined selection pressure.  
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Figure 2.18 ELISA of the UEV-P6 interaction. a) Cyclic Hit 3-3 (including its leader 
sequence) disrupts the UEV-P6 interaction with an IC50 of 2.6 ± 0.1 µM. d) Linear Hit 3.3 
(including its leader sequence) disrupts the UEV-P6 interaction with an IC50 of 11.8 ± 2.0 
µM. c) Cyclic mProcA2.8 does not inhibit the UEV-P6 interaction. d) Linear ProcA2.8 
(including its leader sequence) does not inhibit the UEV-P6 interaction. e) Cyclic Hit 3.3 
core peptide after Glu-C digestion has no effect on the targeted interaction. f) Linear Hit3.3 
core peptide after Glu-C digestion has no effect on the targeted interaction. Data collected 
by Tavassoli and coworkers. 
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2.3 SUMMARY AND OUTLOOK  
We developed a co-expression strategy where the linear substrate peptides and the 
synthetase were over-expressed in E. coli, which was applied in the combinatorial 
biosynthesis of several cyclic lanthipeptide libraries. The successful library production 
satisfied the three key points as mentioned in section 2.1: 1) Enzyme promiscuity: ProcM 
was selected as the synthetase based on its tolerance for 30 native substrates as well as 
bioinformatic studies; 2) Host cell self-immunity: the LanT protein responsible for secretion 
and leader peptide removal was intentionally omitted from the biosynthetic machinery in 
order to accumulate non-toxic, modified lanthipeptides with the leader sequence attached 
inside E. coli cells. 3) Library design: since the sequence of the substrates in part determines 
the final outcome of the products, as discussed in Chapter 1, providing ProcM with certain 
fixed ring scaffolds rather than fully randomized substrates greatly increased the efficiency 
and homogeneity of ring formation. 
   Specifically, I was able to show that ProcM does not only act on its 30 native substrates, 
but also catalyzes the formation of thioether rings on unnatural substrates, as various 
randomized peptide sequences attached to the conserved leader sequence of ProcA could be 
dehydrated and cyclized to different extent, including the complete enzymatic formation of a 
fourteen residue lanthionine ring. Modification of these non-native substrates demonstrated 
the catalytic promiscuity of ProcM, and the peptides (e.g. 2C10 and 2C10S) could be 
potentially used for co-crystalization with ProcM in order to investigate the conformational 
arragement of substrate in the enzyme active sites. 
   Remarkably, ProcM was able to catalyze complete dehydration and cyclization on all 20 
tested substrates in one library that was designed to contain a fixed ring scaffold derived 
from the mProcA2.8 structure. Using this library for genetic selection of protein-protein 
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interaction inhibitors successfully yielded a hit peptide that is able to disrupt the UEV-p6 
complex formation as confirmed in vitro. The observed activity is likely contributed by a 
combination of both the leader sequence and the rings in the core peptide. To the best of 
my knowledge this work is the first successful application of using the cyclic scaffold derived 
from natural products to select for PPI inhibitors. 
   Further in vitro characterization involves identifying the binding partner of Hit 3-3 using 
ITC or fluorescence polarization, and potentially co-crystallization of the complex. In order 
to investigate the critical sequence responsible for binding and also minimize the length of 
the peptide before testing its inhibition activity of virus release in mammalian cells,(44) 
truncations of Hit 3-3 was carried out by cleaving the cyclized peptide with Arg-C, Lys-C or 
Glu-C, and the modified core peptides attached to various length of the leader sequence 
were purified. These peptides were sent to the Tavassoli lab and their inhibition of the UEV-
p6 interaction will be tested in vitro. 
   For library selection, modifications of the ProcM-ProcA co-expression system is required. 
Two critical factors for successful genetic selection are emphasized here: First, sufficient 
library size, as the chance of identifying a true hit based on the RTHS selection is 1 out of 
105-107 library members.(41) Although the theoretical size of the lanthipeptide library is larger 
than this number (e.g. 109 different peptide sequences in library 2A), the actual library size in 
the genetic selection was limited by the transformation efficiency of the selection strain with 
the library plasmids. While 108 library size was observed for the split-intein mediated cyclic 
peptide libraries,(41) my lanthipeptide libraries only achieved a maximum of 105-106. The large 
plasmid size (7.9 kb for libraries in the pARDuetXY vector) is the major problem, as 
transformation efficiency decreases with increased vector size. For example, an efficiency of 
106-107 colony forming unites (cfu) could be obtained with library substrates in the pAR4 
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vector (3.6 kb) with the same RTHS strain. Therefore, it is desired to reduce the 
pARDuetXY plasmid size by, for example, removing the procM gene which is 3.2 kb 
(discussed below). 
  The second key point in genetic selection is the relative concentration level between the 
protein targets and the library compounds being expressed. As sufficient intracellular 
concentration of library compounds is needed to disrupt a targeted protein complex with 
certain binding affinity, it is important to maintain enough room for concentration 
adjustment against different targets, especially those with a tighter binding interaction than 
UEV-p6 (50 μM Kd(49)). For example, 1.3 mM arabinose concentration was used for a split-
intein mediated cyclic peptide library to select for inhibitors against HIV protease 
dimerization (nanomolar Kd
(67)).(43) However, as mentioned above, induction of the library in 
pARDuetXY vector under high dose arabinose concentration failed to generate any hits due 
to the significant delay in cell growth, which was likely contributed by the burden in 
expressing ProcM. Support of this hypothesis was found in Figure 2.18, by comparing the 
growth difference of the negative ProcM control in plate b with plates d and f. It clearly 
showed that expressing ProcM itself slows down the cell growth. Therefore, one solution is 
to remove the procM gene from the library vector and integrate it as single or double copies 
into the chromosome of the selection strains (and perhaps behind a constitutive promoter), 
while the expression level of the substrate peptides could still be adjusted by vector copy 
number and/or arabinose concentration. This solution also significantly reduces the vector 
size from 7.9 kb to 4.7 kb, which could solve the transformation efficiency problem 
mentioned above. 
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2.4 MATERIALS AND METHODS 
2.4.1 Materials 
All chemicals used were purchased from Sigma Aldrich or Fisher Scientific unless noted 
otherwise. Endoproteinases (Glu-C, Lys-C, Asp-N) were purchased from Roche Applied 
Science. Oligonucleotide primers used for molecular cloning and library construction were 
purchased from Integrated DNA Technologies. Phusion High-Fidelity DNA polymerase, 
Taq ligase, dNTP solutions, T4 DNA ligase and all restriction endonucleases were purchased 
from New England Biolabs. Gel extraction, plasmid miniprep, and PCR purification kits 
were purchased from QIAGEN. Protein Calibration Standard I and Peptide Calibration 
Standard II for MALDI-TOF MS were purchased from Bruker. The pAR3 vector was 
purchased from American Type Culture Collection (No. 87026). The pBAD/HisA vector 
was purchased from Invitrogen. E. coli DH5α was used as host for cloning and plasmid 
propagation, and E. coli BL21 (DE3) was used as a host for overexpression. The RTHS 
strains containing RNR or ATIC interaction dimers were obtained from Prof. Benkovic 
from the Pennsylvania State University, while the RTHS strains containing UEV-p6 or 
CMG2-PA interaction dimers were obtained from Prof. Tavassoli from the University of 
Southampton. pET plasmids containing procA2.8, procA1.1 or procM were obtained from Dr. 
Yanxiang Shi. Derivatized lanthionine standards (DD, DL and LL) were obtained from Dr. 
Weixin Tang. 
 
2.4.2 General methods 
For lanthipeptide residue labeling, positive residue numbers are used for amino acids in the 
core peptide counting forwards from the (putative) leader peptide cleavage site. Negative 
residue numbers are used for amino acids in the leader peptide counting backwards from the 
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leader peptide cleavage site. i.e. in ProcA2.8, the C-terminal Gly residue of the leader 
sequence is −1, and when substituted by Lys the mutant is denoted as G-1K. Polymerase 
chain reaction (PCR) amplifications were carried out using an automated thermocycler 
(C1000, BioRAD). DNA sequencing was performed using appropriate primers by ACGT 
Inc. LC-ESI-Q/TOF MS analyses were conducted using a Synapt MS system equipped with 
an Acquity Ultra Performance Liquid Chromatography (UPLC) system (Waters). Matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) 
analyses were conducted at the Mass Spectrometry Facility in UIUC using an UltrafleXtreme 
spectrometer (Bruker Daltonics). For MALDI-TOF MS analysis, samples were desalted 
using ZipTipC18 (Millipore), and spotted with a matrix solution containing 35 mg/mL 2,5-
dihydroxybenzoic acid (DHB) in 3:2 MeCN/H2O with 0.1% TFA onto a MALDI target 
plate. Peptides were desalted by C4 solid-phase extraction (SPE) column and further purified 
by preparative reversed-phase high performance liquid chromatography (RP-HPLC) on a 
Delta 600 instrument (Waters) equipped with a Phenomenex C18 column at a flow rate of 8 
mL/min. For RP-HPLC, solvent A was 0.1% TFA in H2O and solvent B was 4:1 
MeCN/H2O containing 0.086% TFA. An elution gradient from 0% solvent B to 74% 
solvent B over 40 min was used unless specified below. 
 
2.4.3 Plasmid construction for co-expression of ProcA2.8 mutants with ProcM 
A pET15b-derived plasmid containing procA2.8 was used as template for PCR amplification 
of procA2.8 and procA2.8 mutants with truncated leader peptide. A pET28b-derived plasmid 
containing procM was used as template for PCR amplification of procM.(23) PCR primers 
(Table 2.3) were designed with EcoRI and NotI restriction sites in the 5’- and 3’- ends of 
procA variant genes, and with NdeI and KpnI restriction sites in the 5’- and 3’- ends of procM. 
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The procM PCR-amplified products were digested with NdeI and KpnI and inserted into the 
MCS2 of pRSFDuet-1 vector, and the procA PCR-amplified products were digested with 
EcoRI and NotI, and inserted into the MCS1 of the plasmid resulting from the previous step. 
For the control construct without procM in MCS2, the corresponding co-expression vector 
was digested by XhoI to remove most of the procM sequence. The resulting vector fragment 
was re-ligated using T4 DNA ligase. Chemically competent E. coli DH5α cells were 
transformed with each ligation mixture and plated on LB-agar containing kanamycin (50 
mg/L) to screen for positive clones. Plasmid containing procA2.8 (G−1K) was obtained by 
site-directed mutagenesis. 
 
2.4.4 Construction of lanthipeptide library in pRSFDuet-1 
    Library primers (Table 2.3) were designed that added an EcoRI restriction site to the 5' end 
and a NotI restriction site to the 3' end. The reverse primers containing degenerate codons 
were synthesized by IDT using hand-mixed bases and purified by PAGE. (We noted a bias 
in DNA composition if the randomized region of the reverse primers were synthesized using 
machine-mixed bases.) The pRSFDUET-1 containing the procA2.8G−1K leader sequence 
was used as template for PCR amplification of Library 1. pRSFDUET-1 containing procA2.8 
was used as template for PCR amplification of Library 2A. pRSFDUET-1 containing 
procA1.1(G−1E) was used as template for PCR amplification of Library 2B. pRSFDUET-1 
vector containing 2C10S(K−1G) was used as template for PCR amplification of Library 3. 
PCR was carried out using Phusion polymerase by 24 cycles of denaturing (94 °C for 30 s), 
annealing (67 °C for 30 s) and extending (72 °C for 20 s). 
   The PCR products (appearing as a strong band between 250-300 bp) were gel-purified, 
digested with EcoRI and NotI restriction enzymes and purified using a Qiagen PCR 
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purification kit. For construction of Library2B, it was observed that a second PCR step using 
the same forward primer and a normal reverse “zip” primer (Table 2.3) that overlaps with 
the 3’- nondegenerate sequence of the library primer is required, in order to make sure all 
PCR products were properly annealed for downstream digestion and ligation(58) (otherwise 
few ligation colonies was observed, which only happened in the case of Library 2B for 
reasons unknown).  
   The pRSFDuet-1 vector with procM inserted into MCS2 was used for library vector 
construction, the vector was digested with the same restriction enzymes as the PCR products 
and an additional enzyme SbfI to minimize vector self-ligation, dephosphorylated with 
alkaline phosphatase and gel-purified. The digested vector (5 × 50 ng each) was ligated with 
the insert DNA by T4 ligase at a molecular ratio of 1:6 (vector : insert) in five tubes, and the 
reactions were incubated at 15 °C overnight. Each ligation mixture was diluted with 10 
volumes of cold butanol, centrifuged at 20,000 g for 5 min, and the supernatant was 
removed by careful pipetting. The salt-free pelleted DNA was carefully resuspend in 5 μL of 
H2O and used to transform electrocompetent E. coli DH5α cells (NEB). After recovery in 1 
mL of SOC (super optimal broth with catabolite repression) medium (for each 
transformation) for 1 h, 5 μL of the combined culture was plated as serial dilutions on LB-
agar containing kanamycin (50 mg/L) to calculate the library size. The rest of the recovery 
culture was diluted in 10-fold volume of LB containing kanamycin (50 mg/L) and the library 
plasmids were isolated after overnight incubation at 37 °C.  
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Table 2.3 Primers used for library construction (5’-3’) 
Lib2A_2.8_EcoRI_FP AGC CAG GAT CCG AAT TCG ATG TCA GAA GAG CAA 
CTG AAG GCA TTC CTC AC 
Lib2B_1.1_EcoRI_FP GGT CGG AAT TCG ATG TCA GAA GAA CAA CTC AAG GCA TTC ATT GC 
Lib1A_DNY_NotI_FP 
TAA ATA TTG CGG CCG CTT ARN HRN HRN HRN HRN 
HRN HRN HRN HRN HRN HRN HRN HRN HRN HRN HRN 
HRN HRN HRN HRN HTC CCC CAG CCA CAC CTT CCA G 
Lib1C_HDY_NotI_FP 
TAA ATA TTG CGG CCG CTT ARH DRH DRH DRH DRH 
DRH DRH DRH DRH DRH DRH DRH DRH DRH DRH DRH 
DRH DRH DRH DRH DTC CCC CAG CCA CAC CTT CCA G 
Lib2A_2.8NWY_NotI_RP 
TAA ATA TTG CGG CCG CTT AGC ARW NRW NRW NRW 
NGG ATG GAG GCA TAG ARW NRW NRW NRW NRW 
NAC AGG CCG CTC CCC CAG CCA CAC 
Lib2A_2.8NWY_KpnI_RP 
ATA TTG GTA CCT TAG CAR WNR WNR WNR WNR WNG 
GAT GGA GGC ATA GAR WNR WNR WNR WNR WNA 
CAG GCC GCT CCC CCA GCC ACA C  
Lib2B_1.1G-1E_NWY_ 
NotI_RP 
TAA ATA TTG CGG CCG CTT AGC ARW NRW NRW NAG 
TAA AAC GGT TAG CAG TRW NRW NRW NAC AGA AAA 
ACT CCC CAG CCA CAC CTT CC 
Lib3_2C10S_VWK_NotI_RP 
TAA ATA TTG CGG CCG CTT AGT AGC A W BMW BMW 
BMW BMW BMW BMW BMW BMW BMW BMW BAC TGT 
TGT AGT GAT GGT ATC CCC CAG CC 
Lib2A_2.8_NcoI_FP ACG ACC ACC GTC CAT GGG CAT GTC AGA AGA GCA ACT GAA GG 
Lib2B_1.1_NcoI_FP GAG CGG TCC ATG GGC TCA GAA GAA CAA CTC AAG 
GCA TTC 
Lib2B_1.1_NotIzip_RP CGA CTA CCA CGT ACT AAA TAT TGC GGC CGC TTA 
GCA 
Libseq_NotI_RP ACT TAA GCA TTA TGC GGC CGC TTA 
2.8ThrombinCys_EcoRI_FP CAC AGC CAG GAT CCG AAT TCG CTG GTT CCG CGT 
GGA TGT TCA GAA GAG CAA CTG AAG GC 
 
2.4.5 Construction of library vectors compatible with the selection strain 
    For the two-vector system, the pAR3 vector was selected to be the peptide expression 
vector. In order to minimize the redundant N-terminal amino acids encoded by the vector, 
the NcoI site was selected as the digestion site for library substrates since it is most adjacent 
to the start codon. The original pAR3 vector has another NcoI site in the backbone. 
Therefore, this undesired NcoI site was deleted by site-directed mutagenesis (primer 
QCpAR4 sequences are listed in Table 2.4) to generate a unique NcoI in the multiple cloning 
site. The new vector was designated as pAR4.(41)  
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    The pRSFDuet-1 vector was engineered as the procM expression vector. pBR322T vector 
was used as template for PCR amplification of the tetracycline resistance gene. The PCR 
products were digested with AgeI and SphI, then ligated into pRSFDUET-1 vector digested 
with the same enzymes to create pRSF-Tet. The pAR3 vector was used as template for PCR 
amplification of the araC and arabinose promoter sequence (arapAR3_RSFT primer pair). 
The PCR products were digested with XbaI and NdeI, and then ligated into pRSF-Tet vector 
digested with the same restriction enzymes, thus generating pARTet. Electrocompetent E. 
coli DH5α cells were transformed with the ligation mixture and plated on LB-agar containing 
tetracycline (12.5 mg/L) to screen for positive clones.   
   The dual-arabinose promoter vector pARDuetXY was constructed on the pACYCDuet-1 
backbone (primer listed in Table 2.4). pBAD/HisA plasmid was used as template for PCR 
amplification of the araC and Para region (primers: araC_pBADHis_NarI and 
araC_pBADHis_NcoI). The PCR products were digested with NarI and NcoI and ligated 
into digested pACYCDuet-1 vector, which replaced the lacI and T7 promoter in MCS-1. 
Next, the Para sequence was PCR-amplified from pBAD/HisA (primers: 
araC_pBADHis_BsrGI and araC_pBADHis_NdeI), digested with BsrGI and NdeI, and 
cloned into the resulting vector, which replaced the T7 promoter in MCS-2. Finally, the 
terminator sequence from pBAD/HisA was PCR-amplified (primers: araTer_XhoI and 
araTer_Bsu36I), digested with XhoI and Bsu36I and cloned into the resulting vector, giving 
the empty library vector named pARDuetXY. 
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Table 2.4 Primer sequences for vector construction (5’-3’) 
QCpAR4-5’ CTT CGC CCC CGT TTT CAC TAT GGG CAA ATA TTA TAC 
QCpAR4-3’ GTA TAA TAT TTG CCC ATA GTG AAA ACG GGG GCG AAG 
TetpBR322_RSF_AgeI-5’ ACG ATG ATA ACC GGT CTT CCA TTC AGG TCG AGG TG 
TetpBR322_RSF_SphI-3’ AGC TAA CTG GCA TGC ATG GAG AGC TCA TGT TTG AC 
arapAR3_RSFT_XbaI-5’ AGT AGC TCT AGA TTC GAA TAG TTA CGG CTT ATG 
arapAR3_RSFT_NdeI-3’ ATA AAT TCC ATA TGC CAT GGT CTT ACT CCA TCC 
araC_pBADHis_NarI-5’ ATT TAT AGG CGC CAG CGG CAT GCA TAA TGT G 
araC_pBADHis_NcoI-3’ TAG GTC CAT GGT TAA TTC CTC CTG TTA GCC C 
Para_pBADHis_BsrGI-5’ TCG GCA CTG TAC AAA GAA ACC AAT TGT CCA TAT TGC 
Para_pBADHis_NdeI-3’ ATG CCG CAT ATG TTA ATT CCT CCT GTT AGC CC 
araTer_XhoI-5’ ATC CTC GAG TAA TTA AGC TGT TTT GGC GG 
araTer_Bsu36I-3’ AAT ATT CCT GAG GAT AAA ACG AAA GGC CCA GTC 
pMQC_1t2577c_FP GAC TTT TGG GCT TCT CCC ACG GAA CAG CTG G 
pMQC_1t2577c_RP CCA GCT GTT CCG TGG GAG AAG CCC AAA AGT C 
pMQC_2t2775c_FP TGG CTA GCT GGT GCC ACG GTG CCC CG 
pMQC_2t2775c_RP CGG GGC ACC GTG GCA CCA GCT AGC CA 
 
2.4.6 Construction of lanthipeptide libraries in pARDuetXY and pAR4 vector 
   The actual libraries for genetic selection do not require the N-terminal His6-tag. Therefore, 
new forward library primers were designed that added an NcoI restriction site (closest to the 
start codon to eliminate the unnecessary N-terminal residues) at the 5’ end (Table 2.3). The 
reverse Library primers remained the same as before. ProcM was cloned into the MCS-2 of 
pARDuetXY between NdeI and KpnI as described previously. The two NcoI cut sites inside 
the procM gene were deleted by silent mutations via site-directed mutagenesis (pMQC 
primers listed in Table 2.4), resulting in library vector ProcM(t2577c/t2775c)_pARDuetXY. 
   Library 1, 2A, 2B and 3 were cloned into ProcM(t2577c/t2775c)_pARDuetXY as 
described previously, except that NcoI and NotI were used as the restriction sites. Lib2A and 
Lib2B were also cloned into pAR4 vector, using NcoI and KpnI as the restriction sites. 
Library plasmids were eluted in water for maximum electroporation efficiency in the next 
step.  
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2.4.7 Library selection in the UEV-P6 RTHS strain  
   Each selection plate (150 mm diameter × 25 mm) contained 40 mL of minimal medium 
A(68) supplemented with 25 mg/L kanamycin, 2.5 mM 3-AT (3-amino-1,2,4-triazole), 30 
mg/L carbenicillin, 25 mg/L spectinomycin, 35 mg/L chloramphenicol, 1 mM MgSO4, 65 
μM arabinose, 30 μM IPTG, 2% glycerol and 1.5% agar. A negative control plate was also 
made that omitted IPTG. The plates were pre-warmed at 30-33 °C.   
   UEV-p6 RTHS cells (derived from BW27786(69)) were cultured overnight in LB medium 
containing 30 mg/L carbenicillin and 25 mg/L spectinomycin, an aliquot of 1 mL cell 
culture was inoculated into 100 mL of the same medium and the cells were grown until 
OD600 reached 0.5. The cells were quickly chilled in an ice-water bath and incubated on ice 
for 40 min before harvesting (3000 rpm, 15 min, 2 °C). The supernatant was discarded and 
the cell pellets were gently resuspended in 20 mL of ice-cold 10% glycerol and harvested 
again. The washing step was repeated two more times and the resulting electro-competent 
cell pellets were resuspended with a final total volume of 200-250 μL and split into four 
tubes. These freshly made competent cells were transformed (1 mm cuvette, 1.8 kV) with 
the library plasmids (4 × 25 ng), and 0.5 mL of SOC medium pre-warmed at 37 °C was 
immediately added into each transformation. After recovery for one hour at 37 °C, the 
culture was centrifuged (10,000 g, 30 s) and the supernatant discarded by pipetting. An 
aliquot of 0.5 mL of minimal medium A was added into each reaction and the cell pellets 
were thoroughly resuspended by gentle vortexing and slow pipetting. An aliquot of 5 μL of 
the combined culture was plated as serial dilutions on LB-agar containing chloramphenicol 
(35 mg/L) to calculate the library size. And the rest of the culture was evenly spread onto the 
selection plates until all liquid was completely absorbed into the plates.  
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   The selection plates were sealed with parafilm and incubated at 30-33 °C for 2-4 days. The 
growth was compared with cells on the control plate without IPTG, and a growth delay was 
observed on plates with IPTG during this time window. Visible colonies started to show up 
starting on the second day, and normally around the fourth day all background colonies 
started to grow back due to IPTG degradation or antibiotic resistance. 
 
2.4.8 Second selection to eliminate false positives  
The identified colonies that exhibited faster growth than the background colonies were 
inoculated into a 96-well culture plate with 1 mL of LB medium containing 30 mg/L 
carbenicillin, 25 mg/L spectinomycin and 35 mg/L chloramphenicol in each well and 
incubated with constant shaking at 37 °C overnight. Using a multi-channel pipette, each 
culture was sequentially diluted four times (10-fold each time) into minimal medium A.  
   Four sets of plates were made from identical selection medium as described previously, but 
in the absence or presence of IPTG or arabinose. Then 2.5 μL of each dilution culture 
(containing roughly 106, 105, 104 and 103 cells) from each sample were drop-spotted onto 
each plate. The plates were sealed with parafilm and incubated at 30-33 °C for 2-3 days. 
Growth difference was monitored by comparing the samples on the four plates at each 
dilution level, and only those colonies exhibiting both IPTG-dependent inhibition and 
arabinose-dependent growth advantage were selected.  
 
2.4.9 Third selection for plasmid confirmation 
The plasmids were isolated from the hits as well as several negative control colonies 
identified from the second selection. The UEV-p6 strain and another heterodimeric RTHS 
strain (CMG2-PA) were transformed with the plasmids to confirm the specificity of the 
 81 
observed arabinose-dependent growth advantage. Each culture was sequentially diluted and 
drop-spotted onto the same four sets of selection plates with or without IPTG or arabinose 
as described above. The plasmids of the resulting true hits were sent for sequencing. For Hit 
3-3, the peptide sequence was PCR-amplified using the forward Library primer (for 
pRSFDuet vector) and Libseq_NotI_reverse primer (Table 2.3), and cloned between the EcoRI 
and NotI restriction sites in MCS1 of the pRSFDuet vector containing procM in MCS2.   
 
2.4.10 Over-expression of modified ProcA derivatives in E. co l i  
In order to obtain modified ProcA derivatives, E. coli BL21 (DE3) cells were transformed 
with the above-mentioned pRSFDuet derivatives containing His6-tagged procAs and procM 
genes. The cell culture (0.5-2 L) was induced with 0.25 mM IPTG at OD600 between 0.6-0.8, 
and incubated at 18 °C for 18-20 h. For over-expression using the arabinose-promoter 
library vector, 13 μM to 6.5 mM arabinose concentration was used and the cells were 
incubated in minimal medium A or LB culture containing the appropriate antibiotics at the 
temperature specified in the main text. 
 
2.4.11 Overexpression of His6-UEV and GST-p6 
The pET28a plasmid containing UEV between NdeI and XhoI restriction sites and the 
pGEX-2TK plasmid with p6 between BamHI and EcoRI restriction sites (resulting in GST-
tagged p6) were obtained from the Tavassoli lab. The p6 insert was then cloned into the 
MCS1 of pRSFDuet-1 between EcoRI and NotI restriction sites for His6-tag labeling. E.coli 
BL21 (DE3) cells were transformed with the plasmids, induced with 0.25 mM IPTG and the 
proteins expressed at 18 °C for 18-20 h.  
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2.4.12 Purification of His6-tagged ProcA derivatives and His6-tagged p6 peptide 
After harvesting, the pellet was resuspended at 0.1 g/mL in LanA Start Buffer (20 mM 
NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol, pH=7.5). The cell paste was 
subjected to sonication to lyse the cells. Insoluble cell debris was removed by centrifugation 
at 16,500 × g for 45 min. The supernatant was purified by immobilized metal affinity 
chromatography (IMAC) using 2-4 mL of His60 Ni Superflow Resin (Clontech). Following 
1 h incubation at room temperature, the resin was washed with wash buffer (Start Buffer + 
30 mM imidazole), and the peptide was eluted from the resin using elution buffer (start 
buffer + 4 M guanidine hydrochloride + 0.5 M imidazole). The elution fractions were 
desalted by C4 SPE column and purified on a C18 column using the solvent gradient 
described in the General Methods.  
 
2.4.13 Purification of His6-UEV and GST-p6 
All protein purification steps were performed at 4 °C or on ice. After harvesting, the cell 
pellets were suspended at 0.1 g/mL in LanM Buffer A (20 mM HEPES, 0.25 M NaCl, 10% 
glycerol, pH 7.4), and the cells were lysed using a high-pressure homogenizer (Avestin, Inc.). 
Insoluble cell debris was pelleted via centrifugation at 16,500 × g for 45 min at 4 °C. The 
supernatant was filtered using 0.45 μm syringe filters. For His6-UEV, the supernatant was 
loaded onto a 5 mL HisTrap IMAC column pre-charged with Ni2+ and equilibrated in Buffer 
A. The column was washed with 20 mL of Buffer A, then loaded onto an ÄKTA fast 
protein liquid chromatography (FPLC) system (GE Healthcare). The column was further 
washed with a gradient of 0-25% LanM Buffer B (200 mM imidazole, 20 mM HEPES, 0.25 
M NaCl, 10% glycerol, pH 7.4) in buffer A for four column volumes at a flow rate of 1 
mL/min, then the protein was eluted using a gradient of 25-100% Buffer B. UV absorbance 
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at 280 nm was monitored and fractions were collected and analyzed by SDS-PAGE. For 
GST-p6, the filtered supernant after cell lysis was loaded onto a 5 mL GSTrap column pre-
equilibrated in LanM Buffer A at a flow rate of 1 mL/min. The column was washed with 20 
mL of LanM Buffer A, and the GST-p6 was eluted with 10 mL of GST Elution buffer (50 
mM HEPES, 0.25 M NaCl, 25 mM reduced glutathione, pH 7.4) at a flow rate of 1 mL/min. 
The fractions containing the desired protein were combined and concentrated using an 
Amicon Ultra-15 Centrifugal Filter Unit (10 kDa MWCO, Millipore, 2,300 x g). The buffer 
was then exchanged to FP Buffer (50 mM HEPES, 0.2 M NaCl, pH=7.4) using a PD10 
desalting column (GE Healthcare). His6-UEV was obtained with a yield of 40 mg per liter of 
cell culture, and GST-p6 was obtained with a yield of 25 mg per liter cell of culture. Protein 
aliquots were flash-frozen in liquid nitrogen and stored at −80 °C.  
 
2.4.14 Endoproteinase digestion of unmodified or modified peptides 
For peptides prepared during E. coli co-expression, the majority of the leader peptide needs 
to be removed in order to accurately characterize the dehydrations in the core peptide by 
MS. ProcA2.8 derivatives with truncated leader sequence were digested by Asp-N, library 
samples were digested with Glu-C or Lys-C, and the cyclized hit 3-3 was digested with Glu-
C to obtain the core peptide, or with Arg-C or Lys-C for core peptides with different leader 
length. The proteolysis reaction also contained 0.5 mM TCEP to reduce possible disulfide 
bonds in the core peptide. In contrast, when digesting unmodified ProcA2.8 and linear hit 3-
3 by Glu-C, oxidative disulfide bond formation was performed in order to protect the Glu 
and Asp residues in the core peptide sequence from Glu-C cleavage. The linear peptide (150 
μM) was treated with 5 mM each of reduced and oxidized glutathione in 50 mM HEPES 
buffer for 1 h at room temperature, before Glu-C was added. Purification of the digested 
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core peptide sequence was carried out by RP-HPLC on an analytical Phenomenex C18 
column, using the gradient described in the General Methods. 
 
 
2.4.15 N-Ethylmaleimide (NEM) or iodoacetamide (IAA) alkylation assay  
An aliquot of the protease-digested peptide reaction or full-length peptide solution was 
diluted into twice the volume of NEM alkylation buffer containing 500 mM HEPES, 3 mM 
NEM, 0.3 mM Tris(2-carboxyethyl)phosphine) (TCEP) as reducing agent, pH 6.5, or IAA 
alkylation buffer containing 500 mM HEPES, 3 mM IAA, 0.3 mM TCEP, pH 8.0. The 
reaction was incubated at 37 °C for 30 min (for NEM alkylation) or at room temperature for 
1-2 h (for IAA alkylation) in the dark, and analyzed by MALDI-TOF MS. Species containing 
uncyclized free Cys residues that were alkylated were identified by a mass increase of 125 Da 
(for NEM) or 57 Da (for IAA) for each adduct.   
 
2.4.16 HCl hydrolysis of lanthipeptides and derivatization of lanthionine residues 
A sample of around 0.1 mg of purified peptide was hydrolyzed by treatment with 2 mL of 6 
N HCl and heating to 120 °C for 24 h in a sealed tube. The hydrolysate was dried under N2. 
Methanol (5 mL) was cooled in an ice-water bath and acetyl chloride (1.5 mL) was added 
dropwise. This solution was added to the hydrolyzed peptide and the mixture was heated at 
110 °C for l h, then allowed to cool. The solvent was removed under a stream of nitrogen. 
CH2Cl2 (3 mL) and pentafluoropropionic anhydride (1 mL) were added to the vessel at 0 °C. 
The mixture was then heated at 110 °C for 30 min, then allowed to cool and dried under a 
stream of nitrogen. The residue was dissolved in methanol (1 mL), transferred into a new 
vial and the methanol was removed under a stream of nitrogen. 
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2.4.17 Chiral GC-MS analysis of derivatized lanthionine residues 
The hydrolyzed and derivatized samples were analyzed individually using GC/MS. Then 
peptides and each of three lanthionine standards (DD, DL and LL) were individually analyzed 
by GC/MS using a Varian 25 m × 0.22 mm fused silica wall coated open tubular Chirasil-L-
Val (0.12 μm) column on a Waters (Micromass) VG7070E MS instrument with an Agilent 
5890 Series II GC. The sample was introduced into the instrument dissolved in MeOH via a 
pulsed splitless injection. The temperature method used was from 160 °C (5 min), raised to 
180 °C by 3 °C/min, and then held at 180 °C (10 min). The MS was operated in 
simultaneous Scan/SIM mode (monitoring at 365.05 Da for lanthionine). All three 
stereoisomers of lanthionine eluted as distinct peaks at 22-24 min (DD then DL then LL).  
 
2.4.18 ELISA assay characterizing the disruption of UEV-p6 interaction by 
lanthipeptides 
To each well in a clear, nickel coated 96-well plate (Thermo Scientific), 4.2 pM of purified 
His-tagged UEV protein in PBS (Thermo Scientific; 1 tablet dissolved in 100 mL deionized 
water; 100 μL per well), was added and incubated for 1 h at room temperature with rocking. 
The wells were then washed with PBS containing 0.05% TWEEN 20 (Sigma; 3 × 200 μL, 5 
min incubation per wash). The wells were blocked for 1 h with 2% milk solution in 
deionized water (150 μL per well) at room temperature with rocking. Without washing the 
wells, ascending concentrations of lanthipeptide (dissolved in DMSO) with 4.7 pM of 
purified GST-tagged p6 protein in PBS (100 μL) were added and then incubated for 1 h at 
room temperature with rocking. The wells were then washed as before, and mouse anti-GST 
Ab-1 antibody (Neomarkers; 1:1000 made up in 2% milk in deionized water; 100 μL per 
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well) was added and incubated for 1 h at room temperature with rocking. The wells were 
washed, then sheep anti-mouse IgG, peroxidase-linked whole antibody (GE Healthcare; 
1:6000 made up in 2% milk in deionized water; 100 μL per well) was added and the plate 
incubated for 1 h at room temperature with rocking. The wells were washed and 1-Step™ 
Ultra TMB ELISA solution (Thermo Scientific; 100 μL) was added to each well and the 
plate incubated for 15 min at room temperature with rocking. To quench the reaction, 20 
mM sulphuric acid (100 μL) was added to each well and the absorbance at 450 nm measured 
using a Tecan Infinite® M200 PRO platereader. (Data collected by Tavassoli lab) 
 
2.4.19 Fluorescein labeling on Hit3-3 
For fluorescein labeling on cyclized Hit3-3 peptide using fluorescein-5-maleimide (FM), a 
Cys residue was inserted on the N-terminal of the leader peptide after a thrombin cleavage 
site (LVPRGC, thrombin cleaves after the Arg residue (bolded) in the underlined 
recognition sequence). The peptide sequence was PCR-amplified using primers 
2.8ThrombinCys_EcoRI_FP and Libseq_NotI_RP (Table 2.3), and cloned between the EcoRI 
and NotI restriction sites in MCS1 of the pRSFDuet vector containing procM in MCS2. The 
peptide was overexpressed in E. coli and purified as described previously. The additional Cys 
residue did not interrupt the modification on the core peptide, as two non-overlapping rings 
still formed (Figure 2.19). The peptide was then subjected to thrombin cleavage. Thrombin 
was able to remove the N-terminal His6-tag after pro-longed incubation time, and the 
resulted untagged Cys-Hit3-3 peptide was purified by HPLC on a C4 column.  
   The fluorescein labeling reaction contains 20 μM purified peptide, 50 μM TCEP, 0.5 mM 
fluorescein-5-maleimide and 50 mM HEPES, pH=6.9. The reaction was incubated at room 
temperature for 3-4 h in dark and monitored by MALDI-TOF MS (Figure 2.19). After C4 
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SPE desalting, the labeled peptide was further purified by HPLC on a C4 column as 
described in general method.  
 
Figure 2.19 Fluorescein labeling on hit3-3 peptide. a) MALDI-TOF MS shows that co-
expression of thrombin-Cys-hit3-3 and ProcM yielded fully dehydrated peptide (top panel). 
No free Cys residues were detected when the Glu-C digested core peptide was treated with 
NEM (bottom panel). (Green lines indicate fully dehydrated core peptide after Glu-C 
cleavage (two dehydrations for hit3-3), * indicates sodium adduct, ° represents incompletely 
digested core peptide fragments that were cleaved before residue −7 instead of residue −5 
(refer to Figure 2.5).) b) MALDI-TOF tandem MS indicates the formation of two non-
overlapping rings. c) After thrombin cleavage, the Cys-hit3-3 peptide (sequence shown in 
top panel) was labeled with fluorescein-5-maleimide and purified by HPLC (bottom panel). 
Minor species with an additional 18 Da was observed possibly due to hydrolysis of the 
maleimide ring.  
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CHAPTER 3 : POST-TRANSLATIONAL INTRODUCTION OF D-ALANINE INTO 
RIBOSOMALLY SYNTHESIZED PEPTIDES BY THE DEHYDROALANINE 
REDUCTASE NPNJ2 
 
3.1 INTRODUCTION 
D-Amino acids impart a range of favorable properties onto peptides,(1) such as reduced 
susceptibility to proteolysis,(2-7) induction of turns,(8, 9) and self-assembly of higher order 
structures.(10, 11) Unfortunately, the ribosomal machinery is generally specific for L-amino 
acids.(12, 13) Hence, preparation of D-amino acids-containing peptides has been limited mostly 
to chemical synthesis. In the past decade or so, a number of enzymes have been reported 
that post-translationally introduce D-stereocenters into peptides. These include epimerases 
that convert L-amino acids into D-amino acids via a deprotonation-protonation 
mechanism.(14, 15) Such enzymes have been isolated from frog,(16) spider,(14, 17) platypus,(18) and 
sponges.(15) The substrate specificity of the enzymes from frog and platypus has been 
investigated, showing that they are specific for acting on the second amino acid from the N-
terminus,(18, 19) whereas the spider enzyme acts on the third residue from the C-terminus.(14) 
Hence, they are highly position specific. These isomerases have additional disadvantages for 
synthetic purposes in that they thus far have been isolated from native organisms and no 
heterologous expression systems are available. In addition, they tend to give a 
thermodynamic mixture of products. 
   A very different means of introducing D-stereocenters was recently reported that involves 
radical chemistry.(20) During the biosynthesis of proteusin RiPP natural products in 
                                                
2 Reproduced in part with permission from “Post-translational Introduction of D-alanine into Ribosomally 
Synthesized Peptides by the Dehydroalanine Reductase NpnJ” J. Am. Chem. Soc. 2015, 137, 12426 © 2015 
American Chemical Society. 
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cyanobacteria (Chapter 1), radical-S-adenosyl methionine (rSAM) proteins catalyze the 
irreversible epimerization of multiple residues in their substrate peptides.(15) Thus, these 
enzymes offer considerable potential for introducing D-amino acids into ribosomally 
synthesized peptides, although their sequence specificity has not yet been investigated.  
 
Figure 3.1 Naturally occurring lanthipeptides containing D-amino acids. D-amino acids are 
shown in magenta color. (Me)Lan residues with unusual stereochemistry are shown in pink. 
 
   A final method to introduce D-amino acids into ribosomally synthesized peptides involves 
enzymes found in lanthipeptide biosynthesis.  A small subclass of lanthipeptides contains D-
amino acids that are formed by hydrogenation of Dha and/or Dhb. The resulting D-Ala and 
D-amino butyric acid residues have been found in lactocin S,(21) lacticin 3147(22-24) and 
carnolysin (Figure 3.1).(25) The enzymes that carry out the reduction reactions are encoded in 
their biosynthetic gene clusters and fall into two dehydrogenase classes that collectively have 
been termed LanJ enzymes.(26) The protein involved in lacticin 3147 biosynthesis is a 
member of the zinc-dependent dehydrogenases and was the first functionally identified 
dehydro amino acid reductase.(27) Our bioinformatics analysis shows that the enzyme in 
carnolysin biosynthesis belongs to the flavin oxidoreductase superfamily of dehydrogenases. 
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CrnJ-like homologs were also found in other lanthipeptide biosynthetic clusters that have 
not been fully characterized, such as lactocin S (Figure 3.2). We have proposed to designate 
these two enzyme classes LanJA and LanJB, respectively. The proteins involved in the 
biosynthesis of lacticin 3147 and carnolysin have been successfully used in heterologous 
expression systems,(25, 28) but thus far, their activity has not been reconstituted in vitro and 
their substrate specificity has not been investigated in great detail.  
 
Figure 3.2 LanJB enzymes among putative lanthipeptide biosynthetic gene clusters. a) 
Sequence alignment of LanJB proteins identified by genome mining with the consensus 
sequence of pfam03358 (NADPH-dependent FMN reductase). LasN (protein ID 
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CAA91111) was identified in the biosynthetic cluster of lactocin S, which is likely 
responsible for installing the D-Ala onto lactocin S. Protein SPAR83_1964 was identified 
from the putative lanthipeptide biosynthetic cluster in Streptococcus pneumoniae GA44386, 
bthur0011_29270 identified from Bacillus thuringiensis serovar huazhongensis BGSC 4BD1, 
IK9_05151 identified from Bacillus cereus VD166, and EFI65090_1 identified from Bacillus 
cereus SJ1. Other LanJB homologs proteins are included in the gene clusters identified by 
Sareen and coworkers.(29) b) Schematic representation of the putative lanthipeptide 
biosynthetic clusters mentioned above. These clusters also contain putative LanTs for cross-
membrane transportation, putative LanPs for leader peptide removal and putative 
LanIFEGs involved in self-immunity. (* A mutant LanM in B. cereus SJ1 was identified that 
lacks the conserved residues for cyclase activity.)  
 
   We recently reported the presence of a LanJA homolog in the cyanobacterium Nostoc 
punctiforme PCC 73102,(30) and in this work, I reconstituted the activity of this NpnJA enzyme 
in vitro and show that its substrate specificity is low such that it can be used to introduce D-
Ala into a variety of peptides and natural products. A deuterium-label based coupled-enzyme 
assay was also developed to rapidly determine the stereochemistry of the newly-installed 
alanine. 
 
3.2 RESULTS AND DISCUSSION 
3.2.1 NpnJA selectively reduces Dha to D-Ala in the absence of leader sequence, using 
NADPH as cofactor  
 
   The gene cluster in N. punctiforme PCC 73102 is unusual in that it encodes several Ser/Thr-
rich substrate peptides that do not contain Cys residues. These Cys-free peptides appear to 
have co-evolved with a mutant LanM enzyme NpnM that has an intact dehydration site but 
lacks several residues that are critical for cyclization activity.(30) We predicted that this 
biosynthetic machinery might lead to the production of linear D-amino acids-containing 
peptides. However, previous attempts in our laboratory and that of others to express NpnJA 
in E. coli or Lactococcus lactis were unsuccessful.(30, 31)  
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   In this study, I obtained soluble and active NpnJA by expression with an N-terminal 
maltose-binding protein (MBP) in E. coli. The dehydrated substrate NpnA3 was obtained by 
co-expression of the N-terminally hexahistidine tagged peptide (His6-NpnA3) in E. coli with 
NpnM, and purification by Ni2+-affinity chromatography. This procedure resulted in 
formation of one Dha and three Dhb residues in His6-NpnA3 as determined by MALDI-
TOF MS. Incubation of MBP-NpnJA in vitro with dehydrated His6-NpnA3 in the presence of 
NADPH resulted in formation of a product that had increased in mass by 2 Da as shown by 
MALDI-TOF MS (Figure 3.3). NADH was not accepted as co-substrate (Figure 3.3). 
Tandem MS analysis demonstrated that the Dha residue was selectively reduced (Figure 3.3). 
In order to determine the stereochemistry of the newly formed alanine, endoproteinase Lys-
C was used to remove the leader peptide and the purified core peptide was hydrolyzed in 6 
M HCl and derivatized using Marfey’s reagent.(32) Liquid chromatography (LC)-MS analysis 
using a C18 column revealed the presence of two L- and one D-Ala stereoisomers. Since the 
peptide obtained after Lys-C cleavage contains two gene-encoded L-Ala residues, the new 
Ala that originated from Ser has D-configuration (Figure 3.3).  
   Interestingly, MBP-NpnJA was also able to reduce the dehydrated core peptide in the 
absence of the leader peptide (Figure 3.4). Such leader-independent activity has also been 
reported for some other tailoring enzymes during RiPPs biosynthesis,(26) and suggested that 
NpnJA might have relatively relaxed substrate specificity. 
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Figure 3.3 MBP-NpnJA selectively reduces Dha to D-Ala in the dehydrated NpnA3 
substrate. The sequence of NpnA3 precursor peptide is shown above. The italic sequence 
indicates the N-terminal His6-tag from the pRSFDuet vector, and the underlined sequence 
indicates the leader peptide. Residue numbers are labeled under the core peptide. The dashed 
blue line indicates successive increases of 2 Da, starting from the solid green line. a) Control 
reaction containing dehydrated NpnA3 after Glu-C digestion, without MBP-NpnJA or cofactor. 
(calculated monoisotopic m/z 2309.44; observed 2309.36) b) Only very slow reduction of Dha 
was observed with NADH, indicated by the moderate change in isotopic distribution pattern. c) 
Complete conversion from Dha to D-Ala was observed with NADPH. d) Conversion from Dha 
to [α-2H1, β-2H1]-Ala was observed for the coupled-enzyme assay in D2O, using PTDH as 
NADP2H generator. e) ESI-Tandem MS confirmed that the Dha was selectively reduced to 
alanine (magenta). f) Extracted ion chromatogram of the derivatized Ala showed the 
presence of 2:1 L-Ala to D-Ala in the Lys-C digested core peptide fragment (sequence shown 
in top panel), indicating the newly generated Ala had the D-configuration.  
 
 
Table 3.1 Calculated and observed monoisotopic masses of each fragment ion in four-fold 
dehydrated NpnA3 core peptide with Dha reduced to D-Ala after Glu-C digestion (Figure 
3.3, panel e). 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
b11 441.283 441.293 b17 965.615 965.647 y13 1417.890 1417.884 
b12 554.367 554.401 y9 1037.647 1037.669 y14 1530.974 1531.067 
b13 625.404 625.417 y10 1150.731 1150.739 y15 1587.995 1587.991 
y6 740.515 740.508 b19 1161.736 1161.740 y16 1687.063 1687.093 
b15 781.494 781.541 y11 1233.768 1233.784 y17 1758.101 1758.102 
b16 894.578 894.610 y12 1346.852 1346.862    
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Figure 3.4 The leader peptide is not required for MBP-NpnJA activity. a) HPLC trace of the 
dehydrated NpnA3 after Lys-C digestion. The peak highlighted by the red arrow indicates the 
separation of the fully-dehydrated core peptide fragment containing the Dha residue from other 
peptide fragments. b) MALDI-TOF MS of the purified core peptide fragment after Lys-C 
cleavage (see panel c for sequence). c) Isotopic distribution of the dehydrated core peptide 
fragment, the sequence of the peptide is drawn above. (calculated monoisotopic m/z 1516.91; 
observed 1516.81) d) Reduction of Dha (indicated by 2 Da increase from the solid green line to 
the dashed blue line) was observed upon incubating 40 μM core peptide with 1 μM MBP-NpnJA 
overnight. (Figure reproduced with permission from Yang et al. 2015(1)) 
 
3.2.2 The activity of NpnJA is not position-specific 
   Next, I investigated whether MBP-NpnJA would be able to generate D-Ala at non-native 
positions. The three Thr residues in the NpnA3 core peptide were individually mutated to 
Ser, and the mutant peptides (T19S, T23S, and T28S) were co-expressed with NpnM to 
generate dehydroalanines at these positions. In vitro incubation of the dehydrated peptides 
with MBP-NpnJA resulted in reduction at two of the positions (Dha19 and Dha28) as 
determined by tandem MS (Figure 3.5). The observation that Dha23 was not reduced could 
potentially be a consequence of the N-terminal flanking Asp22 residue. Such influence from 
the charged flanking residues has been reported in the case of the homologous enzyme LtnJ 
in L. lactis.(33) Indeed, by mutating Asp22 to Ala, Dha23 was reduced by MBP-NpnJA (Figure 
3.5). Thus, the enzyme is very flexible with respect to the positional specificity, and it is 
selective for reduction of Dha residues. 
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Figure 3.5 MS spectra showing the ability of MBP-NpnJA to introduce D-Ala at mutant 
positions in dehydrated NpnA3 substrate analogues. The substrate peptides with Thr mutated to 
Ser at position 19, 23 or 28 were coexpressed with NpnM in E. coli, treated with MBP-NpnJA in 
vitro and digested with Glu-C. a) MALDI-TOF MS showing the NpnA3(T19S) mutant with 
different dehydration and reduction states of the core peptide. b) ESI-tandem MS on the four-
fold dehydrated species confirmed that Dha13 and Dha19 were both reduced. c) MALDI-TOF 
MS showing the NpnA3(T23S) mutant with different dehydration and reduction state on the 
core peptide. d) ESI-tandem MS on the four-fold dehydrated species confirmed that only Dha13 
was reduced. e) MALDI-TOF MS showing the NpnA3(T28S) mutant with different dehydration 
and reduction states of the core peptide. f) ESI-tandem MS on the four-fold species confirmed 
that the Dha13 and Dha23 were both reduced (the fragment ions in purple color are from the 
three-fold dehydrated species). g) Dehydrated NpnA3(T19S, D22A, T23S, T28S) mutant was 
incubated with MBP-NpnJA in vitro overnight and digested with Glu-C. The MALDI-TOF MS 
shows the different dehydration and reduction states of the core peptide. h) Closer examination 
of the four-fold dehydrated species in panel g revealed that all four Dha residues were reduced 
(red trace), comparing to the starting material (black trace). The dashed blue line indicates 
successive increases of 2 Da, starting from the solid green line (calculated monoisotopic m/z 
2223.4; observed 2223.4).  
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Table 3.2 Calculated and observed monoisotopic masses of the dehydration intermediates 
of the NpnA3 mutant peptides after Glu-C digestion, with Dha reduced to D-Ala (Figure 
3.5, panel a, c, e, g) 
 MH+ ion Calculated 
mass 
Observed 
mass 
MH+ ion Calculated 
mass 
Observed 
mass 
Panel a 
M  2367.47 2367.33 M-3H2O (2 D-Ala) 2317.47 2317.35 
M-H2O (1 D-Ala) 2351.48 2351.33 M-4H2O (2 D-Ala) 2299.46 2299.33 
M-2H2O (2 D-Ala) 2335.48 2335.34    
Panel c 
M  2367.47 2367.58 M-3H2O (1 D-Ala) 2315.45 2315.54 
M-H2O (1 D-Ala) 2351.48 2351.56 M-4H2O (1 D-Ala) 2397.44 2397.51 
M-2H2O (1 D-Ala) 2333.46 2333.56    
Panel e 
M  2367.47 2367.30 M-3H2O (1 D-Ala) 2315.45 2315.29 
M-H2O (1 D-Ala) 2351.48 2351.28 M-4H2O (2 D-Ala) 2299.46 2299.30 
M-2H2O (1 D-Ala) 2333.46 2333.31    
Panel g 
M  2295.45  M-3H2O (3 D-Ala) 2247.46 2247.62 
M-H2O (1 D-Ala) 2279.45 2279.60 M-4H2O (4 D-Ala) 2231.47 2231.62 
M-2H2O (2 D-Ala) 2263.46 2263.62    
 
Table 3.3 Calculated and observed monoisotopic masses of each fragment ions in three or 
four-fold dehydrated NpnA3 mutant peptides after Glu-C digestion, with Dha reduced to D-
Ala (Figure 3.5, panel b, d, f)  
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
Panel b 
b11 441.283 441.285 y10 1150.731 1150.722 y13 1405.890 1405.888 
b13 625.404 625.407 y11 1221.769 1221.749 y15 1575.995 1575.980 
b14 724.473 724.491 y12 1334.853 1334.889    
Panel d 
b13 625.404 625.408 b19 1161.736 1161.737 y13 1403.874 1403.877 
b14 724.473 724.476 y11 1219.753 1219.823 y15 1573.980 1573.978 
y10 1136.716 1136.711 y12 1332.837 1332.818    
Panel f 
b11 441.283 441.286 y10 1138.732 1138.771 y12’ 1350.847 1350.847 
b13 625.404 625.419 y10’ 1154.726 1154.724 y13 1405.890 1405.914 
b14 724.473 724.482 b19 1161.736 1161.731 y13’ 1421.884 1421.896 
b15 781.494 781.508 y11 1221.769 1221.778 y15 1575.995 1575.993 
b16 894.578 894.669 y11’ 1237.763 1237.756 y15’ 1591.990 1591.981 
b17 965.615 965.660 y12 1334.853 1334.875    
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3.2.3 Selective labelling of the Ala residues produced by MBP-NpnJA for 
stereochemistry characterization 
   Given the recently described ability of the sequence of lanthipeptide substrates to 
determine the stereochemical outcome of enzymatic reactions,(34, 35) it was important to verify 
that Dha reduction at non-native positions still resulted in D-Ala. At this point, a challenge 
arose when I tried to characterize the stereochemistry of the newly formed Ala residues 
using the traditional L/D ratio-based strategy: As a consequence of the presence of partially 
dehydrated intermediates that could not be separated from the fully dehydrated and reduced 
core peptide by HPLC (Figure 3.5), the resulting increased L-Ala ratio contributed by those 
intermediates cannot reflect the true L/D ratio in the final product. Therefore, it is difficult to 
confirm if MBP-NpnJA is making purely D-Ala or a mixture of stereoisomers on these new 
positions based on the L/D ratio. To differentiate the newly generated Ala from the existing 
Ala residues, we developed an in vitro coupled-enzyme assay in D2O using deuterium labeled 
cofactor (NADP2H) and an engineered phosphite dehydrogenase (PTDH)(36, 37) as cofactor 
regenerating catalyst (Figure 3.6). Incubation of the Dha-containing substrate together with 
MBP-NpnJA, PTDH, NADP
+ and deuterium-labeled phosphite in D2O, resulted in 
deuterium labeling at the α and β carbons of the newly formed alanine, which, after 
hydrolysis and derivatization, could be readily analyzed independently from the unlabeled L-
Ala residues by LC/MS (Figure 3.6). With this method, we were able to confirm the D-
configuration of the newly formed alanine at the non-native positions (Figure 3.6). 
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Figure 3.6 Selective labeling of the Ala residues produced by MBP-NpnJA to determin their 
stereochemistry a) Coupled enzyme assay using PTDH as NADPH regeneration catalyst. 
After the coupled-enzyme assay, the purified peptide was hydrolyzed and the amino acids 
derivatized using Marfey’s reagent and analyzed by LC-MS. Extracted ion chromatogram of 
the gene-encoded Ala (b, c top panels) or labeled Ala (b, c bottom panels) confirmed that 
the Ala formed by MBP-NpnJA had the D-configuration. d) Summation of MS scans 
spanning the L-FDAA-Ala elution window (shaded area on the left) confirmed that the 
residues are mainly unlabeled as indicated by the green solid line (calculated monoisotopic 
m/z 342.1; observed 342.1). e) Summation of MS scans spanning the D-FDAA-Ala elution 
window (shaded area on the right) confirmed that the residues are mainly labeled as 
indicated by the blue dashed line (calculated monoisotopic m/z: 344.1; observed 344.1). 
  
 
3.2.4 Introducing D-Ala into ribosomal peptides by MBP-NpnJA  
   Encouraged by the apparent substrate tolerance of MBP-NpnJA, I next investigated if the 
enzyme would be able to introduce D-Ala into non-native substrate sequences. Previously, 
Kuipers and coworkers demonstrated the use of LtnJ with non-native substrates in L. lactis, 
but many resulted in low conversions;(28) Since introduction of D-amino acids would be most 
conveniently done in E. coli, we evaluated its use as biosynthetic host. 
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Figure 3.7 Introducing D-Ala into lanthipeptides. The Dha residues highlighted in green 
were reduced by MBP-NpnJA. The authentic D-Ala residues (magenta) in Ltn3147 peptides 
were also successfully introduced by MBP-NpnJA. The full-length LanA peptide with the 
same modification as produced by the native producer strain on its core peptide is termed 
mLanA for modified LanA. e.g. mNisA, mLtnA1 and mLtnA2. The full-length LanA 
peptide with only dehydrations on the core peptides are termed dLanA for dehydrated 
LanA. e.g. dLctA, dLib2A3’ and dLib2A4.  
 
   I first focused on introducing D-alanines into the class I lantibiotic nisin. Nisin exhibits 
strong antimicrobial activity against a wide range of gram-positive bacteria and has been used 
as a preservative in the food industry for six decades.(38) However, the low stability at 
physiological pH has prevented the use of nisin in clinical applications. Specifically, 
hydrolysis at the Dha at position 5 inside the A-ring and at Dha33 account for the observed 
degradation products (Figure 3.7).(39) Many efforts have focused on replacing these Dha 
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residues with L-amino acids via mutagenesis.(40) Herein we demonstrate that these Dha 
residues can be replaced with D-alanines using NpnJA.  
 
Figure 3.8 Introducing D-Ala into nisin. Sequence information of authentic nisin is shown 
on top. The blue dashed line indicates successive increases of 2 Da, starting from the solid 
green line.  a) MALDI-TOF MS of nisin (spot 1 in panel f). The fully dehydrated (with eight 
fold-dehydration) nisin is shown as the major species on the left (calculated monoisotopic 
m/z 3352.55; observed 3352.35). The seven-fold dehydrated nisin with Ser33 escaping 
dehydration(41) is shown on the right as minor species (calculated monoisotopic m/z 3379.56; 
observed 3370.38). b) MALDI-TOF MS of the core peptide of mNisA (NisA coexpressed 
with NisB and NisC in E. coli) after leader peptide removal by Arg-C digestion. c) MALDI-
TOF MS of nisin (20 μM) incubated with MBP-NpnJA (4-5 μM) overnight in vitro (spot 3 in 
panel f), showing one reduction only on the eight-fold dehydrated nisin. d) MALDI-TOF 
MS of core peptide of mNisA’ (generated by co-expressing NisA with NisB, NisC and MBP-
NpnJA in E. coli) after leader peptide removal by Arg-C digestion (spot 2 in panel f), showing 
two reduction events for the eight-fold dehydrated species. e) NEM alkylation of mNisA’ 
(bottom panel) displayed little NEM adduct (blue shadows), indicating that most of the 
thioether rings were formed. f) Growth inhibition assay against L. lactis HP. An aliquot of 10 μL of peptide (5 μM each) was spotted onto sections 1, 2 and 3, respectively. Control 
samples (Arg-C or MBP-NpnJA only) were spotted onto section 4. The nisin derivative with 
one D-Ala exhibited similar antimicrobial activity as authentic nisin, while the nisin derivative 
with two D-Ala residues showed significantly reduced activity. 
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   Dha33 located in the linear C-terminal region of nisin could be reduced by directly 
incubating nisin with MBP-NpnJA in vitro (Figure 3.8, Figure 3.9). The observation that Dha5 
in the A ring was not reduced in this experiment could possibly be the result of unfavorable 
steric effects of the cyclic structure. Therefore, we next performed co-expression of the His6-
NisA precursor peptide with the dehydratase NisB, the cyclase NisC, and MBP-NpnJA in E. 
coli, to assess whether MBP-NpnJA could reduce linear or partially cyclized substrate during 
the biosynthesis process. The peptide was purified by Ni2+ affinity chromatography, the 
leader peptide was removed with endoproteinase Arg-C, and the resulting product was 
analyzed by MS. The mass of the core peptide was increased by 4 Da compared to authentic 
nisin (Figure 3.8) suggesting reduction of two Dha residues. Treating the core peptide with 
the thiol-alkylating reagent N-ethylmaleimide (NEM) yielded only small amounts of NEM 
adduct, indicating that the five cysteines had been mostly cyclized (Figure 3.8). Tandem MS 
analysis also indicated a similar fragmentation pattern as authentic nisin. The fragmentation 
ions further confirmed that one reduction still occurred at Dha33, and suggested that the 
other reduction occurred as a mixture at either Dha3 or Dha5 (Figure 3.9). This nisin analog 
containing two D-Ala displayed strongly reduced antimicrobial activity compared to 
authentic nisin, while the analog with only Dha33 reduced still retained its bioactivity (Figure 
3.8). 
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Figure 3.9 MALDI-TOF tandem MS of the nisin derivatives with zero (a), one (b), or two 
(c) Dha residues reduced by MBP-NpnJA. Alignment of fragment ions indicated very similar 
fragmentation patterns (* indicates decarbonylation (a ion) from the corresponding b ion 
appearing to its right). Panel d, e and f show the zoomed-in view of three representative 
fragment ion sets (b3, y4, and y14). The isotopic mass shift between the three species (top: 
no Dha reduction; middle: one reduction; bottom: two reductions) provided useful 
information regarding the location of the D-Ala residues. The blue dashed line indicates an 
increase of 2 Da each time, starting from the solid green line. d) A b3 ion is commonly 
observed for fragmentation inside the A ring possibly due to the Dha5 residue.(42) A partial 
mass increase of 2 Da was observed for the b3 ion derived from nisin analog with two 
reduced Dha residues, indicating Dha3 was partially reduced in this case; A mass increase of 
2 Da was observed for the y4 ions (e) and y14 ions (f) from the nisin derivatives with one or 
two Dha residues reduced, confirming that Dha33 was reduced since it is the only available 
Dha residue in the fragments. Combining the data from d, e, and f, Dha5 was also partially 
reduced in the nisin derivative with two Dha residues reduced. 
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Table 3.4 Calculated and observed monoisotopic masses of each fragment ion in eight-fold 
dehydrated mNisA core peptide after Arg-C digestion (Figure 3.9, panel a). 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
b3 266.15 265.95 y14 1491.70 1491.80 y23 2349.10 2349.39 
y4 452.26 452.04 y15 1605.75 1605.91    
y13 1360.66 1360.69 y22 2221.00 2221.33    
 
   To further explore the potential utility of NpnJA, we next focused on the class II lantibiotic 
lacticin 3147. Lacticin 3147 belongs to a subclass of lanthipeptides that consist of two post-
translationally modified peptides (Figure 3.10), which act synergistically to exhibit 
antimicrobial activity. Many lanthipeptides have been made in E. coli over the past ten years, 
but lacticin 3147 could only be obtained from the producer strain L. lactis, because LtnJ 
could not be expressed in E. coli in our hands (attempted by Weixin Tang). We therefore 
evaluated the potential use of NpnJA as a LtnJ replacement. Indeed, co-expression of MBP-
NpnJA with the precursor peptides (LtnA1 and LtnA2) and the corresponding synthetase 
(LtnM1 and LtnM2) in E. coli, resulted in up to seven or eight-fold dehydrated, mostly 
cyclized and reduced products in which one and two D-Ala were introduced into LtnA1 and 
LtnA2, respectively (Figure 3.7, Figure 3.10). These observations again show the positional 
tolerance of NpnJA and the selectivity for reducing Dha over Dhb. These findings also open 
up the possibility for production of lacticin 3147 in E. coli, which paves the way for isotopic 
labeling and non-proteinogenic amino acid incorporation to study the mode of action of 
these two-component lantibiotics.  
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Figure 3.10 Introducing D-Ala into LtnA1 and LtnA2. The sequences of mLtnA1 and 
mLtnA2 are shown in panel (a) and (d), respectively. b) MALDI-TOF MS showing that co-
expression of LtnA1 with LtnM1 and MBP-NpnJA resulted in seven-fold dehydrated and 
cyclized peptide as the major species. The high degree of cyclization is shown by the absence 
of considerable NEM alkylation. * indicates oxidized peptides (+16 Da); ° indicates 
gluconoylation on the N-terminal Gly residue (+ 178 Da).(43) c) A mass increase of 2 Da was 
observed for the LtnA1 co-expression product (bottom spectrum) compared to the peptide 
without co-expression with MBP-NpnJA (top spectrum, calculated avg. mass 8154.9; observed 
8154.6). The middle spectrum shows mLtnA1-S7A as a positive control. e) MALDI-TOF 
MS showing that co-expression of LtnA2 with LtnM2 and MBP-NpnJA resulted in eight-fold 
dehydrated and cyclized peptide as the major species. f) A mass increase of 4 Da was 
observed for the LtnA2 co-expression product compared to the peptide without co-
expression with MBP-NpnJA (calculated avg. mass 8418.5; observed 8418.8). The middle 
spectrum shows mLtnA2-S9A/S12A as positive control. Incubation of dehydrated and 
cyclized Ltn3147A1/A2 peptide (generated by co-expression with LtnM1/M2) with MBP-
NpnJA in vitro also resulted in successful Dha introduction (data not shown) g) We were 
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only able to observe good ESI-MS signal for the mLtnA2 core peptide after removing most 
of the leader sequence by GluC digestion. Tandem MS on this peptide confirmed the 
location of the two Ala residues formed by NpnJA to be the same as in the authentic peptide. 
The C-terminal end with dashed underlined font indicates the sequence with cyclized 
thioether rings that was not fragmented in the tandem-MS, as expected. (Figure reproduced 
with permission from Yang et al. 2015(1)) 
 
Table 3.5 Calculated and observed monoisotopic masses of each fragment ions in eight-fold 
dehydrated mLtnA2 core peptide after Glu-C digestion (Figure 3.10, panel g). 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
b2 505.216 505.208 b9 1108.556 1108.567 y18 1850.836 1850.831 
b5 756.343 756.343 b11 1334.722 1334.685 y20 2077.004 2076.998 
b7 924.433 924.438 b12 1405.760 1405.791    
b8 1037.517 1037.490 y17 1779.798 1779.792    
 
   We evaluated one more system to probe the substrate tolerance of NpnJA as a biosynthetic 
tool for introduction of D-Ala into ribosomal peptides. As a proof of concept, we chose two 
different class II lanthipeptide synthetase mutants to first generate Dha from Ser without 
forming the lanthionine rings, followed by conversion of these Dha residues to D-Ala by 
NpnJA. In the first example, the precursor peptide of lacticin 481 (LctA) was treated with the 
dehydratase domain of its synthetase LctM,(44) and MBP-NpnJA reduced both Dha residues 
formed in the core peptide (Figure 3.7, Figure 3.11). In contrast, incubating LctA in vitro with 
the same amount of full-length LctM (with an active cyclase domain) and MBP-NpnJA 
resulted in fully-dehydrated and cyclized peptide without any D-Ala formation (Figure 3.12). 
This observation indicated that (Me)Lan ring formation catalyzed by its designated 
lanthipeptide synthetase is likely more favored than the conversion of Dha to D-Ala. 
Therefore, in order for efficient D-Ala introduction into lanthipeptides, the cyclization 
activity of LanM needs to be minimized or Cys residues in the substrate sequence should be 
avoided.   
   To further challenge this biosynthetic strategy with non-native substrate sequences, I chose 
the enzyme ProcM from the prochlorosin biosynthetic pathway that exhibits great substrate 
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tolerance.(45) As proof of concept, two randomized peptide substrates with four or two Ser 
residues at various positions were fused to the C-terminus of the prochlorosin leader 
sequence (Lib2A3’ and Lib2A4 from Chapter 2, Figure 3.7). Co-expression of each peptide 
with MBP-NpnJA and a mutant ProcM (with three zinc-binding Cys residues mutated to Ala) 
that showed decreased cyclization activity,(44, 46) resulted in dehydration of the Ser residues 
and reduction of the dehydroalanines in the core peptides of Lib2A3’ and Lib2A4, 
respectively (Figure 3.7, Figure 3.11). The D-Ala containing final products were then 
obtained by proteolytic removal of the leader sequence. The core peptides were still partially 
cyclized as shown by NEM alkylation assay (Figure 3.13), either due to non-enzymatic 
cyclization or the remaining activity of the mutant ProcM since it still carries the cyclase 
domain. Attempts on using a truncated ProcM with only the N-terminal dehydratase domain 
(residues 1-660) were unsuccessful, as no dehydration was observed for either Lib2A3’ or 
Lib2A4 (data not shown). Together, the data in this chapter illustrate the potential of using 
the lanthipeptide biosynthesis machinery to introduce D-alanines into ribosomal peptides. 
 
Figure 3.11 Activity of MBP-NpnJA on non-native ribosomal peptides. The blue dashed line 
indicates an increase of 2 Da each time, starting from the solid green line. a) Top panel: 
MALDI-TOF MS of linear LctA peptide treated with the dehydratase domain of LctM, 
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followed by Lys-C digestion. Bottom panel: Up to 4 Da increase was observed when MBP-
NpnJA was co-incubated with the above reaction (calculated monoisotopic m/z (three-fold 
dehydrated LctA with 2 D-Ala) 2794.20; observed 2794.14). b) Up to 6 Da increase was 
observed when Lib2A3’ was co-expressed with the ProcM mutant and MBP-NpnJA, 
followed by Glu-C digestion (calculated monoisotopic m/z 2522.18; observed 2522.19). c) 
Tandem MS confirmed that Ser13 (bold) escaped dehydration, the other three Dha residues 
were reduced. d) Up to 2 Da increase was observed when Lib2A4 was co-expressed with 
ProcM mutant and MBP-NpnJA, followed by Glu-C digestion (calculated monoisotopic m/z 
2614.08; observed 2614.11). e) Tandem MS confirmed that Dha10 escaped reduction, likely  
due to the adjacent Asp12 residue, whereas the other Dha residue was reduced. f) Indeed, 
MBP-NpnJA was able to reduce both Dha residues when Asp12 was mutated to Ile 
(calculated monoisotopic m/z (four-fold dehydrated core peptide with 2 D-Ala) 2201.91; 
observed 2201.66. * indicates sodium adduct).  
 
Table 3.6 Calculated and observed monoisotopic masses of each fragment ions in six-fold 
dehydrated pA1 and four-fold dehydrated pA2 core peptide after Glu-C digestion, with three 
or one Dha residues being reduced to D-Ala, respectively (Figure 3.11, panel c, e). 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
panel c 
y3 336.1927 336.1964 b8 1298.617 1298.601 b16 2023.934 2023.888 
y4 499.2561 499.2542 b9 1381.654 1381.667 b17 2186.998 2187.042 
b2 567.326 567.333 b12 1681.743 1681.710 b18 2334.066 2333.988 
b4 844.432 844.465 b13 1768.775 1768.734 b19 2405.104 2405.076 
b6 1078.532 1078.554 b15 1952.897 1952.951    
panel e 
y5 558.245 558.250 b4 830.416 830.437 b19 2481.047 2481.075 
b2 633.336 633.348 b17 2264.954 2264.916    
b3 716.373 716.380 b18 2378.038 2378.064    
 
 
Figure 3.12 Competition assay of MBP-NpnJA and LctM on LctA substrate. MBP-NpnJA 
failed to introduce D-Ala into LctA substrate when LctA (100 μM) was co-incubated with 
full-length LctM (1 μM) and MBP-NpnJA (1 μM) for 30 min. The MALDI-TOF MS shows 
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the four-fold dehydrated core peptide after Lys-C cleavage (calculated monoisotopic m/z 
2772.16; observed 2772.56). 
 
Figure 3.13 Partial cyclization on dLib2A3’ and dLib2A3’ by ProcM mutant. MALDI-TOF 
MS of the core peptide of dLib2A3’ (panel a) and dLib2A4 (panel b) after co-expression 
with ProcM mutant and MBP-NpnJA, and GluC proteolysis (top panels). NEM alkylation on 
the core peptide (bottom panels) indicated that both peptides were partially cyclized. 
 
3.2.5 Investigating the sequence specificity of MBP-NpnJA 
   As described above, the activity of MBP-NpnJA was hampered when an Asp residue was 
adjacent to the Dha residue (e.g. Asp22 flanking Dha23 in NpnA3 T23s mutant, and Asp12 
flanking Ser11 in mLib2A4). When the Asp22 residue was mutated to Ala, or the Asp12 
residue was mutated to Ile, the enzyme activity was restored and the adjacent Dha residues 
were reduced (Figure 3.5g, 3.11f). These observations indicate that the adjacent amino acids 
flanking the Dha residue might be important for enzyme recognition/activity.  
   To investigate whether MBP-NpnJA has preference for certain adjacent amino acids over 
the others, I generated a series of mutant NpnA3 substrates where either Leu12 or Val14 
flanking the wild-type Ser13 residue was mutated to different amino acids (Table 3.7). 
Following co-expression with NpnM, each dehydrated substrate (40 μM) was incubated with 
MBP-NpnJA (1 μM) in vitro, and the reaction quenched by Glu-C or Lys-C digestion at 
different time points (20 min, 40 min, 1.5 h, 3.5 h or with 10 μM MBP-NpnJA overnight). 
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The conversion from Dha to D-Ala on the four-fold dehydrated species was monitored by 
MALDI-TOF MS (Figure 3.14). Table 3.7, columns III and IV summarize the different 
activity of MBP-NpnJA regarding the N and C-terminal residues flanking Dha33, as tested by 
this in vitro assay. Columns V and VI summarize all other examples of residues adjacent to 
various Dha positions described in this chapter, as tested by co-expressing MBP-NpnJA in 
E. coli unless specified otherwise. Residues that resulted in unsuccessful Dha reduction are 
highlighted in red in this table. 
 
Table 3.7 Influence of the amino acids flanking Dha on NpnJA activity. (NA indicates this 
mutant was not tested) 
In vitro assay Co-expression in E. coli unless specified Group by 
side chains 
Amino 
acids N-terminal 
to Dha13 
C-terminal to 
Dha13 
N-terminal to DhaX C-terminal to DhaX 
K 1.5 h 
conversion 
NA NA K29(NpnA3 T28S), 
K34(nisin) 
R 1.5 h 
conversion 
Overnight 
conversion 
NA NA 
H NA NA NA H12(dLctA) 
D 3.5 h 
conversion 
Overnight 
conversion, 
(partial 
conversion by 
co-expression) 
D12(NpnA3 L12D), 
No conversion: D18 
(NpnA3 I18D, T19S) 
No conversion: 
D11(Lib2A4),  
 
 Charged  
E 3.5 h 
conversion 
Overnight 
conversion 
NA NA 
C NA NA C10(Lib2A4 D12I) NA 
S NA NA S13(Lib2A3’) NA 
T NA NA NA NA 
N NA NA N17(dLctA, 
overnight in vitro) 
NA 
Polar, 
uncharged  
Q NA NA NA NA 
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Table 3.7 continue 
G Incomplete 
dehydration 
NA NA NA 
A NA NA A22(NpnA3 T19S 
D22A T23S T28S, 
overnight conversion 
in vitro ) 
A12(mLtn3147A2) 
V NA 20 min 
conversion 
V32(nisin) V14(NpnA3), 
V20(Lib2A3’) 
I NA NA I18(NpnA3 T19S), 
I7(mLtn3147A2), 
I15(Lib2A3’), 
I10(dLctA), I4(nisin) 
I9(mLtn3147A2), 
I15(Lib2A3’), 
I17(Lib2A4) 
I12(mPA2 D12I) 
Nonpolar, 
aliphatic 
L 20 min  
conversion 
NA L12(NpnA3), 
L27(NpnA3 T28S), 
L10(mLtn3147A1),  
L20, L24(NpnA3 
T23S), 
L8(mLtn3147A1), 
L5(nisin) 
F NA 3.5 h 
conversion 
F6(mLtn3147A1), 
F18(Lib2A3’), 
F15(Lib2A4) 
NA 
Y NA NA NA Y17(Lib2A3’) 
Aromatic 
W Overnight 
conversion 
NA NA W19(dLctA, overnight 
in vitro) 
Other P 3.5 h 
conversion 
No conversion NA NA 
 
   As shown in the table, NpnJA exhibits good tolerance regarding Dha residues flanked by 
nonpolar aliphatic amino acids such as Val, Ile, Leu and Phe (Figure 3.14b). The enzyme is 
also tolerant to positively charged residues (Lys and Arg). Bulky residues such as Trp slow 
down the enzyme activity, and negatively charged residues (Asp, Glu) often have negative 
effect, especially when they are C-terminal to the Dha residue. Secondary structure also can 
hamper the activity of NpnJA, such as a Pro residue C-terminal to Dha, as well as the 
observation that the Dha5 residue in nisin A ring could not be accessed by the enzyme. 
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Table 3.8 Calculated and observed monoisotopic masses of each four-fold dehydrated 
NpnA3 mutant core peptide after Glu-C or three-fold dehydrated core peptide after Lys-C 
digestion (Figure 3.14). 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
MH+ 
ion 
Calculated 
mass 
Observed 
mass 
WT 2309.44 2309.36 L12W 2382.44 2382.29 
L12K 2324.45 2324.37 V14R 2366.48 2366.48 
L12R 2352.46 2352.65 V14D 2324.40 2325.69 
L12D 2311.39 2311.20 V14E 1546.88 1546.88 
L12E 1532.86 1533.12 V14P 2307.43 2307.89 
L12P 2293.41 2293.27 V14F 2357.44 2357.72 
 
 
3.2.6 Utilizing NpnJA to investigate the Ser dehydration pattern of NpnM. 
Mutating the amino acids adjacent to Dha residues not only altered the activity of MBP-
NpnJA, but also changed the dehydration pattern of NpnM, as different levels of partially 
dehydrated intermediates were observed for each mutant peptide (Figure 3.15). Interestingly, 
for those mutants that resulted in Dha being successfully reduced to D-Ala as confirmed by 
the mass of the four-fold fully dehydrated species, closer examination of the monoisotopic 
mass of their partially dehydrated intermediates revealed interesting insights into the 
dehydration process. For the wild type NpnA3 peptide co-expressed with NpnM, treatment 
by MBP-NpnJA gave a +2 Da shift for not only the four-fold dehydrated species, but also 
the two and three-fold dehydrated intermediates (Figure 3.15). Since there is only one Dha 
residue (Dha13) in the core peptide that could be reduced, this observation indicates that 
Ser13 was already dehydrated in these two intermediates. A similar dehydration pattern was 
observed for L12P, L12W and V14F mutants, where all intermediates were reduced upon 
treatment with MBP-NpnJA (Figure 3.15). However, for the L12K, L12R, V14R, V14D and 
V14E mutants, the data clearly shows that only the four-fold dehydrated species were 
reduced by MBP-NpnJA, while the mass of the other intermediates remained unchanged, 
indicating that Ser13 was dehydrated only in the four-fold dehydrated peptide (Figure 3.15).  
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Figure 3.15 continue on next page 
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Figure 3.15 MALDI-TOF MS showing the different dehydration and reduction pattern of 
each NpnA3 mutant peptide. The dehydration patterns are shown in blue traces, and the 
reduction patterns after incubation with MBP-NpnJA are shown in red traces. Dehydration 
intermediates are marked on top of each mutant (M as no dehydration, −1 as one-fold 
dehydration, −2 as two-fold dehydration, and so on), and their monoisotopic mass 
highlighted by the solid green line. The dashed blue line indicates the theoretical 
monoisotopic mass upon reduction of the Dha residue (increase by 2 Da) on each 
dehydration intermediate. 
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Table 3.9 Calculated and observed monoisotopic masses of each dehydration intermediates 
for NpnA3 mutant core peptide before incubating with MBP-NpnJA (Figure 3.15). 
 MH+ ion Calculated mass Observed mass MH+ ion Calculated mass Observed mass 
WT 
M  2381.48 2381.41 M-3H2O  2327.45 2327.36 
M-H2O  2363.47 NA M-4H2O  2309.44 2309.36 
M-2H2O  2345.46 2345.36    
L12K 
M  2396.50 2396.32 M-3H2O  2342.46 2342.15 
M-H2O  2378.49 2378.29 M-4H2O  2324.45 2324.27 
M-2H2O  2360.48 2360.26    
L12R 
M  2424.50 2424.70 M-3H2O  2370.47 2370.66 
M-H2O  2406.49 2406.68 M-4H2O  2352.46 2352.65 
M-2H2O  2388.48 2388.66    
L12D 
M  2383.43 2383.25 M-3H2O  2329.40 2329.15 
M-H2O  2365.42 2365.23 M-4H2O  2311.39 2311.21 
M-2H2O  2347.41 2347.21    
L12E 
M  1586.90 1587.17 M-2H2O  1550.88 1551.06 
M-H2O  1568.89 1569.14 M-3H2O  1532.87 1533.12 
L12P 
M  2365.45 2365.34 M-3H2O  2311.42 2400.29 
M-H2O  2347.44 2347.23 M-4H2O  2293.41 2293.29 
M-2H2O  2329.43 2329.40    
L12W 
M  2454.48 2454.33 M-3H2O  2400.45 2247.62 
M-H2O  2436.47 NA M-4H2O  2382.44 2382.29 
M-2H2O  2418.46 NA    
V14R 
M  2438.52 2438.53 M-3H2O  2384.49 2384.52 
M-H2O  2420.51 2420.49 M-4H2O  2366.48 2366.47 
M-2H2O  2402.50 2402.48    
V14D 
M  2397.44 2397.77 M-3H2O  2343.41 2343.74 
M-H2O  2379.43 2379.76 M-4H2O  2325.40 2325.72 
M-2H2O  2361.42 2361.75    
V14E 
M  1600.92 1600.88 M-2H2O  1564.89 1564.89 
M-H2O  1582.91 1582.92 M-3H2O  1546.88 1546.88 
V14P 
M  2379.47 2379.86 M-3H2O  2325.44 2325.79 
M-H2O  2361.46 2361.84 M-4H2O  2307.43 2307.75 
M-2H2O  2343.45 2343.84    
V14F 
M  2429.49 2429.79 M-3H2O  2375.45 2375.74 
M-H2O  2411.47 2411.76 M-4H2O  2357.44 2357.73 
M-2H2O  2393.46 2393.75    
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   Being aware of the caveat that these partially dehydrated species might not necessarily 
reflect sequential intermediates generated from one order of dehydration, but could also 
represent products resulted from separate catalytic paths possessing a different order of 
dehydration, herein I refrain from drawing the conclusion that the order (or directionality) of 
dehydration was changed for these mutants. However, these results clearly showed that a 
single amino acid mutation in the substrate sequence could alter the dehydration pattern of 
the synthetase. This observation reveals the complexity of lanthipeptide biosynthesis, and 
should be kept in mind in future studies of the order of dehydration when using site-directed 
mutagenesis of the substrate peptide. 
 
 
3.3 SUMMARY AND OUTLOOK 
   In summary, I present the first successful in vitro reconstitution and characterization of a 
dehydroalanine reductase. NpnJA exhibits remarkable substrate tolerance and high 
conversion, and this enzyme could be coupled with substrate tolerant lanthipeptide 
dehydratases for engineering D-alanine residues into various peptide sequences. Unlike the L-
amino acid epimerases mentioned in section 3.1, MBP-NpnJA is tolerant to Dha residues at 
different positions along the substrate peptide and does not require a leader peptide. 
However, NpnJA does have a preference regarding the amino acids adjacent to the Dha 
residue, and favors nonpolar aliphatic amino acids (Val, Ile, Leu).  
   For more general application of the D-Ala incorporation strategy, optimization on the 
LanM + NpnJA co-expression system in E. coli is required. For example, although ProcM 
showed good substrate tolerance regarding dehydration of Ser residues in a given sequence, 
the remaining cyclization activity of ProcM needs to be minimized to prevent competing 
lanthionine formation with the Dha residues. Alternatively, Cys residues have to be omitted 
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in the substrate sequence. As for the activity of MBP-NpnJA, it is demonstrated that the 
conversion yield on unfavored substrate in vitro could be improved by increasing the enzyme 
to substrate ratio under extended incubation time (e.g. NpnA3 V14D mutant, Figure 3.14). 
Therefore, a similar effort is suggested to improve the conversion yield in E. coli by adding 
additional copies of MBP-NpnJA, or, alternatively, reducing the relative amount of substrate 
production using a lower-copy number expression vector. 
 
 
3.4 MATERIALS AND METHODS 
3.4.1 Materials 
All chemicals used were purchased from Sigma Aldrich or Fisher Scientific unless noted 
otherwise. Endoproteinases (Glu-C, Lys-C, Arg-C) were purchased from Roche Applied 
Science. Oligonucleotide primers used for molecular cloning were purchased from 
Integrated DNA Technologies. Phusion High-Fidelity DNA polymerase, Taq ligase, dNTP 
solutions, T4 DNA ligase and all restriction endonucleases were purchased from New 
England Biolabs. Gel extraction, plasmid miniprep, and PCR purification kits were 
purchased from QIAGEN. Protein Calibration Standard I and Peptide Calibration Standard 
II for MALDI-TOF MS were purchased from Bruker. E. coli DH5α was used as host for 
cloning and plasmid propagation, and E. coli BL21 (DE3) was used as a host for 
overexpression. The plasmids for Ltn3147 co-expression were obtained from Dr. Weixin 
Tang. 
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3.4.2 General methods 
For lanthipeptide residue labeling, positive residue numbers are used for amino acids in the 
core peptide counting forwards from the (putative) leader peptide cleavage site. Negative 
residue numbers are used for amino acids in the leader peptide counting backwards from the 
leader peptide cleavage site. i.e. in the lacticin3147 A1 precursor peptide, the serine residue in 
the core peptide which is converted to D-Ala is 7, and when substituted by alanine the 
mutant is denoted as LtnA1(S7A). Polymerase chain reaction (PCR) amplifications were 
carried out using an automated thermocycler (C1000, BioRAD). Gibson assembly reaction 
solutions were made based on a published protocol.(47) DNA sequencing was performed 
using appropriate primers by ACGT Inc. LC-ESI-Q/TOF MS analyses were conducted 
using a Synapt MS system equipped with an Acquity Ultra Performance Liquid 
Chromatography (UPLC) system (Waters). Matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF MS) analyses were conducted at the Mass 
Spectrometry Facility at UIUC using an UltrafleXtreme spectrometer (Bruker Daltonics). 
For MALDI-TOF MS analysis, samples were desalted using ZipTipC18 (Millipore), and 
spotted with a matrix solution containing 35 mg/mL 2,5-dihydroxybenzoic acid (DHB) in 
3:2 MeCN/H2O with 0.1% TFA onto a MALDI target plate. Peptides were desalted by C4 
solid-phase extraction (SPE) column and further purified by preparative reversed-phase high 
performance liquid chromatography (RP-HPLC) on a Delta 600 instrument (Waters) 
equipped with a Phenomenex C18 column at a flow rate of 8 mL/min. For RP-HPLC, 
solvent A was 0.1% TFA in H2O and solvent B was 4:1 MeCN/H2O containing 0.086% 
TFA. An elution gradient from 0% solvent B to 74% solvent B over 40 min was used unless 
specified otherwise. 
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3.4.3 Bioinformatic searches for LanJ-like proteins 
The nucleotide and amino acid sequences of LanJ-like enzymes, their LanA substrates and 
the synthetase LanMs were obtained from the National Center for Biotechnology 
Information (NCBI) sequence database. To identify LanJ-like enzymes, BlastP searches were 
performed using the NpnJA protein sequence (for LanJA enzymes) or CrnJ (for LanJB 
enzymes) as the query. The individual adjacent open reading frames (ORFs) were analyzed 
with the Conserved Domain Database in order to identify putative LanMs or other enzymes 
involved in lanthipeptide biosynthesis (e.g.: LanT for cross-membrane transportation, LanP 
for leader peptide removal). To identify putative LanAs, the short ORFs around LanM and 
LanJ were inspected manually. 
 
3.4.4 Plasmid construction for expression of His6-MBP-NpnJA 
Synthetic npnJA gene was ordered as double-stranded gBlock DNA from Integrated DNA 
Technologies (Table 3.10). In order to generate the gene encoding the His6-MBP-NpnJA 
fusion protein, two separate PCRs were performed which generated two DNA fragments: 
Fragment 1 contained the MBP gene with two His6-tags on both the 5’ side and 3’ side, as 
well as a thrombin cleavage site on the 3’ end, which was amplified from a modified pET28a 
vector with MBP insert; Fragment 2 contained the npnJA gene as well as a 20 bp additional 
sequence on its 5’ end that overlapped with the 3’ end of fragment 1. The two fragments 
were inserted via Gibson Assembly into the multiple cloning site (MCS)-1 of pRSFDuet 
vector linearized by NcoI and NotI digestion.  
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3.4.5 Plasmid construction for co-expression of MBP-NpnJA 
For co-expression of MBP-NpnJA in E. coli with substrate peptides that were also His6-
tagged, a similar two-fragment PCR was performed, except that the two His6-tags were not 
introduced. The resulting fragments were inserted into the MCS-1 of pACYCDuet and 
pCDFDuet vector, respectively. 
 
3.4.6 Plasmid construction for co-expression of NpnA3 mutants with NpnM 
The pRSFDuet co-expression plasmid containing wild-type His6-NpnA3 in MCS-1 and 
NpnM in MCS-2 was obtained as previously described.(30) The co-expression plasmids 
containing genes encoding the NpnA3 mutants NpnA3-T19S, NpnA3-T23S, NpnA3-T28S, 
and NpnA3-T19S/D22A/T23S/T28S were generated by site-directed mutagenesis using the 
above plasmid as template. 
 
3.4.7 Plasmid construction for co-expression of Ltn3147A1/A2 with LtnM1/M2 
The genes encoding Ltn3147A1/A2 and LtnM1/M2 were PCR-amplified form pBAC105 
plasmid extracted from Lactococcus lactis IFPL1052.(48) The ltnM1 gene was cloned into MCS2 
of pRSFDuet plasmid between AatII and XhoI restriction sites, and the ltnA1 gene was then 
cloned into the MCS-1 between BamHI and HindIII restriction sites. The ltnM2 gene was 
cloned into MCS2 of pRSFDuet plasmid between NdeI and KpnI restriction sites, and the 
ltnA2 gene was then cloned into the MCS-1 between BamHI and NotI restriction sites. The 
LtnA1-S7A and LtnA2-S9A/S12A mutants were generated by site-directed mutagenesis 
using the above plasmids as template.  
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3.4.8 Plasmid construction for co-expression of library substrates with ProcM mutant 
The mutant ProcM used in this study had the three zinc-binding Cys residues in its cyclase 
domain mutated to Ala (C924A, C970A, C971A). The pRSFDuet vector containing this 
mutant ProcM gene in MCS-2 was obtained as previously described.(44, 46) Substrates Lib2A3’ 
and Lib2A4 (Chapter 2) were subsequently cloned into the MCS-1 of the above vector via 
Gibson assembly between the EcoRI and NotI restriction sites.  
 
3.4.9 Overexpression of MBP-NpnJA and 17X-PTDH-A176R in E. co l i  
E. coli BL21 (DE3) cells were transformed with plasmid pET15b containing the mutant 
17X-PTDH-A176R, which has improved NADPH regeneration efficiency.(37) E. coli BL21 
(DE3) cells were co-transformed with the plasmid containing His6-MBP-NpnJA and the 
chaperone plasmid pGro7 (Clonetech). Cultures were inoculated from a single colony 
transformant and grown overnight at 37 °C in LB broth supplemented with 100 mg/mL 
ampicillin (for PTDH), or 50 mg/mL kanamycin and 25 mg/mL chloramphenicol (for 
MBP-NpnJA). The overnight culture was inoculated as 1:100 dilution into 1 L of LB broth, 
and cells were grown at 37 °C to an O.D.600 between 0.6-0.8. Expression was induced by 
the addition of 0.2 mM IPTG, and the culture was incubated at 18 °C for 18 h.   
 
3.4.10 Over-expression of modified LanAs in E. co l i  
In order to obtain dehydrated LanAs containing D-Ala expressed in E. coli, E. coli BL21 
(DE3) cells were co-transformed with the above-mentioned pRSFDuet derivatives 
containing lanA and lanM genes and with the pACYCDuet vector containing the MBP-
NpnJA gene. In the case of the class I lanthipeptide nisin which requires both NisB and NisC 
protein for dehydration and cyclization, E. coli Bl21 (DE3) cells were transformed with the 
 127 
pRSFDUet plasmid harboring His6-NisA & NisB,
(49) the pACYCDuet plasmid containing 
NisB & NisC, and the pCDFDuet plasmid containing MBP-NpnJA. For the control over-
expression without D-Ala introduction, the plasmid harboring MBP-NpnJA was omitted 
during transformation. The cell culture (0.5-2 L) was induced with 0.25 mM IPTG at OD600 
between 0.6-0.8, and incubated at 18 °C for 18 -20 h. 
 
3.4.11 Purification of MBP-NpnJA and 17X-PTDH-A176R 
All protein purification steps were performed at 4 °C (cold room) or on ice. After 
harvesting, the cell pellets were suspended at 0.1 g/mL in LanM Buffer A (20 mM HEPES, 
0.25 M NaCl, 10% glycerol, pH 7.4), and the cells were lysed using a high pressure 
homogenizer (Avestin, Inc.). Insoluble cell debris was pelleted via centrifugation at 16,500 × 
g for 45 min at 4 °C. The supernatant was filtered using 0.45 μm syringe filters and loaded 
onto a 5 mL HisTrap IMAC column pre-charged with Ni2+ and equilibrated in Buffer A. 
The column was washed with 20 mL of Buffer A, then the sample was loaded onto an 
ÄKTA fast protein liquid chromatography (FPLC) system (GE Healthcare). The column 
was further washed with up to 25% LanM Buffer B (200 mM imidazole, 20 mM HEPES, 
0.25 M NaCl, 10% glycerol, pH 7.4) in buffer A at a flow rate of 1 mL/min, then the protein 
was eluted using a gradient of 25-100% Buffer B. UV absorbance at 280 nm was monitored 
and fractions were collected and analyzed by SDS-PAGE. The fractions containing MBP-
NpnJA were combined and concentrated using an Amicon Ultra-15 Centrifugal Filter Unit 
(30 kDa MWCO, Millipore, 2,300 x g). The buffer was then exchanged back to Buffer A 
using a PD10 desalting column (GE Healthcare). MBP-NpnJA was obtained (Figure 3.16) 
with a yield of 30 mg per liter cell culture, and 17X-PTDH-A176R was obtained with a yield 
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of 100 mg per liter cell culture. Protein aliquots were flash-frozen in liquid nitrogen and 
stored at −80 °C.  
	  
Figure 3.16 SDS-PAGE of purified MBP-NpnJA. The left lane of the gel (7.5%) was loaded 
with purified MBP-NpnJA (calculated mass 86.8 kDa), and the right lane was loaded with the 
protein ladder. (Figure reproduced with permission from Yang et al. 2015(1))  
 
3.4.12 Purification of MBP-NpnJA and 17X-PTDH-A176R in buffer made in D2O 
In order to perform the PTDH-MBP-NpnJA coupled-enzyme assay in D2O, around 5-10 mg 
of each enzyme obtained in the previous section was separately concentrated to 0.5 mL by 
ultrafiltration (30 kDa MWCO), diluted with 5 mL of 20 mM HEPES, 0.25 M NaCl, pD 7.6 
in D2O, and then concentrated to 0.5 mL again. The dilution and concentrating step was 
repeated one more time with the same D2O buffer, resulting in an enzyme stock with 
D2O:H2O over 99:1. Protein aliquots were flash-frozen in liquid nitrogen and stored at −80 
°C.  
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3.4.13 Purification of modified LanA peptides 
After harvesting, the pellet was resuspended at 0.1 g/mL in LanA Start Buffer (20 mM 
NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol, pH=7.5). The cell paste was 
subjected to sonication to lyse the cells. Insoluble cell debris was removed by centrifugation 
at 16,500 × g for 45 min. The supernatant was purified by immobilized metal affinity 
chromatography (IMAC) using 2-4 mL of His60 Ni Superflow Resin (Clontech). Following 
1 h incubation at room temperature, the resin was washed with 5-10 resin volumes of wash 
buffer (Start Buffer + 30 mM imidazole), and the peptide was eluted from the resin using 3 
resin volume of elution buffer (start buffer + 4 M guanidine hydrochloride + 0.5 M 
imidazole). The elution fractions were desalted by C4 SPE column and purified on a C18 
column using the solvent gradient described in the General Methods. For LtnA1 and A2 
peptides, the purified peptide powder was stored at −80 °C under N2.  
 
3.4.14 MBP-NpnJA in v i tro  Assay 
To test the activity of MBP-NpnJA in vitro, substrate peptide (40 μM) was incubated with 1 
μM enzyme in the presence of 0.5 mM NADPH in 50 mM HEPES buffer at pH 7.4 for 30 
min at room temperature unless specified. For complete conversion of Dha33 residue of 
nisin to D-Ala, 20 μM of nisin was incubated with 4-5 μM MBP-NpnJA at pH 6.9 at room 
temperature overnight. To test the influence of the adjacent amino acids flanking the Dha 
residue on the activity of MBP-NpnJA, the incubation time was increased, and the assay was 
quenched by GluC or LysC digestion (1:10 (w/w) protease to protein ratio, 20 min, r.t) at 
different time points (20 min, 40 min, 1.5 h, 3.5 h or with 10 μM MBP-NpnJA overnight). 
The conversion from Dha to D-Ala on the fully dehydrated species was monitored by 
MALDI-TOF MS.  
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3.4.15 Coupled-enzyme assay in D2O 
For selective labeling of the MBP-NpnJA-generated Ala to distinguish it from the gene-
encoded L-Ala in the peptide sequence, substrate peptide (25 μM, 3-8 mg) was incubated 
with 0.5 μM MBP-NpnJA, 0.5 μM 17X-PTDH-A176R, 0.5 mM NADP+, and 0.5 mM 
deuterium-labeled phosphite (prepared as previously described(50)) in 50 mM HEPES buffer 
in D2O, pD=7.6. The reaction was incubated at room temperature overnight. The reaction 
was desalted with C4 SPE column and the peptide was further purified by C18 RP-HPLC as 
described in the General Methods.  
 
3.4.16 LanM in v i tro  assay 
As an alternative to obtaining dehydrated and cyclized peptide by co-expressing LanA and 
LanM in E. coli, the linear LanA substrate (100 μM) was incubated in vitro with 1 μM LanM 
enzyme (same purification procedure as MBP-NpnJA) in the presence of 1 mM ATP, 1 mM 
MgCl2, and 0.5 mM TCEP in 25 mM HEPES buffer at pH=7.4 overnight at room 
temperature. 
 
3.4.17 Endoproteinase digestion of unmodified or modified LanA peptides 
For peptides prepared during E. coli co-expression or in vitro assays, the majority of the leader 
peptide needs to be removed in order to accurately characterize the reduction of Dha in the 
core peptide by MS. NpnA3 and mutants were digested by Glu-C or Lys-C, LtnA2 was 
digested by Glu-C, LctA was digested with Lys-C, and ProcA derivatives were digested with 
Glu-C or Lys-C. The proteolysis reaction also contains 0.5 mM TCEP to reduce possible 
disulfide bonds in the core peptide. Purification of the digested core peptide sequence was 
 131 
carried out by RP-HPLC on an analytical Phenomenex C18 column, using the gradient 
described in the General Methods. 
 
3.4.18 N-Ethylmaleimide (NEM) alkylation assay to detect uncyclized Cys residues 
An aliquot of the protease-digested peptide reaction or full-length peptide solution was 
diluted into twice the volume of NEM alkylation buffer containing 500 mM HEPES, 3 mM 
NEM, 0.3 mM TCEP, pH 6.5. The reaction was incubated at 37 °C for 30 min and analyzed 
by MALDI-TOF MS. Species containing uncyclized free Cys residues that were NEM-
alkylated were identified by a mass increase of 125 Da for each adduct.   
 
3.4.19 Marfey assay for chiral analysis of Ala residues 
A sample of around 0.1 mg of purified peptide was hydrolyzed by treatment with 2 mL of 6 
N HCl and heating to 120 °C for 24 h in a sealed tube. The hydrolysate was dried under N2. 
To a total of 1 μmol amino acids in an eppendorf tube, 1.44 μmol of a 1% acetone solution 
of Marfey’s reagent (FDAA, N-(5-fluoro-2,4-dinitrophenyl)-D-alaninamide) and 8 μmol of a 
1 M solution of NaHCO3 were added. The reaction mixture was heated with frequent 
shaking over a hot plate at 40 °C for 1 h and then cooled to RT. The reaction was quenched 
by adding 8 μmol of 2 M HCl and diluted with 0.2 mL MeOH. Standards (L or D-Ala) were 
treated with identical procedures.  
 
3.4.20 LC-MS analysis for derivatized Ala residues 
The FDAA-derivatized samples (with around 2 nmol of derivatized Ala residues) were 
injected onto a Synapt LC-MS (Waters) equipped with a C18 UPLC column. The molecular 
weight and retention times were compared with those of standard FDAA-derivatized Ala 
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residues. Acetonitrile/water containing 0.1% formic acid was used as the mobile phase with 
a linear gradient elution mode (10-22.5% MeCN, 15 min) at a flow rate of 0.18 mL/min. A 
mass range of m/z 100-3000 was covered with a scan time of 1 s, and data were collected in 
the positive ion mode. Glu-1-Fibrinopeptide B (Glu-Fib) was used as external calibration 
standard. Extracted ion chromatograms were generated with an m/z window of 342.1±0.2 
Da for FDAA-Ala residues and 344.1±0.2 Da for FDAA-[α-2H1, β-2H1]-Ala residues, 
respectively. 
 
3.4.21 Agar diffusion growth inhibition assay 
The growth inhibition activity of nisin with D-Ala incorporation was determined against 
Lactococcus lactis HP. Nisin extracted from commercial Nisaplin (Danisco)(51) was used as 
positive control. Liquid molten GM17 agar (25 mL; 4% M17, 0.5% glucose, 1.5% agar) was 
cooled to 42 °C and seeded with 200 μL of dense overnight culture (approx 108-109 CFU 
mL-1) of the indicator strain L. lactis HP. After agar solidification in a Petri dish, samples 
were applied onto the medium. Assay samples were diluted in 10 μL of sterile water to give a 
final concentration of 5 μM. Plates were incubated for 15 h at 30 °C and antibacterial activity 
was qualitatively determined by the presence or absence of a zone of growth inhibition. 
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Table 3.10 Sequence of NpnJA 
Accession 
number  
ACC81659.1 
MMRNIAICSNEVENLILGQDSVKTIDMNGILVRCGLLRTENIYFDRNAVSNRFKVLV
KKKAFSCNYRDKSIIFRITKQAPENTFYVVGSDFVGEVIATGSEVTELKVGDRVIAN
NAYPESDALEAFPGIPSNHASKEYQVFHQAKLIKIPLEMSDEIAAAFSIGGQTSYSIVR
KFNPTKGSNILVTAAKSNTSLFVINALKKYDVNIYATSTSRLFEEELRAMGVKKVIL
VESKPNSLLENQSIQNIVAETGGFDCVFDPFFDLYLGQSVELMKIGAKYITCGLYDQ
YFELINQSFTPFSLNTNHIMGSVMTKNLQIIGNCLGLTEDLKNAIQDYALGHLNVVI
DSVFTGKDIEGFFERTYNAKDRFGKVVYKYE 
NpnJA 
nucleotide 
sequence used 
in this study 
ATGATGAGAAATATTGCAATGATGAGAAATATTGCAATTTGCAGTAACGAAGTT
GAAAATTTAATCCTTGGACAAGATTCCGTAAAAACCATAGATATGAATGGTATT
CTTGTTCGTTGTGGCTTGCTTCGTACCGAAAATATTTATTTTGATCGAAATGCCG
TAAGCAATCGATTTAAAGTCTTAGTTAAGAAAAAAGCTTTTTCCTGTAATTACCG
CGACAAGAGTATTATTTTTAGAATCACTAAACAAGCACCTGAAAATACGTTTTAT
GTCGTTGGTTCAGATTTTGTTGGCGAAGTTATTGCTACTGGTTCGGAAGTAACA
GAATTAAAAGTTGGCGATAGAGTTATTGCTAATAATGCCTATCCAGAATCAGAC
GCACTAGAGGCATTTCCTGGCATACCTAGCAACCACGCCTCAAAAGAATATCAG
GTATTTCATCAAGCCAAGTTAATAAAAATACCTCTAGAAATGTCAGATGAAATTG
CTGCTGCTTTTAGTATTGGAGGGCAAACAAGCTACAGCATCGTTCGCAAGTTTA
ATCCAACAAAAGGCTCTAATATTTTAGTTACCGCAGCTAAATCTAATACTTCCTT
GTTTGTAATTAATGCCTTGAAAAAGTACGACGTGAATATTTATGCCACAAGTAC
CTCAAGGCTTTTTGAGGAAGAACTCAGAGCGATGGGAGTCAAAAAGGTGATTC
TAGTCGAGTCAAAACCTAACAGTTTACTAGAAAATCAGTCAATTCAAAACATCGT
TGCAGAAACAGGCGGATTTGATTGTGTATTCGATCCCTTTTTCGATCTCTATTTA
GGACAGTCCGTTGAACTAATGAAGATCGGAGCGAAGTACATAACCTGTGGACT
ATACGATCAATACTTTGAATTAATTAATCAAAGCTTTACTCCATTTTCATTAAATA
CTAACCACATTATGGGATCGGTTATGACCAAAAATCTTCAAATTATTGGTAATTG
TCTTGGTTTAACCGAAGACCTCAAAAATGCTATTCAAGACTATGCTTTAGGCCAT
TTAAATGTAGTAATTGACTCTGTTTTTACTGGCAAAGATATAGAAGGTTTCTTCG
AGCGAACCTATAACGCAAAAGATAGATTTGGCAAAGTAGTCTATAAGTACGAGT
AA 
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CHAPTER 4 : DEMONSTRATION OF THE REVERSIBILITY OF THE 
MICHAEL-TYPE CYCLIZATIONS DURING LANTHIPEPTIDE BIOSYNTHESIS3 
 
4.1 INTRODUCTION 
As discussed in Chapter 1.3, during lanthipeptide biosynthesis, several experimental findings 
have lead to the hypothesis that not only the enzyme, but also the substrates in part 
determine the outcome of the cyclization process. One possible mechanism would be 
thermodynamic control of product formation, which requires the Michael-type cyclization 
processes to be reversible in order to obtain the desired ring topology.(1) However, such 
reversible cyclization, indicated by the opening of the (methyl)lanthionine rings, has never 
been demonstrated for lanthipeptides.  
   A recent study showed that the class II lanthipeptide synthetase ProcM could exchange the 
α-proton of methyllanthionine residues with protons derived from solvent in some but not 
all of its products.(2) As the exchange process must be an enzyme catalyzed reaction due to 
the low acid dissociation constant of the peptide α-protons (pKa>23),(3) one possible 
mechanism involves a reverse cyclization process with a ring-opened intermediate (Scheme 
4.1). Alternatively, exchange could also result from a deprotonation-reprotonation sequence 
without ring opening (Scheme 4.1).  
                                                
3 Reproduced in part with permission from “The Michael-type cyclizations in lantibiotic biosynthesis are 
reversible” ACS Chem. Biol, 2015, 10, 1234. © 2015 American Chemical Society. 
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Scheme 4.1 Two mechanisms for α-proton exchange of deuterium-labeled 
(methyl)lanthionines by lanthipeptide synthetases. a) Exchange by deprotonation-
reprotonation. b) Exchange by retro-Michael reaction followed by Michael addition. During 
the step labeled H2O, the deuteron that is initially on the active site base exchanges with 
protons from solvent. (Scheme reproduced with permission from Yang et al. 2015(1)) 
 
   In this study, I tested the class II lanthipeptide synthetase HalM2 from haloduracin 
biosynthesis (Figure 4.1), and class I lanthipeptide cyclase NisC from nisin biosynthesis 
(Figure 1.2) as examples. The results demonstrate that HalM2 not only is able to exchange 
the α-proton of all four thioether rings in its product with protons from solvent, but that the 
enzyme also catalyzes retro-Michael type additions that open up the ring structures. In 
addition, ring opening was also observed for NisC.  
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Figure 4.1 Lanthionine formation in lanthipeptide biosynthesis. a) Formation of 
dehydroamino acids (Dha/Dhb) from Ser/Thr, followed by the Michael-type addition of 
Cys residues to Dha/Dhb to generate lanthionine/methyllanthionine residues, respectively. 
Performing the biosynthesis assay in H2O or D2O results in protium (green) or deuterium 
(purple) labeling at the α-carbon of the thioether rings. b) The post-translational maturation 
of HalA2 catalyzed by HalM2.  
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4.2 RESULTS AND DISCUSSION 
4.2.1 Exchange of the α-proton of (methyl)lanthionine 
To test the ability of HalM2 to deprotonate at the α-position of the (methyl)lanthionine 
residues in its product, a prerequisite for a retro-Michael process (Scheme 4.1), HalA2 was 
modified by HalM2 in buffer made in D2O. The reaction was analyzed by matrix-assisted 
laser-desorption time-of-flight mass spectrometry (MALDI-TOF MS).  Seven dehydrations 
and incorporation of four deuterium atoms were observed (Figure 4.2a), as expected for a 
peptide cyclized by four Michael-type additions in D2O. The product peptide was then 
treated with N-ethylmaleimide (NEM), which alkylates free thiols. As anticipated, no NEM 
adducts were observed indicating that all four thioether ring structures were formed (Figure 
4.5a).  
   The dehydrated and cyclized HalA2 product (termed mHalA2 for modified HalA2)(4) with 
four deuterium atoms incorporated was purified by high-performance liquid 
chromatography (HPLC) and incubated with HalM2 in buffer made in H2O. The assay 
mixture was analyzed by MALDI-TOF MS at various time points, revealing a time-
dependent replacement of the four deuterium atoms with protium (Figure 4.2a-e). NEM-
treatment of the intermediates after inactivating HalM2 at acidic pH(5) showed that the MS 
intensity of NEM-adduct species was very low, suggesting that the peptides remained mostly 
cyclized.  
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Figure 4.2 MALDI-TOF MS demonstrating step-wise replacement of deuterium atoms with 
protium when deuterium-incorporated mHalA2 (20 μM) was incubated with HalM2 (10 μM) 
in H2O. The blue dashed lines show the exchange of one to four deuterons with protons 
(labeled as 1-4 ex) after a) 0 min, b) 3 min, c) 15 min, d) 3 h, and e) 8 h. f) No exchange was 
observed after incubation with HalM2-H791A for 16 h. (Figure reproduced with permission 
from Yang et al. 2015(1)) 
 
   The exchange process occurs stepwise with several intermediates in which one to four 
deuteriums have been exchanged (Figure 4.2). To determine if the exchange process displays 
directionality, the intermediates were analyzed by MALDI-TOF tandem mass spectrometry. 
It is important to point out that the fragmentation patterns of all the exchanged 
intermediates remain almost identical (Figure 4.3), indicating that the peptides did not 
undergo changes in the ring topology during the entire process.  
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Figure 4.3 Tandem MS of exchange intermediates. Modified HalA2 containing four 
deuteriums at the α-position of the four (Me)Lan residues was incubated with HalM2 in 
aqueous buffer. The reaction mixture was then monitored over time for exchange of the 
four deuteriums with protiums from solvent. The intermediates (with the number of 
exchanged deuteriums in the major species shown on the left) were then digested by 
endoproteinase Glu-C to remove the majority of the leader peptide and analyzed by tandem 
MS. The fragmentation pattern of each exchange intermediate is similar, indicating that the 
ring topology remained unchanged during the exchange process. (Figure reproduced with 
permission from Yang et al. 2015(1)) 
 
Closer analysis of each set of fragment ions revealed that the first two exchanges occur at 
the two C-terminal rings (rings C and D, Figure 4.4b), as illustrated by the y9 ion. The close 
proximity of these two rings prevented formation of fragment ions that could distinguish 
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whether the first exchange occurs in the C- or D-ring. However, the third exchange clearly 
occurs at the B-ring as deduced by comparing the y9 ions with the y14/y18 ions of three-
fold exchanged peptide (Figure 4.4b). The b6/b7/b8 ions did not have sufficient resolution 
to localize the last exchanged position, and the b1/b2 ions have a Dhb at position 1 and 
therefore also do not report on exchange.(6-9) However, the final exchange does not occur C-
terminal to Dhb7 as shown by the y18 ion of four-fold exchanged peptide (Figure 4.4b). It 
also does not take place N-terminal to Dhb1 as shown by the b−1 ions (Figure 4.4b).  
Hence, by process of elimination, the fourth and last exchange must take place at the A-ring. 
Therefore the observed order of exchange is the opposite of the order of cyclization,(10) 
implying that the exchange process reflects the reversal of the cyclization steps.  
 
   If the exchange process involves a retro-Michael reaction, rather than simply 
deprotonation and reprotonation of the enolate (Scheme 4.1), and if the exchange process 
indeed reflects the reverse process of cyclization, then the observation of four exchanges 
implies that the B-D rings must all be open in order for the fourth and last exchange to take 
place in the A-ring. This hypothesis could explain why it took 3-5 h to complete each of the 
last two exchanges whereas the first two exchanges were completed within 15 min (Figure 
4.2). However, as mentioned above, NEM-treatment of the exchange intermediates after 
HalM2 inactivation indicated very little ring-opened structures at any given time (vide infra). 
This observation is not unexpected since thio-Michael addition is an exergonic process and 
therefore the ring-closed forms are favored over the open forms.(11) 
 145 
 
Figure 4.4 Analysis on tandem MS of exchange intermediates. a) Tandem MALDI-TOF 
MS of mHalA2. b) Representative fragment ion sets (y9, y14, y18, and b−1) of intermediates 
present during the exchange process. The predominant number of exchanged deuterons in 
each peptide mixture is shown on the left.  * represents a minor ion resulting from 
fragmentation in the A ring. Such fragmentation inside a ring when it contains a 
dehydroamino acid has been observed previously.(6-9) (Figure reproduced with permission 
from Yang et al. 2015(1)) 
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4.2.2 Interception of ring-opened intermediates 
I next attempted to trap the ring-opened intermediates by adding aliquots of the exchange 
reaction with deuterium labeled mHalA2 into an NEM alkylation solution without 
inactivating HalM2, with the aim of intercepting any free thiols that may be formed in the 
exchange process. Indeed, several alkylation products were observed that contained one to 
three NEM adducts, and a peptide with four NEM adducts was also observed under 
prolonged incubation time with HalM2 and NEM (Figure 4.5c, d). Closer examination of the 
mass of each ion confirmed that the α-deuterium removal occurred alongside the NEM 
alkylation, and that the peptide containing four NEM adducts had all four deuteriums 
removed (Figure 4.6). No such products were observed in control experiments in which 
HalM2 was omitted (Figure 4.5a). The ability to alkylate free thiols in the presence of HalM2 
and NEM is consistent with the presence of a very small amount of ring opened product at 
any given time such that trapping of the thiol by NEM can drive the equilibrium towards the 
ring-opened forms. Collectively, these results indicate that the exchange process occurs via a 
HalM2 catalyzed retro-Michael addition. 
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Figure 4.5 MALDI-TOF MS data demonstrating the interception of free cysteine residues 
formed by the retro-Michael reaction. Shown are spectra of a) deuterium-labeled mHalA2 
incubated with NEM for 16 h in the absence of HalM2; b) deuterium-labeled mHalA2 
incubated with HalM2 for 1 h, followed by HalM2 inactivation, and treatment of the assay 
with NEM for 2 h. c) deuterium-labeled mHalA2 incubated with HalM2 for 1 h, followed by 
addition of NEM, and incubation of the assay for 2 h and d) for 24 h. e) Deuterium-labeled 
mHalA2 was incubated with HalM2-H791A for 1 h, and the assay solution was treated with 
NEM for 16 h. (Figure reproduced with permission from Yang et al. 2015(1)) 
 
   It is important to point out the additional observation that the exchange process occurred 
faster than the NEM alkylation when HalM2 was incubated with mHalA2 in the NEM 
buffer. As shown in Figure 4.6, the alkylated peptides are actually mixtures of peptides with 
various amounts of deuterium atoms having been removed, with the extent of exchange 
increasing with time. The spectra also show that for a subset of the peptides in each 
alkylation state, the number of deuterium atoms that have been exchanged is greater than the 
number of NEM adducts. This is true for peptides in all alkylation states except the four-
fold alkylated peptide (which only can have a maximum of four exchanges). The larger 
extent of exchange than alkylation is likely a consequence of having an active enzyme in the 
NEM alkylation assay. Therefore, each ring-opened intermediate can undergo one of two 
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competing reactions: NEM alkylation of the Cys or enzyme catalyzed Michael addition onto 
the dehydro-amino acid that was just generated by ring opening. The latter apparently is 
more efficient (and perhaps even occurs when the ring-opened product is still in the active 
site), resulting in exchange without alkylation. The data show as many as four exchanges in 
the peptide with a single NEM adduct, suggesting that the enzyme opens and closes the 
rings multiple times before a ring-opened peptide is trapped by NEM.  
	  
Figure 4.6 MALDI-TOF MS of each ring-opened intermediates trapped by NEM 
alkylation. The numbers at the top of the spectra (−4*, −3*, etc) show where the 
monoisotopic peaks (0 ion) would be for peptides that have undergone 4, 3 etc exchanges. 
(Figure reproduced from Yang et al. 2015(1)) 
 
   Because of these considerations, the exchange assay has more information regarding the 
enzyme catalyzed ring opening process than the alkylation assay, since the latter is 
determined at least in part by the rate of non-enzymatic alkylation of Cys residues in 
different sequence contexts. Moreover, after the first alkylation, the peptide is a non-natural 
substrate for which the rate of the next ring opening may be compromised and even the 
order of ring opening could be affected. Therefore, such caveats must be considered when 
using the order of NEM alkylation to determine the directionality of ring opening (see 
below).
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   In addition to the observation of ring-opened intermediates on α-deuterium labeled 
mHalA2 substrate, I also observed very similar alkylated intermediates when HalM2 was 
incubated in the presence of NEM with mHalA2 substrate containing protiums at the α-
positions of the four thioether rings (Figure 4.7). Moreover, the exchange and ring-opening 
process of HalM2 did not require ATP, consistent with previous observations that the 
cyclization reaction of class II lanthionine synthetases is not ATP-dependent.(12) However, 
the leader peptide appears to be required since no ring opening could be detected when 
haloduracin β was incubated with HalM2 in the presence of NEM (Figure 4.8). Overall, the 
data strongly suggest that HalM2 catalyzes thioether ring formation/opening in a reversible 
manner.  
	  
Figure 4.7 Interception of free cysteine residues formed by the retro-Michael reaction 
during incubation of HalM2 with mHalA2 that contains protiums at all four α-positions of 
the thioether rings. a) mHalA2 incubated with NEM for 16 h in the absence of HalM2. b) 
mHalA2 (20 μM) was incubated with HalM2 (10 μM) for 1 h, NEM was added, and the 
assay was incubated for 20 min, c) 2 h, and d) 24 h prior to analysis by MALDI-TOF MS.  
(° represents a fragment of HalM2 after Glu-C digestion). (Figure reproduced with 
permission from Yang et al. 2015(1)) 
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Figure 4.8 MALDI-TOF-MS spectra showing the dependence on the leader peptide for the 
reverse cyclization process. a) Haloduracin β was treated with NEM in the absence of 
HalM2 for 20 h. b) Haloduracin β (20 μM) was incubated with HalM2 (10 μM) for 1 h, then 
treated with NEM and incubated for 20 h.  (Figure reproduced with permission from Yang 
et al. 2015(1))  
 
Given the observed products of retro-Michael reaction catalyzed by HalM2, we next 
performed the alkylation assay with the class I lanthipeptide cyclase NisC. We first generated 
the dehydrated and cyclized peptide mNisA by co-expression of NisA, NisB, and NisC in 
Escherichia coli.(6) Following incubation of NisC with mNisA that has five thioether rings 
(Figure 4.9a), we observed the formation of ring-opened intermediates over time represented 
by peptides with one to five NEM adducts (Figure 4.9c). We analyzed the species with one, 
two and three NEM adducts by tandem mass spectrometry (Figure 4.10). The data show that 
the Cys in the C-ring is alkylated first followed by the Cys of the E-ring, and the Cys forming 
the D-ring. As discussed above, important caveats exist with respect to using the sites of 
NEM alkylation as readout for the order of ring opening. Most importantly, non-enzymatic 
NEM alkylation is in competition with enzymatic re-formation of the ring. Hence, a Cys for 
which this competition is more favorable towards NEM alkylation might be observed as the 
first-captured alkylation site even if it is not the first ring opened by the enzyme.  
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Figure 4.9 NisC catalyzed retro-Michael reaction. a) The posttranslational maturation of 
NisA catalyzed by the dehydratase NisB and the cyclase NisC. b) MALDI-TOF MS 
spectrum of mNisA treated with NEM for 16 h in the absence of NisC. c) MALDI-TOF 
MS of mNisA incubated with NisC for 1 h, and then treated with NEM for 12 h. (* 
represents NisA peptides that were incomplete dehydrated;(6) ° represents the leader peptide 
of mNisA). (Figure reproduced with permission from Yang et al. 2015(1)) 
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Figure 4.10 Tandem MS of ring-opened intermediates of mNisA with one to three NEM 
adducts. a) Tandem MS of mNisA with three NEM adducts indicates that the opened C, D 
and E rings were captured by NEM alkylation; b) Tandem MS of mNisA with two NEM 
adducts indicates that the opened C and E rings were captured by NEM alkylation; c) 
Tandem MS of mNisA with one NEM adducts indicates that the opened C ring was 
captured by NEM alkylation; (* indicates decarbonylation (a ion) from the corresponding b 
ion appearing to its right). (Figure reproduced with permission from Yang et al. 2015(1)) 
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4.2.3 A conserved His is likely responsible for enolate protonation 
With the establishment that exchange of the α-protons of (methyl)lanthionine residues is 
associated with ring opening, we were able to investigate the role of His791, which is present 
in the cyclization domain of HalM2, and is highly conserved among class I and class II 
synthetases (Figure 4.11). Mutation of His791 to Ala significantly decreased the cyclization 
activity of HalM2 with linear HalA2 (Figure 4.12). Previous studies based on the crystal 
structure of NisC have proposed that this residue could either serve as the active site acid 
that protonates the enolate intermediate during ring formation, or the base that deprotonates 
the Cys prior to the Michael addition (Scheme 4.1).(13) However, it is unlikely that the residue 
is responsible for both proton transfers, since the anti-addition mechanism of the Michael-
type addition requires the acid/base to be placed on opposite faces of the dehydroamino 
acid. If His791 acts as the base to deprotonate the Cys, and hence as acid to protonate the 
Cys in a retro-Michael process, we anticipated that the ring-opening process with mHalA2 
might be hampered by mutating this residue, while α-proton exchange would be unaffected. 
Incubation of deuterium-labeled mHalA2 with HalM2-H791A completely abolished both 
the exchange and ring-opening activities (Figures 4.2f and 4.5e). These observations suggest 
that His791 serves as the active site acid that protonates the enolate intermediate during ring 
formation and deprotonates the α-proton of the thioether rings during ring opening.  
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Figure 4.11 Sequence alignment showing the conserved His residue among class I 
lanthipeptide cyclases and class II lanthipeptide synthetases. Highly conserved residues are 
shown in bold. Conserved His residues proposed for enolate protonation in this paper are 
shown in green. Conserved active site residues critical for zinc ion binding are shown in red. 
The residue numbers on the top are based on HalM2, the residue numbers on the bottom 
are based on NisC. (Figure reproduced with permission from Yang et al. 2015(1)) 
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Figure 4.12 Activity comparison of HalM2-H791A and HalM2 on HalA2 substrate. Parallel 
assays with HalM2 or HalM2-H791A were incubated at room temperature. At different time 
points, an aliquot of the assay was quenched at acidic pH. The sample was subjected to 
MALDI-TOF MS to determine the dehydration state of the full-length peptide. In order to 
determine the cyclization state, the quenched reaction was neutralized to pH between 6.0-
6.5, followed by NEM alkylation and MALDI-TOF MS analysis.  
   When HalA2 was incubated with HalM2, complete dehydration and cyclization was 
observed within 30 min (panels b and c). When HalA2 was incubated with HalM2-H791A, 
complete dehydration was observed within 1.5 h (f), while the cyclization process was 
significantly slowed down (g and h) (* represents species with incomplete dehydration). The 
decrease in dehydration activity upon decreasing the cyclization activity is fully consistent 
with a recent kinetic study on HalM2 that showed that the last few dehydrations do not 
commence until after the first cyclizations have been completed.(14) (Figure reproduced with 
permission from Yang et al. 2015(1)) 
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4.3 SUMMARY AND OUTLOOK 
This chapter describes the first direct evidence for reversible Michael-type addition during 
lanthipeptide biosynthesis. HalM2 and NisC were shown to be capable of opening up 
multiple rings under the conditions of catalysis, even though at equilibrium only the ring-
closed peptide was observed. This work also provides support for the role of the conserved 
His residue in the active site of class I and class II synthetases, which we propose protonates 
the enolate intermediate during ring formation. These findings suggest that thermodynamic 
control over the ring topology cannot be ruled out, and may help provide further insights 
towards the role of the peptide sequence in determining the cyclization pattern. 
   For future directions, firstly, it would be interesting to test if the lanthipeptide synthetase is 
able to “correct” a kinetically preferred structure that is of higher energy. This could help 
explaining the substrate tolerance of the biosynthetic machinery. Such non-native cyclic 
peptides would need to be prepared through chemical synthesis or non-enzymatic cyclization. 
While this remains to be tested for HalM2 and NisC, very interesting observations were 
lately shown for the substrate-tolerant synthetase ProcM. ProcM is able to exchange the α-
protons in mProcA3.3 (Figure 2.2), one of its product, with a very slow exchange rate on the 
secondly-formed ring.(15) However, ProcM was unable to catalyze the reversible cyclization,(15) 
nor could this enzyme convert an incorrect, ring topology generated by non-enzymatic 
cyclization back to the wild-type mProcA3.3,(16) which suggests the ring formation of ProcM 
is not likely under thermodynamic control. In addition, kinetic assays showed that ProcM 
and HalM2 behave very differently during catalysis. While the rates of the cyclization 
reactions appeared to get faster as HalA2 matures towards the well-evolved final product, 
the opposite trend was observed in ProcA2.8 and ProcA3.3 maturation, because the second 
cyclization was much slower than the first ring formation.(14, 15) This observation is not 
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surprising from an evolution point of view, as a flexible “evolution intermediate”(17) enzyme 
pocket that tolerates substrates with various ring topologies might not match well with every 
substrate for optimal kinetic efficiency. From a mechanistic point of view, the knowledge 
gained from this chapter about the role of the conserved His residue is helpful. A hypothesis 
is proposed here, as the ProcA substrate matures into the final product, it does not fit well in 
the ProcM pocket anymore, and thus the conserved His859 residue (Figure 4.11)(16) in 
ProcM could only slowly protonate the enolate intermediate during the second ring 
formation, which could explain the slow product formation. And in the reverse direction, 
His859 could only slowly (or not at all) deprotonate the α-proton of the last formed ring, 
which could also explain the slow D-H exchange of mProcA3.3 and no exchange in 
mProcA2.8. 
   In this case, if the proper fitting of substrate to the enzyme pocket is critical for the α-
proton extraction and ring opening to happen, it is unlikely that a “wrong” ring topology 
that does not fit well into the active site could still be opened and fixed by the enzyme, as 
already shown by ProcM. Therefore, the reversible enzyme-catalyzed cyclization shown in 
this chapter does not necessarily suggest that LanM enzymes produce the most thermally 
stable product. Based on the observation that only the well-evolved HalM2-mHalA2 and 
NisC-mNisA undergo significant ring openings, while ProcM-mProcAs do not, the 
reversible cyclization process might rather be a result of the co-evolution of the enzyme and 
substrate for efficient product formation under evolutionary pressure.  
   In addition, the discovery of the reverse cyclization–mediated α-proton exchange provides 
an alternative route for deuterium labeling at the α-position of the (Me)Lan rings: Instead of 
incubating the linear peptide or dehydrated peptide with a class II synthetase or class I 
cyclase in D2O, α-deuterium incorporation could also be achieved through α-proton 
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exchange, by incubating the enzyme in D2O with the cyclized substrate that is readily 
obtained by co-expression in E. coli.(6) This strategy would be especially useful for labeling 
class I lanthipeptides that otherwise require the reconstitution of the tRNA-dependent 
dehydratase activity either in E. coli or in vitro.(18, 19) Last but not least, for those class III 
lanthipeptides that contain the carbocyclic labionin motifs (Chapter 1.2.1), it would be 
interesting to test if the synthetase is also able to open up the labionin residue, which 
involves enzymatic cleavage of a carbon-carbon bond.  
 
 
4.4 MATERIALS AND METHODS 
4.4.1 Materials.  
All chemicals were purchased from Fisher Scientific or Aldrich unless noted otherwise. 
Peptide Calibration Standard II for MALDI-TOF MS was purchased from Bruker. mNisA, 
NisC, HalA2 and HalM2 were produced in Escherichia coli as previously described.(6, 20) 
Haloduracin β was purified from Bacillus halodurans C-125, as described previously.(21) 
 
4.4.2 Preparation of deuterium labeled mHalA2   
The in vitro modification reaction contained 40 μM His6-tagged HalA2, 1 μM HalM2, 1 mM 
ATP, 1 mM MgCl2, and 0.5 mM TCEP in 25 mM HEPES at pD=8.2 in D2O. The reaction 
was incubated at room temperature overnight, and mHalA2 was purified by reversed-phase 
HPLC using analytical C18 column. mHalA2 separated well from the unmodified HalA2 
peptide (Figure 4.13), which eliminates the formation of α-proton labeled mHalA2 from 
linear HalA2 as a false positive signal on MS during the exchange assay in H2O. mHalA2 
peptide was digested with endoproteinase Glu-C to generate the core peptide with a 13 
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amino acid residue overhang on the N-terminus. The complete incorporation of four 
deuterium atoms into the core peptide was confirmed by MALDI-TOF MS. 
 
Figure 4.13 HPLC separation of mHalA2 after in vitro biosynthesis assay. The elution 
gradient started from 8% acetonitrile in 0.1% TFA to 44% acetonitrile in 0.1% TFA over 35 
min.  a) trace of mHalA2 after the assay. b) trace of HalA2 as starting material.   
 
4.4.3 D-H exchange assay 
The exchange assay contained 20 μM deuterium-labeled mHalA2, 10 μM HalM2, 0.5 mM 
TCEP, 25 mM HEPES at pH=7.8 in H2O. The reaction was incubated at room temperature. 
At different time points, aliquots of the reaction were subjected to Glu-C digestion and 
MALDI-TOF MS to monitor the extent of exchange.  
 
4.4.4 NEM alkylation assay 
An aliquot of the above assay was diluted into twice the volume of NEM alkylation buffer 
containing 500 mM HEPES, 3 mM NEM, pH=6.5. The reaction was incubated at 37 °C. At 
different time points, an aliquot of the reaction was desalted with a C4 Solid Phase 
Extraction (SPE) cartridge The samples were eluted from the SPE column by 50% aqueous 
acetonitrile with 0.1% TFA and the solvent was removed by centrifugal evaporation and 
lyophilization. For the ring-opening assay on mNisA, 20 mM mNisA was incubated with 5 
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mM NisC and 0.5 mM TCEP in 25 mM HEPES buffer (pH=6.9) at room temperature for 1 
h, followed by the same NEM alkylation procedure as described above. The resulting 
peptide was subjected to endoproteinase Glu-C (for mHalA2) or Arg-C (for mNisA) 
digestion and MALDI-TOF MS to determine the alkylation state of the core peptide. The 
NEM alkylation assay with haloduracin β was performed under the same conditions as with 
the full-length mHalA2 peptide.  
 
4.4.5 Activity of HalM2 and HalM2-H791A mutant on HalA2 substrate  
The assay solution contained 40 μM HalA2, 1 μM HalM2 or HalM2-H791A, 0.5 mM TCEP, 
0.5 mM ATP, and 0.5 mM MgCl2 in 25 mM HEPES at pH=7.8. The reaction was incubated 
at room temperature. At different time points, an aliquot of 5 μL of the assay was added into 
10 μL of sodium citrate buffer (160 mM, pH=3.0) and incubated at room temperature for 10 
min to quench the reaction. The sample was subjected to MALDI-TOF MS to determine 
the dehydration state of the full-length peptide. In order to determine the cyclization state, 
the quenched reaction was neutralized with 8-11 μL of 500 mM HEPES buffer (pH=6.9) to 
pH between 6.0-6.5, followed by addition of 1 μL of 50 mM NEM. The reaction was 
incubated at 37 °C for 15 min and subjected to MALDI-TOF MS analysis.  
 
4.4.6 MALDI-TOF mass spectrometry. 
After desalting using a zip-tip (C18), samples were analyzed by MALDI-TOF mass 
spectrometry on a Bruker UltrafleXtreme spectrometer using a matrix solution containing 35 
mg/mL 2,5-dihydroxybenzoic acid (DHB) in 3:2 MeCN/H2O with 0.1% TFA. Peptide 
Calibration Standard II was used as external standard.  
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CHAPTER 5 : BIOSYNTHESIS AND MODE OF ACTION OF HALODURACIN4  
 
5.1 INTRODUCTION 
Due to the rapid spread of multi-drug resistant bacterial strains,(1) antimicrobial peptides are 
being developed as potential sources of antibiotics to treat infections.(2) The lantibiotic group 
of bacteriocins exhibits high antimicrobial activity against Gram-positive bacteria including 
drug resistant strains.(3) A growing class of two-component lantibiotic systems utilize two 
peptides that are each post-translationally modified to an active form and act in synergy to 
provide antibacterial activity.(4) Examples include lacticin 3147,(5, 6) staphylococcin C55,(7, 8) 
plantaricin W,(9) haloduracin,(10, 11) cytolysin,(12) lichenicidin,(13) and carnolysin.(14)  
 
Figure 5.1 Structure and biosynthesis of haloduracin α	   and haloduracin β. For 
reconstitution in E. coli, the last four amino acids in each leader peptide were mutated to the 
Factor Xa proteolysis site (IEGR) for ease of leader sequence removal. 
 
                                                
4 Reproduced in part with permission from “Production of lantipeptides in Escherichia coli” J. Am. Chem. Soc. 
2011, 133, 2338. Copyright © 2010 American Chemical Society 
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   Haloduracin (composed of Halα and Halβ peptides) is a two-component lantibiotic that 
shows high potency against a range of Gram-positive bacteria (Figure 5.1).(10, 15) Haloduracin 
has a similar efficacy as that of the commercially used lantibiotic nisin, and is more stable at 
pH 7 than nisin in buffer,(15) which bodes well for potential treatment against infections, as 
well as to serve as food preservative under neutral or basic conditions.  
   However, previously, haloduracin could only be obtained from the producer strain on 
solid, rich medium,(10) preventing isotopic labeling for NMR study or non-proteinogenic 
amino acid incorporation to probe its mode of action. In the first part of this chapter, I 
describe the successful production of haloduracin in E. coli, using the co-expression strategy 
described in Chapter 2.(16) 
   For the mode of action of haloduracin, it has been proposed that, like other two-
component lantibiotics, haloduracin uses Halα to recognize a target molecule at the cell 
surface, likely lipid II (Figure 5.2),(21) which then generates a binding site for Halβ, which 
forms pores that result in membrane damage and depolarization and ultimately cell death 
(Figure 5.3).(15) Lipid II is the essential recycling precursor that transports the disaccharides-
pentapeptide building block from the bacterial cytoplasm to the outside for peptidoglycan 
cell wall assembly (Figure 5.2).(21) It has been demonstrated that Halα indeed binds to lipid II 
with nanomolar affinity in a 2:1 stoichiometric fashion by an in vitro transglycosylation 
inhibition assay(22). Fluorescently labeled Halβ also co-localizes with labeled Halα on Bacillus 
subtilis cells, with a similar localization pattern as that of lipid II.(23)  
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Figure 5.2 The role of lipid II during biosynthesis of peptidoglycan cell wall.(17-19) Lipid II is 
synthesized in the cytoplasm, with undecaprenyl(20) phosphate as the carrier for the 
disaccharide pentapeptide building block. Lipid II is then translocated such that the 
disaccharide pentapeptide faces out, where it is polymerized via transglycosylation and 
crosslinked by transpeptidation on the peptide side chain. 
 
   However, direct evidence of Halβ binding to Halα – lipid II complex is still lacking. In this 
work, isothermal titration calorimetry (ITC) and liposome leakage assays were used to probe 
the binding interaction of the lipid II–Halα–Halβ complex. I also describe the large-scale 
biosynthesis of lipid II, lipid I,(24) and short-chain lipid II derivatives in vitro.  
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Figure 5.3 Previously proposed mode of action of haloduracin.  
 
 
5.2 RESULTS AND DISCUSSION 
5.2.1 Production of haloduracin in E. co l i  
The gene for HalA1 with a Factor Xa protease cleavage site (halA1_Xa) between its leader 
and core peptide was inserted into MCS1 of pRSFDUET-1, and the gene of its bifunctional 
modification enzyme HalM1 was inserted into MCS2. E. coli BL21 (DE3) cells were 
transformed, grown at 37 °C, and induced as described in Chapter 2. After harvest, lysis, 
IMAC purification, and proteolysis with Factor Xa to remove the leader peptide, the 
modified core peptide Halα was obtained (Figure 5.4). Similar results were obtained for Halβ 
by co-expression of HalA2_Xa with HalM2 (Figure 5.4). The purified Halα thus obtained 
was combined with Halβ for bioactivity assays and demonstrated very similar antimicrobial 
activity against Lactococcus lactis HP as an authentic sample of these peptides obtained from 
the producing organism(15) (Figure 5.4). Repeating the expression in minimal medium 
required for producing isotopically labeled product for NMR studies was also successful 
albeit the yield was reduced (approximately 1 mg of pure mHalA1 per liter of culture). 
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Figure 5.4 Production of haloduracin in E. coli. a) MALDI-TOF MS showing that the core 
peptides of mHalA1 and mHalA2 after Factor Xa cleavage (top panel) has the same mass as 
authentic Halα and Halβ, respectively (bottom panel. Halα: Calculated monoisotopic m/z 
3046.29 (reduced); observed 3046.37. Halβ: Calculated monoisotopic m/z 2331.05; observed 
2331.28). b) MALDI-tandem MS of the core peptide of mHalA2 after Factor Xa cleavage 
(top panel) showed a very similar fragmentation pattern as that of authentic Halβ (bottom 
panel). The sequence of Halβ is shown above. c) Antimicrobial activity of haloduracin 
against L. lactis HP. (1) authentic nisin; (2) nisin produced in E. coli; (3) Halα produced in E. 
coli combined with authentic Halβ; (4) authentic Halα combined with Halβ produced in E. 
coli; (5) authentic Halα and Halβ; (6) Halα and Halβ both produced in E. coli.  
 
5.2.2 In vi tro  assembly of lipid II and derivatives 
Lipid II, lipid I and its short chain derivatives were assembled in vitro in large scale by MraY 
and MurG (Figure 5.2).(24) In short, undecaprenol was isolated from natural resources(25) and 
phosphorylated as described.(26) UDP-MurNAc-pentapeptide was purified from Staphylococcus 
simulans.(27) Lipid II was assembled in vitro in the presence of undecaprenol phosphate, UDP-
MurNac-pentapeptide and UDP-GlcNAc by Micrococcus luteus membrane vesicles containing 
MraY and MurG. The crude product after butanol extraction was further purified by anion 
exchange chromatography. For lipid I assembly, the same procedure was followed except 
UDP-GlcNAc was omitted. For short chain lipid II assembly, cis, cis-farnesyl or trans, trans-
farnesyl phosphate was provided, and the crude product was purified by reversed-phase 
HPLC using a C18 column. The purified lipid II analogues were characterized by ESI-MS 
and TLC (Figure 5.5, Figure 5.11). 
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Figure 5.5 ESI-MS of lipid II and lipid II analogues. a) Lipid II; b) lipid I; c) short chain 
farnesyl lipid II. (A small amount of analogues with decaprenyl or dodecaprenyl carrier (10-
Lipid I/lipid II, 12-lipid I/lipid II) was also observed (labeled in blue line).) 
 
Table 5.1 Calculated and observed masses of each ion in Figure 5.5.  
 ion Calculated 
mass 
Observed 
mass 
ion Calculated 
mass 
Observed 
mass 
Panel a 
[M-H]- lipid II  1874.05 1873.8 [M-2H]2- 10-lipid II  902.49 902.8 
[M-H]- 10-lipid II  1805.99 1805.7 [M-2H]2- 12-lipid II  970.55 970.6 
[M-H]- 12-lipid II  1942.11 1941.9 [M-3H]3- 10-lipid II  601.33 601.6 
[M-2H]2- lipid II  936.52 936.9 [M-3H]3- 12-lipid II  646.70 647.0 
[M-3H]3- lipid II  624.01 624.3    
Panel b 
[M-H]- lipid I  1670.97 1670.6 [M-2H]2- 10-lipid I  800.95 801.2 
[M-H]- 10-lipid I 1602.89 1602.9 [M-2H]2- 12-lipid I 869.01 869.3 
[M-H]- 12-lipid I 1739.03 1738.6 [M-3H]3- 10-lipid I 533.63 533.8 
[M-2H]2- lipid I 834.98 835.3 [M-3H]3- 12-lipid I 579.01 579.2 
[M-3H]3- lipid I 556.32 556.5    
Panel c 
[M-H]- 3-lipid II  1329.55 1329.9 [M-2H]2- 3-lipid II  664.27 664.6 
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5.2.3 ITC analysis of lipid II-haloduracin interaction 
In order to mimic the membrane environment where binding of haloduracin to lipid II takes 
place, several approaches were utilized, including micelles,(28, 29) liposomes,(30, 31) organic 
solvents (10-15% DMSO, v/v),(32) or using short-chain water-soluble lipid II analogues(32) 
that do not require membrane mimics. In all cases, vancomycin was used as a positive 
control due to its known binding to lipid II analogues with micromolar dissociation 
constants.(33)  
   I first started with titrating short-chain lipid II into vancomyin, nisin or Halα in aqueous 
solution (25 mM HEPES, pH=7.5) since this system does not require other membrane-
mimicking compounds. Vancomycin exhibited a Kd of 1-2 μM with an approximate molar 
ratio of 2:1 (vancomycin to 3-lipid II) for both cis cis, or trans, trans-3-lipid II (Figure 5.6). 
However, nisin and Halα showed no binding to cis, cis-3-lipid II (Figure 5.6), while 
precipitation was observed upon titrating nisin or Halα	   with trans, trans-3-lipid II. Such 
precipitation was also observed previously.(32) Supplementing the buffer with Ca2+ ions or 
adding organic solvent to the buffer (acetonitrile or DMSO up to 50% v/v) did not prevent 
the precipitation. These results indicate the complexity of lipid II-lantibiotic interactions, as 
it could not be simplified in aqueous solution instead of in a membrane-like environment. In 
addition, the configuration of the polyprenyl units adjacent to the pyrophosphate group in 
lipid II analogues appears to be important for the binding interaction as well. 
 170 
 
Figure 5.6 Calorimetric titration of farnesyl-lipid II with vancomycin, nisin or Halα. Cis, cis-
lipid II (top panel) or trans, trans-3-lipid II (bottom panel) was titrated into vancomycin (a), 
nisin (b) or Halα	  (c), respectively. The top graph shows the heat released after each injection 
(Peaks are pointing upwards, representing the value of heat flow during an exothermic 
binding process). The bottom graph displays the integrated heat per injection, which is 
displayed against the molar ratio of lipid II versus the different compounds used. (The 
volume of the titration syringe is 50 μL, while the volume of the analyte cell is 191 μL.) 
 
   Next, full-length lipid II was incorporated into micelles by re-suspending the dry lipid II 
film in 1% DPC (dodecylphosphocholine) buffer. However, all three compounds exhibited 
weak binding, including vancomycin (data not shown). Considering that lipid II itself is able 
to form micelles due to its amphipathic structure and has been directly used in ITC study 
focused on nukacin ISK binding, which resulted in a sub-micromolar Kd.
(28) I also tried 
directly titrating lipid II (prepared as described(28)) into a solution of Halα. However, 
although heat release was observed partially due to micelle dilution, there was no indication 
of tight binding (Figure 5.7a).  
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   I was only able to observe a micromolar Kd between lipid II and each of the three 
compounds when 10-15% DMSO was used as co-solvent for both titrant and analyte 
(Figure 5.7). Heat release was also observed upon adding Halβ to the Halα: lipid II complex 
under the same conditions (Figure 5.7). However, the observed affinity does not correlate 
well with the nanomolar Kd estimated for nisin
(34, 35) and Halα(22) previously.  
 
Figure 5.7 Calorimetric titration of lipid II with vancomycin, nisin or haloduracin. a) 
Calorimetric titration of lipid II (in micelle forms) with Halα. b-g) ITC in 15% DMSO, 25 
mM HEPES, pH=7.5 (for vancomycin and haloduracin) or pH=6.5 (nisin). Micromolar Kd 
was observed when titrating vancomycin (b), nisin (c) or Halα (d) into lipid II. Halβ also 
displayed binding isotherms only when titrating into a 1:1 mixture of Halα and lipid II (g), 
but not when titrating into Halα	   (e) or lipid II (f) separately. The top graph in each panel 
shows the heat peaks after each injection (Peaks are pointing upwards, representing the value 
of heat flow during an exothermic binding process). The bottom graph displays the 
integrated heat per injection, which is displayed against the molar ratio of titrant to analyte. 
(The volume of the titration syringe is 50 μL, while the volume of the analyte cell is 191 μL.) 
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   Incorporation of lipid II into LUV (large-unilamellar vesicles) liposomes is a better strategy 
to mimic the double-layer membrane environment than all previous approaches. Before ITC 
titration, a liposome leakage assay was performed to investigate the membrane disruption 
behavior of nisin and haloduracin in the presence or absence of lipid II. 
 
5.2.4 Haloduracin is able to disrupt model membranes in the absence of lipid II 
Two types of model LUV liposomes were used, the first one was made up of zwitterionic 
phosphatidylcholine (PC) that are commonly present in plant and mammalian cells but 
absent from most gram-positive bacteria.(36) The second one was made up of a 3:1 molar 
ratio of phosphatidylglycerol (PG) and phosphatidylethanoamine (PE), resulting in a net 
negative charge that mimics gram-positive bacterial membranes such as Bacillus subtilis.(37) 
Both types of liposomes were incorporated with or without 0.1 mol % of lipid II,(35) and 
contained 50 mM carboxyfluorescein (CF) as indicator for membrane leakage. The CF-
loaded liposomes were mixed with nisin or haloduracin that have been shown to form pores 
in gram-positive bacterial membranes.(15, 35) The fluorescence intensity change was measured, 
and the final intensity change after adding TritonX-100 (which fully disassembled the 
liposomes) was taken as the 100% leakage value. 
   As shown in Figure 5.8a, nisin induced CF leakage specifically on lipid II-doped liposomes, 
although low-level leakage was also observed on PG-PE liposomes without lipid II due to 
the electrostatic interaction between nisin and PG.(34) However, haloduracin was able to 
induce CF leakages on all liposomes, regardless of the presence of lipid II (Figure 5.8b). 
Such leakage, however, requires the presence of both α and β peptides (Figure 5.8c), which 
was similarly observed for cytolysin (Figure 5.8d). These results indicate the different mode 
of action between nisin and the two-component lantibiotics. While Halα still binds to lipid II 
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and inhibits transglycosylation during cell wall formation, the synergistic membrane 
disruption ability of the α and β peptides of haloduracin (and cytolysin) does not critically 
require the presence of lipid II.  
 
 
Figure 5.8 Carboxyfluorescein leakage from liposome model membrane systems. a) The 
presence of 0.1 mol % lipid II in DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) 
liposomes or 3:1 molar ratio of DOPG (1,2-dioleoyl-sn-glycero-3-phosphoglycerol)/POPE 
(1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine) liposomes increases nisin’s pore 
formation activity. b) Haloduracin (Halα and Halβ) is able to disrupt all model membranes 
in the presence or absence of lipid II. c) Both α and β peptides are required for 
haloduracin’s membrane disruption activity. d) Both S and L peptides are required for 
cytolysin’s membrane disruption activity. (Liposome concentrations were 200 μM on a 
phosphorus basis. NA in the figure indicates data not tested) 
 
5.3 SUMMARY AND OUTLOOK 
In this study, different lipid II analogues were produced in sufficient quantity (mg level) 
using the biosynthetic machinery (MraY and MurG enzymes) isolated from M. luteus for 
biophysical studies. It was shown that the configuration of the polyprenyl units adjacent to 
the pyrophosphate group of lipid II appears important for lantibiotic binding, but not for 
vancomycin binding. ITC study using full-length lipid II indicated the binding interaction 
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between Halα-lipid II and Halα-Halβ-lipid II, while very weak binding was observed 
between lipid II and Halβ, or between both Halα and Halβ peptide. Interestingly, disruption 
of model membranes required the presence of both α and β peptide units, but not lipid II. 
Similar activity was also observed for cytolysin, which might in part explain the hemolytic 
activity of these two-component lantibiotics. 
   For future study on the interaction between haloduracin and lipid II, while the binding 
between Halα and lipid II could still be measured on liposome carriers by ITC, the binding 
of Halβ to lipid II in the presence of Halα	  on liposomes might be too complicated to be 
detected by ITC measurement due to the heat associated with membrane disruption.  
   A slightly revised model of the mode of action of haloduracin is suggested here: The tight 
binding between Halα	   and lipid II not only inhibits transglycosylation during cell wall 
biosynthesis, but also recruits Halβ to the membrane. The association of the α and β peptide 
with membrane phospholipids induces disruption of the membrane structure, likely through 
pore formation (Figure 5.9). Although lipid II is not required to disrupt model membranes, 
possibility cannot be ruled out that more stable, or larger pores were formed on bacterial 
membranes that facilitated the disruption process in the presence of lipid II.  
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Figure 5.9 Proposed mode of action of haloduracin (revised). 
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5.4 MATERIALS AND METHODS 
5.4.1 Materials.  
All chemicals were purchased from Fisher Scientific or Aldrich unless noted otherwise. 
Staphylococcus simulans strain and undecaprenol sources were provided by Prof. Breukink in 
Utrecht University. Micrococcus luteus DSM 1790 was purchased from DSMZ. Cytolysin was 
provided by Dr. Weixin Tang. 
 
5.4.2 General methods 
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF 
MS) was carried out on a Bruker UltrafleXtreme. Electrospray ionization quadrupole mass 
spectrometry was carried out on a Waters ZMD Quadrupole instrument. Haloduracin and 
nisin was obtained as described in chapter 4. 
 
5.4.3 Phosphorylation of undecaprenol 
An aliquot of trichloroacetonitrile (360 μmol, 36 μL) was quickly added to a stirred solution 
of undecaprenol (52 μmol) and tetra-n-butylammonium dihydrogen phosphate (270 μmol) 
in 300 μL dichloromethane. The solution was stirred or vortexed thoroughly for 15 min at 
room temperature and the liquid was evaporated afterwards. The residue was dissolved in 
0.4 mL of butanol and washed four times with 0.25 mL of butanol-saturated water. The 
butanol was evaporated and the residue was dissolved in 0.5 mL of tetrahydrofuran (THF), 
followed by addition of 40 µl 25% ammonia. A precipitate was formed, and the solution was 
stirred for 15 min at room temperature, followed by addition of 1 mL of a 1:1 mixture of 
toluene and methanol. The solution was left overnight at –20 °C. The supernatant was 
 177 
collected, evaporated and the residue was dissolved in 1.5 mL acetone or methanol. The 
reaction was monitored with silica TLC developed in chloroform/methanol/9% ammonia 
(2/1.2/0.3), and visualized by iodine vapor. Undecaprenyl phosphate has an Rf around 0.5 
(Figure 5.11a). This crude extract was stored at –20 °C under nitrogen and could be directly 
used for lipid II assembly. 
 
5.4.4 Extraction of UDP-MurNAc-pentapeptide (UM) from S. s imulans  
S. simulans was grown in MF broth (1% peptone, 0.3 % meat extract, 0.2 % NaCl, 0.15 % 
yeast extract, pH 7.0, 0.1% sucrose) at 37 °C to an OD 600 between 0.7 and 1.0, followed by 
the addition of chloramphenicol (130 mg/L) and further incubated for 15 min. Vancomycin 
(18 mg/L) was added and the incubation was prolonged for 45 min. The cells were 
harvested, re-suspended in water (10 mL per liter of culture) and added drop-wise into two 
volumes of boiling water. The boiling was continued for another 15 min and the samples 
were cooled down. After centrifugation at 23,000 g for 15 min, the supernatant was collected 
and lyophilized to dryness. The crude extract was stored at –20 °C and could be directly used 
for lipid II assembly.  
   To analyze this crude extract, the sample was injected onto a C18 analytical HPLC column 
and eluted with isocratic condition at 50 mM ammonium acetate pH 5.2. UM eluted at 9 min 
with absorbance at 260 nm, which was confirmed by MALDI MS in negative ion mode 
(Figure 5.10). 
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Figure 5.10 MALDI-TOF MS of UDP-MurNAc-pentapeptide. a) UDP-MurNAc-
pentapeptide and its sodium adducts observed by MALDI-TOF MS in negative ion mode 
(calculated monoisotopic m/z: 1148.34; observed: 1148.61). b) Fragmentation pattern by 
MALDI-TOF tandem MS (UDP calculated monoisotopic m/z: 401.98; observed: 402.83. 
parent ion calculated monoisotopic m/z 1148.34; observed: 1149.29). 
 
5.4.5 Extraction of membrane vesicles from Micrococcus luteus  DSM 1790 
M. luteus was revived by streaking the glycerol stock on MF agar plate (1% peptone, 0.3 % 
meat extract, 0.2 % NaCl, 0.15 % yeast extract, pH 7.0, 0.1% sucrose, 1.5% agar) and 
incubation at 37 °C for 24 h. The colonies should be yellow pigmented. Single colony or 
multiple colonies were inoculated into 10 mL of MF broth and incubated at 37 °C with 
aeration for 24 h. If necessary, the culture was passed one more time to achieve active cell 
growth (OD600 >2 within 24 h). 
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   Cells were grown in 6 L of MF culture at 37 °C overnight to an OD600 of 5.0-7.0, harvested 
and washed with cold lysis buffer (50 mM Tris-HCl, pH 7.5). The cell pellets were re-
suspended in 20 mL of lysis buffer per gram of cells. Then, lysozyme (20 mg/g cells), DNase 
and RNase (0.5 mg/g cells) were added followed by an immediate addition of MgCl2 to give 
10 mM final concentration. The cells were incubated at 30 °C for 1.5 hour with gentle 
rocking. The solution would become more viscous and transparent due to cell lysis. Next, 
EDTA was added to 15 mM final concentration, followed by another 15 min incubation. 
Finally, MgCl2 was added to reach a final concentration of 25 mM, and the suspension was 
centrifuged for 45 min at 600 x g at 4 °C to remove cell wall debris.  
   The dense supernatant containing the membrane vesicles was collected and centrifuged for 
30 min at 23,000 x g at 4 °C. The pellet was re-suspended in as small as possible volume of 
lysis buffer (~1 mL per gram of wet cells), and homogenized thoroughly with a Potter-
Elvehjem homogenizer on ice. The purified membrane vesicles were aliquoted and stored in 
liquid nitrogen. They could be stored up to one year before use. Membrane concentrations 
are expressed as lipid-Pi, and were determined by extraction of the total phospholipids as 
described in section 5.4.10. 
 
5.4.6 Lipid II and lipid I in v i tro  assembly 
The following is a description of a small-scale lipid II synthesis that can be scaled up by a 
factor of at least 200. Since the yield of lipid II assembly depends on the concentration of 
UM crude extract and the activity of membrane vesicles, which vary from batch to batch. It 
is recommended to first try different amounts of membranes and UM in order to achieve 
total conversion of undecaprenyl phosphate as judged by TLC. For a 150 μL test reaction, 
an aliquot of 5 μL undecaprenyl phosphate crude extract was dried under nitrogen and re-
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suspended in the same volume of detergent buffer (2% m/v Triton X-100 in 100 mM Tris 
pH 8) with vigorous vortexing. Various amounts of 10% (m/v) UM crude extract and 
membrane solution were also added into the reaction solution. The final reaction solution 
contains 10-20 nmol polyprenyl phosphate, 100 nmol UG (UDP-GlcNAc), 100 nmol UM, 
membrane vesicles (40-80 nmol lipid-Pi), 100 mM Tris-HCl, pH 8, 5 mM MgCl2, and 1% 
(w/v) Triton X-100. For lipid I assembly, the same reaction was performed in the absence of 
UG. 
   The suspension was incubated at 30 °C for 1-2 h, followed by extraction of the lipids by 
200 μL of (2:1 v/v) butanol/ 6 M pyridine-acetate pH 4.2 (prepared by mixing 
approximately 1:1 v/v ratio of glacial acetic acid with pyridine). The yellow butanol phase 
was collected after brief centrifugation, and washed with 150 μL of butanol-saturated water. 
To analyze the reaction products, 10 μl of the butanol phase was dried under vacuum. The 
lipid film was dissolved in chloroform/methanol (1:1), and then applied in total to a silica 
TLC plate. The TLC plate was developed in chloroform/methanol/9% ammonia 
(2/1.2/0.3), dried, and the spots visualized by iodine vapor. The lipid II appeared with an Rf 
around 0.1-0.2, after the bulky detergent spot. Lipid I has a slightly higher Rf (Figure 5.11). 
 
5.4.7 Purification of lipid II and lipid I 
All the purification steps were handled in the fume hood, with chloroform-resistant 
glassware and Teflon tubing. The solvent in the butanol phase resulted from previous step 
was removed by rotary evaporation under high vacuum. The residue was dissolved in 
chloroform/methanol/water (2:3:1) and applied to a DEAE-cellulose column (acetate form). 
After extensive washing of the column with at least 20 column volumes of 
chloroform/methanol/water (2:3:1) to remove Triton X-100, the reaction products were 
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eluted with a linear gradient (100 column volumes total flow) from 
chloroform/methanol/water (2:3:1) to chloroform/methanol/300 mM ammonium 
bicarbonate (2:3:1) with a gravity-driven gradient maker. Fractions were collected every one 
column volume. Lipid II and lipid I started to elute at approximately 180-200 mM 
ammonium bicarbonate, right after the cardiolipin spots (Figure 5.11c, d). After analysis of 
the fractions by TLC, the lipid II containing fractions were pooled, the chloroform and 
methanol evaporated, and the remaining volatile salts and water removed by freeze-drying. 
The lipid II was re-suspended in chloroform/methanol (1:1) and stored under N2 at -20 °C. 
 
Figure 5.11 Assembly and purification of lipid II and lipid I. a) TLC of undecaprenol and 
butanol extract of undecaprenyl phosphate. b) TLC of butanol extract of lipid I and lipid II 
(compound indicated by red arrow). c) Elution fractions of lipid I after anion exchange 
chromatography. Fractions 31-40 were collected. d) Elution fractions of lipid II after anion 
exchange chromatography. Fractions 30-50 were collected. 
 
5.4.8 Preparation of DEAE-cellulose resin (acetate form) 
DEAE cellulose (Cellulose N,N-diethylaminoethyl ether, Sigma) was soaked in 1 N HCl (15 
g in 400 mL), filtered, washed, stirred in 1 N KOH, and filtered again. The resin was re-
suspended with gentle stirring for about 0.5 h in glacial acetic acid, filtered, and re-suspended 
in absolute methanol. The suspension was filtered and washed repeatedly with methanol 
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until the filtrate is free from the smell of acetic acid. The suspension was stored in methanol 
in a closed glass container. The loading capacity is around 3 mg lipid II per mL of resin. 
 
5.4.9 Assembly and purification of short-chain lipid II analogues 
No detergent or butanol extration was needed for the synthesis of short-chain Lipid II 
variants. In this case an excess of farnesylphosphate (phosphorylated from farnesol using the 
same procedure in 5.4.3) over the UDP-MurNAc-pentapeptide was used, as farnesol is easier 
to obtain than undecaprenol. The reaction was incubated for 2 h at room temperature. 
Membranes were removed by centrifugation at 23,000 x g and the supernatant was washed 
with water-saturated butanol to remove unreacted farnesyl phosphate and other lipids. The 
material from the water phase was further purified by reversed-phase HPLC on a 
Phenomenex semi-prep C18 column. The column was equilibrated in 50 mM ammonium 
carbonate, and the sample was eluted with a linear gradient from 50 mM ammonium 
bicarbonate to 100 % methanol in 45 min at a flow rate of 8 mL/min. Farnesyl-lipid II (3-
lipid II) eluted at approximately 70% methanol (Figure 5.12). 
 
Figure 5.12 HPLC purification of farnesyl-lipid II on a C18 column. 
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5.4.10 Quantification of phospholipids  
Lipid samples (20-80 nmol) were transferred into clean glass tubes and the solvent was 
completely evaporated. Aliquots of 0.45 mL of 8.9 M H2SO4 were added and the samples 
were digested in a heated block at 225 °C for about 20 min. The tubes were cooled at room 
temperature for 5 min, then 150 μL of 30% aqueous H2O2 aq was added and heated at 225 
°C for another 30 min until the yellow color has disappeared. The tubes were cooled down 
to room temperature, diluted with 3.9 mL of Millipore H2O, then mixed with 0.5 mL 2.5 % 
ammonium molybdate and 0.5 mL of 10% ascorbic acid. The tubes were incubated at 100 
°C for 7 min and allowed to cool down to room temperature. Standard phosphorus samples 
(0.65 mM, Sigma) were prepared in the same way. The absorbance was measured at 820 nm, 
and the concentration of inorganic phosphate calculated from a standard phosphorus curve. 
For determination of Lipid II concentration, the calculated concentration was divided by 
two due to the presence of two phosphate groups in one lipid II molecule. 
 
5.4.11 Mass Spectrometry of lipid II 
Lipid II was dissolved in ammonium acetate pH=5/methanol (30:70, v/v) to a 
concentration of 20-25 μM. MS spectra of lipid II were recorded with an ESI/quadrupole 
mass spectrometer (negative ion mode).  
 
5.4.12 Isothermal titration calorimetry 
Experiments were performed using a NANO ITC (TA Instruments). The titrant and analyte 
were dissolved in the same buffer (25 mM HEPES, pH=7.6 for 3-lipid II titration; 15% 
DMSO (v/v) in 25 mM HEPES, pH=7.5 for titrations in the presence of DMSO; 1% DPC 
in 25 mM HEPES, pH=7.5 for titrations in the presence of micelle; For nisin titration, same 
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buffer composition was used with pH=6.5 instead of 7.5). Immediately prior to use, all 
solutions were degassed under vacuum at 20 °C for 12 min. The reference cell of the 
instrument was filled with the same buffer to be used in the titration. 
   Lipid or peptide solution was loaded into a 50 μL titration syringe, and the titrant was 
injected into the sample cell (volume = 191 μL) at 25 °C, with constant stirring at 300 rpm. 
The volume of the first injection was 0.86 µL. Due to the large error commonly associated 
with the first injection of ITC experiments, the heat of this injection was not included in the 
analysis of the data. Next, twenty-one 2.34 µL injections were performed. The spacing 
between each injection was 300 seconds to allow the instrument to return to baseline before 
the next injection was made. Data analysis was performed using the NanoAnalyze software 
(TA Instruments). 
 
5.4.13 LUV liposome leakage assay 
Chloroform solutions of DOPC or DOPG-POPE (3:1 molar ratio) with and without 0.1 
mol % lipid II were mixed by vortexing, and the solvent was removed under a slow stream 
of N2. The lipid mixture was thoroughly dried overnight using a centrifugal evaporator under 
vacuum. The dried lipid films were hydrated by the addition of 25 mM HEPES, pH=7.5 
containing 50 mM carboxyfluorescein, followed by vigorous vortexing for five minutes. The 
hydrated lipid films were extruded 21 times through polycarbonate filters with a 0.2 μm pore 
size. Following the extrusion, vesicles were purified on a Sephadex G50 column (equilibrated 
with 25 mM HEPES, pH 7.5) to remove the excessive dyes. Vesicle concentration was 
determined by phosphate determination, as described in section 5.4.10. The final vesicle 
concentration used was 200 μM (final lipid-Pi). To measure the liposome leakage, the change 
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in fluorescence (excitation 490 nm, emission 520 nm) was monitored upon addition of 
different concentrations of lantibiotics for a total period of 15 min. The percent leakage was 
determined at 7 min, and the maximum leakage was determined 7 min after addition of 
0.1%(m/v) Triton-X100 detergent. The assays were performed in duplicates. 
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